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SUMMARY 
Background: Young women with Polycystic Ovary Syndrome (PCOS) may have 
increased measures of cardiovascular risk.  It is difficult to determine how much of 
this risk is due to PCOS itself and how much is due to obesity and insulin resistance, 
which are common in PCOS and are themselves associated with greater 
cardiovascular risk. 
Aims and Methods: The study aimed to determine if arterial stiffness, carotid 
intima-media thickness and diastolic dysfunction were increased in young women 
with PCOS independently of the effects of obesity.  A cross-sectional study of 
women with PCOS and healthy volunteers aged 16-45 years was undertaken.  
Subjects had a comprehensive assessment of body composition (including computed 
tomography assessment of visceral fat), measurements of arterial stiffness (aortic 
pulse wave velocity; aPWV), common carotid intima-media thickness (ccIMT), 
diastolic function (longitudinal tissue velocity; e’:a’) and metabolic measures 
including an oral glucose tolerance test to assess insulin area under the curve 
(IAUC), a marker of insulin resistance. 
Results: After adjustment for age and body mass index, PCOS subjects had greater 
insulin response (IAUC) following glucose challenge (adjusted difference [AD] 
35900 pmol min/l, P<0.001), higher testosterone (AD 0.57 nmol/l, P<0.001) and 
high molecular weight adiponectin (AD 3.01µg/ml, P=0.02) than controls.  There 
were no significant differences in aPWV (AD -0.13m/s, P=0.33), ccIMT (AD -
0.01mm, P=0.13) or e’:a’ (AD -0.01, P=0.86).  After adjustment for age, height and 
central pulse pressure, aPWV and e’:a’ were associated with log visceral fat and 
IAUC.  After adjusting for log visceral fat, the relationships between aPWV or e’:a’ 
and IAUC were only party attenuated.  There was no relationship between 
cardiovascular measures and adiponectin or testosterone.  
Conclusions: Insulin resistance and central obesity are associated with subclinical 
dysfunction in young women, but a diagnosis of PCOS does not appear to confer 
additional risk at this age. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Polycystic Ovary Syndrome 
1.1.1 Introduction 
Polycystic ovary syndrome (PCOS) is characterised by hyperandrogenism, ovarian 
dysfunction (oligo-anovulation and subfertility) and polycystic ovaries.  The 
pathogenesis remains to be fully elucidated although insulin resistance is thought to 
play a role. Briefly reviewing the historical and scientific literature provides an 
insight into the difficulties of defining the syndrome and the evolution of the current 
diagnostic criteria.  
1.1.2 Historical Overview and Diagnosis  
Hippocrates (460-377 BC) noted ‘women whose menstruation is less than three days 
or is meagre, are robust, with a healthy complexion and masculine appearance; yet 
they are not concerned about bearing children nor do they become pregnant’[1].  
This could be one of the first documented accounts of PCOS. However, reviewing 
historical documentation and applying diagnoses retrospectively must be done with 
caution.  The paper, ‘Le virilisme pilaire et son association a l’insuffisance 
glycolytique (Diabète des femmes à barbe) by Achard and Thiers in 1921 [2] 
associates insulin resistance with hirsutism and is sometimes referred to as an early 
description of PCOS.  However, a review of this case report in 2000 concluded that 
there was little evidence for PCOS and that non-classical adrenal hyperplasia was a 
more likely diagnosis [3]. 
In 1935 Stein and Leventhal reported a case series of seven women aged between 20 
and 33 years with infertility, amenorrhoea and bilateral polycystic ovaries at 
2 
 
laparotomy.  Four of the women were noted to have hirsutism, one woman had acne 
and three were obese [4].  This is thought to be the first definitive description of the 
syndrome which bore the name ‘Stein-Leventhal syndrome’ until the middle of the 
twentieth century when it became known as PCOS.   
During the 20
th
 century, it became possible to assay hormone levels and in 1990 The 
National Institute of Health (NIH) consensus group included biochemical 
hyperandrogenism as a diagnostic criterion for PCOS [5].  However, polycystic 
ovarian morphology was not considered to be important for diagnosis at this time.  
With the ability to non-invasively assess the ovaries using ultrasound, this was 
revised and included in the 2003 Rotterdam criteria for diagnosis of PCOS
 
[6].  The 
diagnostic criteria were updated in 2006 by the Androgen Excess and PCOS (AE-
PCOS) Society
 
[7].  Outlined in Table 1.1 are the main consensus groups and the 
definitions of PCOS that were agreed upon.  The Rotterdam criteria include a 
broader spectrum of PCOS than the NIH and AE-PCOS society criteria, as 
hyperandrogenism does not need to be present for the diagnosis.  In December 2013, 
the Endocrine Society endorsed the Rotterdam criteria for the diagnosis of PCOS in 
pre-menopausal women [8].  
Recently it has been suggested that Anti Mullerian Hormone (AMH) measurement 
could itself become a diagnostic criterion for PCOS
 
[9] or as a substitute for 
polycystic ovarian morphology on ultrasound
 
[10]. However, others have found very 
high levels of AMH to be specific but not sensitive for PCOS and do not support its 
use in the diagnosis [11].  The diagnosis of PCOS continues to be debated and is 
likely to evolve with time. 
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Table 1.1 Diagnosis of Polycystic Ovary Syndrome 
Consensus Group Year Criteria 
National Institute of Health (NIH) 
Bethesda, USA
5
 
 
1990 Chronic anovulation and                         
Clinical and/or biochemical signs of 
hyperandrogenism  and        
Exclusion of other aetiologies* 
European Society for Human 
Reproduction and Embryology and 
the American Society for 
Reproductive Medicine 
Rotterdam
6
 
2003 Oligo- and/or anovulation and/or 
Clinical and/or biochemical signs of 
hyperandrogenism and/or 
Polycystic Ovaries and 
Exclusion of other aetiologies* 
( 2 or more of the first three criteria must be 
present and the exclusion of other 
aetiologies)  
The Androgen Excess and PCOS 
Society (AE-PCOS)
7
 
2006 Hyperandrogenism (clinical and/or 
biochemical) and 
Ovarian dysfunction (oligo-anovulation 
and/or polycystic ovaries) and 
Exclusion of other aetiologies* and ** 
*Congenital Adrenal Hyperplasia, Androgen secreting neoplasms, Cushing’s syndrome, 
Thyroid dysfunction, Hyperprolactinaemia, Idiopathic Hirsutism and **Syndromes of severe 
insulin resistance 
 
 
1.1.3 Limitations of Research 
PCOS is a syndrome and not a disease entity; it is a collection of clinical features for 
which there is no single diagnostic test. The disorder is heterogeneous and different 
phenotypes exist depending on the diagnostic criteria used.  There are no 
internationally agreed assays for measuring androgens in women, nor which 
androgens should be measured. The Endocrine Society have stated that biochemical 
hyperandrogenism refers to an elevated serum androgen level and includes an 
elevated total, bioavailable or free serum testosterone level [8].  It is acknowledged 
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in the guideline that there is no absolute level which is diagnostic of PCOS. The 
ultrasound criterion for diagnosis of PCOS is also debated, with one group recently 
suggesting that the follicle number should be increased from to 12 to 19 [9].  These 
factors must be taken into account when comparing research studies as the groups 
studied may not be comparable.  
1.1.4 Pathogenesis  
The aetiology of PCOS is yet to be determined and is likely to be multifactorial.  
Hypotheses have focused on the following observed physiological abnormalities: 
hypersecretion of Luteinising Hormone (LH), increased ovarian androgen production 
and insulin resistance.  Other hypotheses include prenatal androgen exposure, low 
birth weight and premature pubarche, and adipose tissue expandability. 
1.1.4.1 Abnormal Hypothalamic Pituitary Function 
Hypersecretion of LH relative to follicle stimulating hormone (FSH) from the 
pituitary was one of the earliest findings in women with PCOS.  This has been 
attributed to an increased gonadotropin-releasing hormone (GnRH) pulse frequency 
from the hypothalamus which increases production of LH relative to FSH [12]. The 
higher LH levels result in an increase in ovarian theca cells androgen production [13] 
as explained below.    
The disordered GnRH secretion could be secondary to an intrinsic defect in the 
GnRH pulse generator.  An alternative explanation is that GnRH is less sensitive to 
and less inhibited by oestradiol and progesterone in women with PCOS [14].   
Treatment with anti-androgens restores the GnRH pulse sensitivity to oestradiol and 
progesterone inhibition feedback [15].  This suggests that the hypothalamus and 
pituitary have a role in the pathogenesis of PCOS but hyperandrogenism precedes 
5 
 
the disordered GnRH secretion.  A hypothalamic-pituitary defect is unlikely to 
explain the pathogenesis of PCOS alone, as not all women with PCOS have elevated 
LH levels. 
1.1.4.2 Ovarian Androgen Production 
In the ovary, theca cells synthesise androgens and granulosa cells synthesise 
oestrogen.  LH stimulates the theca cells to produce androstenedione mediated by 
cytochrome P-450c17.  The androstenedione is then converted to testosterone by 17 
β-hydroxysteroid dehydrogenase (17β) or aromatized by cytochrome P-450arom to 
form oestrone.  Oestrone is then converted to oestradiol also within the granulosa 
cell. FSH regulates the aromatase activity of the granulosa cells. In normal women 
androstenedione is preferentially converted to oestradiol. 
In PCOS the theca cells are more efficient at converting androstenedione to 
testosterone than normal theca cells [16]. There is also evidence to suggest increased 
theca cell proliferation [13] and increased cytochrome-P17 transcription within the 
PCOS theca cells [17]. The ovaries preferentially synthesise androgens when there is 
a higher LH relative to FSH concentration which is another contributing factor to the 
higher ovarian androgen production in PCOS. 
1.1.4.3 Insulin Resistance 
Insulin resistance is defined as a decreased ability of insulin to stimulate glucose 
uptake in adipocytes, skeletal and cardiac muscle cells, suppress hepatic glucose 
production and suppress lipolysis.  In people with insulin resistance, higher levels of 
insulin are required to achieve the metabolic effects of insulin [18].  In 1980 basal- 
and glucose-stimulated hyperinsulinaemia was reported in women with PCOS 
compared to weight-matched controls [19]. The positive correlation of insulin and 
6 
 
androgen levels in women with PCOS suggests that insulin might contribute to the 
hyperandrogenism [19].  Interestingly, insulin action on steroidogenesis in the PCOS 
ovary is preserved but insulin action on glucose metabolism is decreased [20]. Theca 
cells from women with PCOS are more responsive to the androgenic effects of 
insulin than controls [21].  Insulin also acts synergistically with LH in the ovary, to 
increase androgen production [22].   
In the liver, insulin decreases the synthesis of sex hormone binding globulin, 
resulting in an increase in free testosterone in the circulation [23].    
Insulin may also have an effect on the hypothalamic-pituitary axis. In rat pituitary 
cells, it has been shown that insulin enhances GnRH-mediated LH and FSH 
secretion [24].    
The hyperinsulinaemia in PCOS could potentially explain the LH hypersecretion and 
the increased ovarian androgen production. 
1.1.4.4 Prenatal Androgen Exposure 
In 1982 it was demonstrated that female rhesus monkeys exposed to exogenous 
androgens prenatally had ambiguous genitalia at birth [25].  Long-term follow up of 
the monkeys found the development of a PCOS-like phenotype, in particular those 
that were overweight, with hyperinsulinaemic androgen excess, elevated LH levels, 
polycystic ovaries, dyslipidaemia and increased visceral adiposity [26].  However, 
this finding has yet to be confirmed in humans.  A longitudinal study of 244 
unselected girls recruited prenatally, failed to demonstrate an association between 
diagnosis of PCOS at age 15 and maternal hyperandrogenism throughout pregnancy 
or foetal hyperandrogenism at birth [27]. The diagnosis of PCOS in adolescents is 
challenging and a longer follow up and larger study group may have yielded 
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different results. It is also possible that the sampling of androgens during pregnancy 
missed a window of maternal or foetal androgen excess [28]. 
1.1.4.5 Low-birth Weight and Premature Pubarche 
Girls with low birth weight and premature pubarche, experience menarche before 12 
years of age and develop hyperinsulinaemic androgen excess [29].  Ibanez et al have 
treated this group with metformin pre and during puberty and have found this 
prevents the development of features of PCOS [30].  The adipose tissue 
expandability hypothesis, explained below, could explain why low birth weight girls 
are predisposed to developing PCOS.   
1.1.4.6 Adipose Tissue Expandability 
The adipose tissue expandability theory, proposed by Virtue and Vidal-Puig [31], is 
based on the idea that subcutaneous (SC) adipose tissue has a limited capacity to 
expand safely.  Once the individual capacity (determined by genetic and 
environmental factors) has been exceeded, a lipotoxic state develops.  This is 
characterised by dyslipidaemia, an unfavourable adipocytokine profile and lipid 
deposition in non-subcutaneous adipose tissue and organs such as the liver or 
muscle, resulting in insulin resistance.  This theory could explain the 
hyperinsulinaemic androgen excess seen in PCOS.  Some patients develop 
symptoms after a period of weight gain. Other women with PCOS are of normal 
weight and these women may have exceeded their individual capacity of adipose 
tissue expansion.  
The prenatal and early years is an essential time when the adult number of 
adipocytes is determined.  Low birth-weight babies have their growth restricted in 
utero and it is proposed that the number of pre-adipocyte precursors are reduced, 
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reducing the amount of adipose tissue development.  Some will catch-up during the 
post natal period but development of fat free mass is prioritised, resulting in little 
subcutaneous fat mass accumulation.  These girls will therefore have a lower set 
point for exceeding their individual capacity for adipose tissue expansion and 
therefore may be predisposed to developing PCOS [32].   
1.1.4.7 Genetic Factors 
There is often a clustering of PCOS within families [33, 34] and twin studies have 
shown a heritability of 75% for PCOS with a correlation of 0.71 between 
monozygotic twins and 0.38 between dizygotic twins [35].  This suggests that there 
is a genetic predisposition/factor involved in the aetiology of PCOS.  There have 
been numerous studies looking for a genetic defect in PCOS using a candidate gene 
approach, but the results of these are inconclusive [36].  The candidate gene 
approach is limited by the lack of understanding into PCOS and it is hoped that using 
the genome-wide association study (GWAS) approach will overcome this.  An initial 
GWAS in China found association of PCOS (Rotterdam criteria) with the following 
three loci: 2p16.3 (luteinising hormone/choroidogonadotrophin receptor; LHCGR), 
2p21 (thyroid associated protein; THADA) and 9q33.3 (DENN/MADD domain 
containing 1A; DENND1A) [37].   Two of these loci, THADA and DENND1A have 
been confirmed to be present in a European PCOS cohort (NIH criteria) but there 
was insufficient power to confirm LHCGR as a risk locus [38].   McAllister et al 
have demonstrated overexpression of DENND1A in polycystic ovary theca cells and 
concluded that the gene plays a key role in the hyperandrogenaemia seen in PCOS 
[39].  A GWAS has identified THADA as a novel Type 2 diabetes (T2DM) gene 
associated with pancreatic beta cell dysfunction [40]; this might explain in part the 
increased risk of T2DM observed in PCOS.   
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The FTO gene has been associated with obesity and a meta-analysis of European 
data [41] and Chinese data [42] have confirmed the association of the FTO gene with 
PCOS.  In the Chinese data, this positive association was observed in both obese and 
non-obese women.   
The Chinese have demonstrated different genotype-phenotype correlations of PCOS 
[43] which suggests it is a heterogeneous condition with different genes contributing 
to the different phenotypes seen.   
1.1.5 Prevalence  
PCOS is the commonest endocrinopathy in pre-menopausal women.  During the 
1990s, studies in the United States of America (USA) [44, 45], Spain [46] and 
Greece [47] using the NIH criteria for diagnosis, found prevalence rates of PCOS 
between 4-6.8%. However, an Oxford study conducted at the same time found 
prevalence rates of between 8% (using NIH criteria) and 26% (using polycystic 
ovaries on ultrasound and an additional feature of PCOS as diagnostic criteria) [48].  
In a study of unselected obese, Spanish women a PCOS prevalence rate of 28.3% 
was demonstrated using the NIH criteria [49]. More recent studies [50-52] have 
found similar prevalence rates of PCOS using all three consensus group definitions; 
these are summarised in Table 2.  However, an analysis of a USA commercial 
medical database estimated the prevalence of PCOS at 1.6% [53].  This much lower 
prevalence rate in a large population group of 12,171,830 may be attributed to the 
analysis relying on International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes and none of the group were assessed clinically.  
March et al [50] in their community Australian study found that 68% of women with 
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PCOS were undiagnosed and this could also contribute to the difference in 
prevalence rates seen between the studies in Table 1.2 and the American study. 
Table 1.2 Prevalence of Polycystic Ovary Syndrome by Different Diagnostic 
Criteria   
Study Group Population 
number 
NIH Rotterdam AE-PCOS 
Australia
50 
728 8.7% 11.9% 10.2% 
Iran
51 
1126 7.1% 14.6% 11.7% 
Turkey
52 
392 6.1% 19.9% 15.3% 
 
1.1.6 Clinical Features 
Traditionally, PCOS has been seen as a syndrome with reproductive and 
dermatological features but more recently metabolic components have been 
recognised. 
1.1.6.1 Reproductive 
Approximately 70% of women with PCOS have oligomenorrhoea or amenorrhoea 
[54]. Menstrual cycles are irregular and can be anovulatory resulting in infertility in 
up to 30% [54].  Women with PCOS are also more likely to develop gestational 
diabetes in pregnancy and have a higher risk of pregnancy complications than 
controls [55]. 
1.1.6.2 Dermatological 
Hirsutism is present in 66% of women with PCOS, 25% have male pattern balding 
or acne, and acanthosis nigricans (a sign of insulin resistance) is seen in 2.5% [54]. 
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1.1.6.3 Metabolic 
Women with PCOS are commonly overweight or obese.  Although prevalence rates 
vary greatly (6-100%) depending on population studied and diagnostic criteria used, 
a recent systematic review and meta-analysis estimated the pooled prevalence to be 
61% [56]. Insulin resistance is common in PCOS with prevalence rates reported 
from 44 to 70% [57] and has been shown to be independent of obesity [58].  
Dyslipidaemia is present in up to 70% of women with PCOS [59].  There is an 
adverse lipid profile with high triglycerides, low high-density lipoprotein cholesterol 
(HDL-cholesterol), increased low density lipoprotein cholesterol (LDL-cholesterol) 
and increased non HDL-cholesterol [60].  A meta-analysis has found that this 
adverse profile remained after body mass index (BMI) matching [60].  Hypertension 
has been reported to be up to three times higher in PCOS women compared to 
controls [61] however, obesity could be an important confounding factor [62].  
Impaired glucose tolerance (IGT) and T2DM are elevated in women with PCOS in 
both BMI and non-BMI matched studies [63] and will be discussed in more detail 
later.  With many of the individual components of the metabolic syndrome more 
prevalent in the PCOS population, it is not surprising that the prevalence of 
metabolic syndrome is itself increased [63].  Obstructive sleep apnoea (OSA) has 
been found to be five- to thirty-times higher in women with PCOS compared to 
BMI-matched controls [64].  Non-alcoholic fatty liver disease (NAFLD) has been 
found in 0-100% of women with PCOS depending on the criteria used for diagnosis 
of both PCOS and NAFLD and the presence of obesity [65]. 
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1.1.7 Natural History 
The clinical features of PCOS could result in long term health consequences for 
women with the syndrome.   
1.1.7.1 Cancer 
Oligomenorrhoea or amenorrhoea in the presence of pre-menopausal oestrogen 
levels could in theory lead to endometrial hyperplasia and an increased risk of 
endometrial cancer.  A recent meta-analysis has found that women with PCOS have 
an increased risk of endometrial cancer (Odds Ratio (OR) 2.79; 95% Confidence 
Interval (CI) 1.31-5.95, p<0.008) and in those under 54 years of age this was 
increased further (OR 4.05; 95% CI 2.42-6.76, P<0.00001) [66].   The meta-analysis 
also evaluated breast and ovarian cancers.  There was no significant increased risk in 
either breast or ovarian cancer, except in women under 54 years of age where there 
was an increased risk of ovarian cancer (OR 2.52; 95% CI 1.08-5.89, p<0.03) [66]. 
However, no adjustment was made for obesity,which is common in PCOS and is 
itself a risk factor for endometrial cancer.  Work conducted in our own group has 
used a large, community-based database to show that women with PCOS did not 
have an increased risk of cancer, including endometrial, compared to age- and BMI-
matched controls [67]. 
1.1.7.2 Cardiovascular Disease  
Obesity, hypertension, dyslipidaemia and T2DM are all risk factors for 
cardiovascular disease.  In 1992 a metabolic risk factor model predicted a 7 fold-
increase in myocardial infarction (MI) in women with PCOS [61].  However, early 
retrospective cohort studies of women with PCOS did not reveal a significant excess 
of cardiovascular death or morbidity [68, 69] compared to the general population. 
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The nurses’ health study, a prospective cohort study of 82,439 nurses with 14 years 
of follow-up, found a significantly increased risk of non-fatal or fatal coronary heart 
disease in women who had reported very irregular menstrual cycles (age-adjusted 
relative risk 1.67, 95% CI 1.35-2.06) which remained after adjustment for body mass 
index and other confounding factors (multivariate risk ratio 1.53, 95% CI 1.24-1.90) 
[70].  Although there was no confirmed diagnosis of PCOS in these women, the 
commonest cause for irregular menstrual cycles is PCOS.  A second prospective 
cohort study with follow-up for 40 years found an increased risk of cardiovascular 
mortality in women who had a past history of irregular menstrual cycles (age 
adjusted hazard ratio 1.42, 95% confidence interval 1.03-1.94), but this did not 
remain significant after adjusting for BMI (age adjusted hazard ratio 1.35, 95% CI 
0.97-1.52) [71].  A subgroup analysis of The Women’s Ischemia Syndrome 
Evaluation (WISE) study found that postmenopausal women with features of PCOS 
had a significantly worse cumulative 5-year cardiovascular event-free survival than 
women without clinical features of PCOS, 78.9% versus 88.7% p=0.006 [72].  A 
meta-analysis in 2011 found the relative risk for coronary heart disease or stroke to 
be 2.02 comparing women with PCOS to women without PCOS.  This increased 
relative risk was reduced to 1.55 following adjustments for body mass index (BMI) 
[73].  However, the research group who predicted a 7-fold increase in myocardial 
infarction in women with PCOS did not confirm this in their own 21 year controlled 
follow-up study.  There was no difference in MI, stroke or mortality between the two 
groups, although the PCOS group had a higher prevalence of hypertension and 
elevated triglyceride levels [74].  Work conducted in our own group has used a large, 
community-based database to show that women with PCOS did not have an 
increased risk of large vessel disease but there was an increased risk of T2DM 
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compared to age- and BMI-matched controls [67].  The studies to date are therefore 
conflicting with respect to clinical cardiovascular disease.  Further, large prospective 
cohort studies are thus needed with clearly defined PCOS phenotype groups and a 
longer term follow-up, in order to clarify this association. 
1.1.7.3 Type 2 Diabetes 
As mentioned above, there is an increased risk of developing T2DM in PCOS.  A 
number of research groups have studied this and the prevalence rates for T2DM in 
women with PCOS vary from 1.6%-10% depending on the criteria used for the 
diagnosis and the age, ethnicity and BMI of the population.  This is summarised in 
Table 1.3. 
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Table 1.3 Prevalence of Type 2 Diabetes in Polycystic Ovary Syndrome 
Author Population Type 2 Diabetes 
Ehrmann et al 
1999
75 
122 USA PCOS 
Oligo/amenorrhoea+hisutism, acne 
Infertility+hyperandrogenism 
Mean age 25.5 
ADA criteria 
10% T2DM 
Legro et al 1999
76 
254 US PCOS, 80 controls 
Anovulation and biochemical hyperandrogenism 
Age 14-44,  
WHO criteria 
7.5% T2DM 
Palmert et al 
2002
77 
27 USA adolescents 
Oligomenorrhoea + biochemical 
hyperandrogenism 
Mean age 16.7 and BMI 38.4 
WHO criteria 
3.7% T2DM 
Ehrmann et al 
2005
78 
408 USA women 
Oligo/amenorrhoea + biochem hyperandrogenism 
Mean age 28.7 BMI 36.2 
ADA criteria 
4% T2DM 
Trolle et al 2005
79 
91 Danish women (27 OGTT) 
Oligo/amenorrhoea + elevated testosterone (NIH) 
Mean age 30.3 BMI 32.9 
WHO criteria 
1.1%T2DM 
(FPG) 
Chen et al 2006
80 
102 Chinese women  
Rotterdam criteria 
14-41 years, mean BMI 21.74 
WHO criteria  
1.9% T2DM 
Vrbikova et al 
2007
81 
244 Czech PCOS, 57 controls 
Rotterdam criteria 
Mean age 27.4 BMI 27.5 
 
1.6% T2DM 
Weerakiet et al 
2008
82 
 
170 Thai women 
Rotterdam criteria 
Mean age 28.6 and BMI 27.1 
ADA criteria 
10% T2DM 
ADA, American Diabetes Association; WHO, World Health Organisation; T2DM, Type 2 diabetes; 
FPG, fasting plasma glucose; OGTT, oral glucose tolerance test 
 
 
  
1.2 PCOS and Glucose Tolerance 
As outlined above, insulin resistance contributes to the pathogenesis of PCOS, and 
T2DM is seen in up to 10% of women with the syndrome.  Insulin resistance and 
beta cell dysfunction contribute to glucose intolerance which can progress to 
diabetes. This will be discussed in more detail along with the relationship to obesity 
and inflammation in the following section. 
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1.2.1 Insulin Resistance 
Insulin resistance (IR) has previously been defined and its contribution to the 
pathogenesis of PCOS outlined.   
The prevalence of IR in PCOS varies greatly in published studies, from 44-95% [57, 
83, 84] compared to 10-25% of the general population [83].  The wide variation 
could be attributed to the use of different diagnostic criteria for PCOS, different 
methods to assess and define IR, and differences in BMI and ethnicity.  For example, 
a group investigating IR in different phenotypes of PCOS, found that 71.4% of the 
study population were IR.  However, 80.4% of the classic phenotype, 65% of the 
ovulatory phenotype and 38.1% of the normoandrogenic phenotype were IR [85].  
An Australian group found that 95% of obese women with PCOS had IR compared 
to 75% of lean women with PCOS [84]. 
Insulin binds to its cell membrane receptor and activates intracellular cascades 
through the phosphoinositide 3-kinase (PI3K) pathway and the mitogen-activated 
protein kinase (MAPK) signal transduction pathway [86].  The PI3K pathway 
mediates glucose uptake by increasing the translocation of the insulin-responsive 
glucose transporter, GLUT 4, from intracellular vesicles to the cell surface; increases 
glycogen synthesis via activation of Akt/protein kinase B (Akt/PKB) and regulates 
protein synthesis and degradation via rapamycin (mTOR) [87]. The MAPK pathway 
controls cell growth and differentiation [87].  In women with PCOS, abnormalities in 
cell responsiveness to insulin and insulin signalling defects have been described.   
The major defect is in the early stages of insulin signal transduction, post receptor 
binding.  This has been demonstrated in adipocytes [88, 89] and skeletal muscle [90, 
91].  The defect appears to be secondary to increased inhibitory serine 
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phosphorylation of the insulin receptor and insulin receptor substrate (IRS)-1 [57].  
In adipocytes there is also reduced expression of GLUT-4 [92].  As mentioned 
previously, in ovarian granulosa-lutein cells insulin resistance is selective, affecting 
metabolic but not other actions of insulin [20].   However, in skeletal muscle it is 
thought that both metabolic and mitogenic pathways are affected [93]. 
1.2.2 Beta Cell Dysfunction 
Insulin is secreted by pancreatic β-cells in response to a glucose stimulus.  More 
insulin is secreted in an environment of insulin resistance, resulting in 
hyperinsulinaemia [94].  When the β-cells are not able to secrete enough insulin to 
meet the body’s requirements, glucose intolerance develops [95]. Therefore, insulin 
secretion should be investigated in the context of insulin sensitivity. 
Increased fasting insulinaemia and increased insulinaemia at 2 hours after an oral 
glucose tolerance test (OGTT) have been demonstrated in women with PCOS 
(regardless of diagnostic group) in comparison to age-matched controls [96].  
However, the control women had a significantly lower body mass index than the 
PCOS subjects and therefore obesity could be a confounding factor.  Other studies 
have found reduced insulin secretory responses to intravenous glucose and meals 
when expressed relative to the degree of insulin resistance, in women with PCOS 
[97, 98].  The disposition index (DI), the product of insulin sensitivity and insulin 
secretion, is reduced in both obese and lean women with PCOS when compared to 
age- and weight-matched controls [99].  These studies suggest that there is a defect 
in insulin secretion in response to glucose in women with PCOS. 
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1.2.3 Glucose Intolerance 
When the body is no longer able to maintain blood glucose levels in the normal 
range, glucose intolerance develops.  This occurs when there is a defect in the 
secretion of insulin and/or the pancreatic cells are unable to compensate for the 
body’s insulin resistance.  The World Health Organisation definitions of 
dysglycaemia and diabetes are in Table 1.4. 
Table 1.4 World Health Organisation: Thresholds for Diagnosis of Diabetes and 
Dysglycaemia. 
 Venous plasma glucose (mmol/L) 
Normal Fasting <6.1 and 
2hr glucose during OGTT  <7.8 
Diabetes Fasting ≥ 7.0 or 
2 hour glucose during OGTT ≥ 11.1 or 
HbA1c ≥48mmol/mol 
Impaired Glucose 
Tolerance 
Fasting <7.0 and 
2 hour glucose during OGTT ≥ 7.8 and <11.1 
Impaired Fasting 
Glycaemia 
Fasting ≥ 6.1 and <7.0 
OGTT, Oral glucose tolerance test 75 grams of glucose.  An HbA1c 42-47mmol/mol identifies people 
with ‘pre diabetes’.  Adapted from the World Health Organisation Website 
 
As insulin resistance and beta cell dysfunction are present in women with PCOS, 
IGT would be expected.  A recent meta-analysis found an increased prevalence of 
IGT in women with PCOS (OR 2.48; 95% CI 1.63-3.77) and this remained in studies 
who had BMI-matched women (OR 2.54; 95% CI 1.44, 4.47) [100].  The prevalence 
of IGT in PCOS ranges from 9.4-35% [75-82] depending on diagnostic criteria used 
for PCOS and IGT and the age, BMI and ethnicity of the subjects.  The highest 
prevalence was in an American population; in a similar aged, unscreened female US 
population the prevalence of IGT was 1.6% (Third National Health and Nutrition 
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Survey).  In women with PCOS, increasing age, a first degree relative with diabetes 
and a higher BMI increases the risk of developing IGT and T2DM  [75, 76, 78, 101].    
There is an excess of IGT in women with PCOS.  This is important as IGT identifies 
individuals at high risk of developing T2DM and is itself a risk factor for 
cardiovascular disease [102, 103].  With intervention it is possible to reduce the risk 
of patients with IGT developing T2DM [104, 105].  Therefore, it would be important 
to identify women with PCOS who have IGT as it possible to intervene and improve 
their cardiovascular risk profile.  It is debated how and when women with PCOS 
should be screened for glucose intolerance.  The Androgen Excess Society 
recommends that all PCOS patients should be screened with an OGTT on diagnosis; 
women with IGT should have an annual OGTT to look for the development of 
T2DM and women with normal glucose tolerance should have a biannual OGTT 
[106].  The National Institute for Health and Care Excellence (NICE) have also 
recommended an OGTT at diagnosis and an annual OGTT to women with IGT.  
They suggest an annual OGTT should be considered in women at high risk of 
T2DM; strong family history of T2DM, BMI more than 30 (more than 25 in Asians) 
and in women who have had gestational diabetes.  All women who do not have an 
annual OGTT should have a biannual OGTT or a fasting glucose annually and an 
OGTT if the fasting glucose is more than 5.6 mmol [107]. An OGTT is costly for the 
patient and healthcare provider.  Research groups have attempted to identify the 
highest risk individuals but these have often used biochemical tests not routinely 
available in clinical practice [80-82].  One group used decision tree modelling based 
on medical history and clinical data only and were able to identify all women with 
normal glucose tolerance and allowed a 22% reduction in the number of OGTTs 
[108].  Measurement of glycated haemoglobin (HbA1c) is now accepted as a 
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diagnostic criterion for diabetes but it has not been shown to be effective in 
identifying IGT in women with PCOS [109]. 
1.2.4 Type 2 Diabetes 
PCOS is recognised by the American Diabetes Association as a non-modifiable risk 
factor for Type 2 Diabetes.  A meta-analysis has found an increased prevalence of 
Type 2 Diabetes in PCOS, [OR 4.43 (95% CI 4.06, 4.82)] and in BMI matched 
populations, [OR 4.00 (95% CI 1.97, 8.10)] [100].  The progression to type 2 
diabetes is about 2-3% per year and as with IGT, higher BMI and family history of 
type 2 diabetes are strong predictors [76,101].  Fasting plasma glucose is advocated 
as a screening test for type 2 diabetes but in women with PCOS this underestimates 
the prevalence of type 2 diabetes by 50% [76].  An OGTT is the most reliable 
method to diagnose type 2 diabetes but as mentioned previously is expensive and 
time consuming.  There have been a few studies looking at HbA1C for the diagnosis 
of type 2 diabetes in PCOS but these have shown HbA1c to be inferior to the OGTT 
[109-111]. Currently screening for type 2 diabetes in PCOS should be in line with 
guidance from the Androgen Excess Society and NICE.  Identifying type 2 diabetes 
in women with PCOS is important as there is significant morbidity and mortality 
attached to the diagnosis and it is itself a risk factor for cardiovascular disease.  It 
allows women to receive appropriate treatment and screening for microvascular 
disease.   
1.2.5 Obesity and Visceral Adiposity 
Obesity and in particular visceral adiposity (intra-peritoneal fat, also known as 
central fat) are independent risk factors for cardiovascular disease [112, 113, 114].  
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Visceral adiposity is also a risk factor for Type 2 diabetes independent of body mass 
index [115].   
A systematic review and meta-analysis has found that in women with PCOS the 
prevalence of obesity and overweightness varies from 6-100% with a pooled 
estimated prevalence of 61% (95% CI 54-68%) [56].   When obesity alone is 
considered, the prevalence is 12.5-100% with a pooled estimated prevalence of 49% 
(95% CI 42-55%) and this is significantly higher in studies comparing women with 
and without PCOS [56].  The prevalence of central obesity ranged from 20-85.5% 
with a pooled estimate of 54% (95% CI 43-62%) and in studies comparing women 
with and without PCOS, the prevalence of central obesity was significantly higher 
[56].  
 It is not known whether PCOS itself contributes to obesity/central adiposity or 
whether obesity/central adiposity contributes to PCOS.  A Spanish study diagnosed 
PCOS in 28.3% of overweight/obese women consulting for weight loss compared to 
an overall prevalence of PCOS in 6.5% pre-menopausal Spanish women [116].  
However, not all women who are obese have PCOS and not all women with PCOS 
are obese, so obesity alone does not cause PCOS but may unmask the phenotype in 
women predisposed to developing the condition.  In support of this, losing 5% of 
body weight has been shown to result in significant improvements in symptoms of 
hyperandrogenism and ovulatory function in women with PCOS [117]. 
As outlined above, women with PCOS [56] and non-obese women with PCOS [118] 
may have greater central adiposity than BMI matched controls.  However, the former 
study used waist circumference >80 cm and waist to hip ratio >0.85 and the latter 
used ultrasound to assess central adiposity.  These methods are not the gold standard 
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and one study, using Magnetic Resonance Imaging (the gold standard), did not find 
any difference in body fat distribution between PCOS patients and BMI-matched 
controls [119].  Central obesity in PCOS worsens hyperandrogenaemia [120, 121], 
anovulation [122] and is associated with greater insulin resistance [120, 123]. 
1.2.6 Inflammation 
Central adiposity is associated with insulin resistance and cardiovascular disease, as 
discussed above, and has also been associated with low-grade inflammation [124].  
C-reactive protein (CRP), an acute phase reactant that is a marker of systemic 
inflammation is elevated in obesity [125] and is itself an independent risk factor for 
type 2 diabetes and cardiovascular disease [126].   
Interleukin-6 (IL-6), secreted by adipocytes and stromovascular cells, and tumour 
necrosis factor alpha (TNFα), secreted by macrophages infiltrating adipocytes, are 
both mediators of inflammation.   They are associated with obesity [127] and both 
interfere with insulin signalling in adipose tissue resulting in insulin resistance [128, 
129].   
Circulating inflammatory markers in PCOS have recently been examined in a meta-
analysis.  No significant differences were found in TNF-α or IL-6 but CRP was 96% 
higher in women with PCOS compared to controls, an observation which remained 
even after studies with mismatches for BMI or prevalence of obesity were excluded 
[130].   
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1.3 PCOS and Cardiovascular Risk  
Impaired glucose tolerance, type 2 diabetes, obesity, visceral adiposity and chronic 
inflammation are independent cardiovascular risk factors and were discussed above.  
This section will examine the presence of other cardiovascular risk factors in patients 
with PCOS, including hypertension, dyslipidaemia and smoking status.   
1.3.1 Hypertension 
In a large retrospective, Chinese study, the prevalence of hypertension in PCOS was 
19.2% compared to 11.9% in controls [131].  Hypertension has been reported to be 
up to three times higher in PCOS women compared to controls [61].   After 
matching for body mass index, the Chinese study found that hypertensive PCOS 
patients had significantly higher lipid, insulin and glucose levels than those who 
were normotensive [131] suggesting that hypertension in PCOS could be a marker 
for a worse metabolic profile, increasing the risk factors for cardiovascular disease or 
a marker for the metabolic syndrome.  One study investigating the effect of obesity 
and androgens on blood pressure, found that overweight women with PCOS had 
similar frequencies of undiagnosed hypertension to overweight men and higher than 
those in non-hyperandrogenic women [132].  They also found that weight excess and 
hypertension in men and women with PCOS increased left ventricular wall thickness 
(a marker of target organ damage) [132].  Obesity could be an important 
confounding factor [62].  However, a Taiwanese study found that higher free 
androgen index was associated with increased systolic and diastolic blood pressure 
independent of age, BMI and insulin resistance [133].  
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1.3.2 Dyslipidaemia 
Dyslipidaemia is present in up to 70% of women with PCOS [59].  It can present 
with different patterns, including low levels of high-density lipoprotein cholesterol 
(HDL-cholesterol), and increased triglycerides, low density lipoprotein cholesterol 
(LDL-cholesterol) and non HDL-cholesterol [60]. The most common pattern is the 
atherogenic lipoprotein phenotype characterised by hypertriglyceridemia and 
decreased HDL-cholesterol.  It is the pattern most commonly seen in type 2 diabetes 
and thought to be a consequence of insulin resistance.  It is seen most commonly in 
obese PCOS patients and is present in up to 70% of American women with PCOS 
and only 50% of Italian women with PCOS [134].  The prevalence of increased 
levels of LDL-cholesterol in women with PCOS is lower and ranges from 24 to 40% 
[134, 135] and is less dependent on body weight [60].  Non-HDL cholesterol is also 
significantly higher in women with PCOS, and remains so after adjusting for BMI 
[60].   
1.3.3 Smoking 
Work conducted in our group, using a large community-based database, found that 
39% of women with PCOS were current or ex-smokers compared to 35.1% of 
controls [67]. Women with PCOS who smoke have a worse lipid profile than PCOS 
non-smokers [136, 137]. Increased testosterone and fasting insulin levels have been 
demonstrated in PCOS smokers compared to non-smokers [138], but another study 
found no differences in androgen levels [136].  As obesity may be a confounding 
factor in cardiovascular risk in women with PCOS, an Italian group studied smoking 
in lean PCOS women and found that smoking increased markers of cardiovascular 
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risk in this group [139].  After adjustment for BMI, triglyceride levels were still 
higher in PCOS smokers than non-smokers [136]. 
1.3.4 Non-Alcoholic Fatty Liver Disease 
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in more than 
5% of hepatocytes (confirmed on imaging or histology) with no significant alcohol 
history or other cause found for the hepatic steatosis.   There is evidence from cross-
sectional studies that NAFLD is associated with increased cardiovascular risk and 
disease [140-142].  However, the evidence for this from cohort studies is conflicting 
[143].  Potential co-founders are obesity and Type 2 diabetes which are commonly 
present in patients with NAFLD, and are themselves independent risk factors for 
cardiovascular disease.   
NAFLD is present in 0-100% of women with PCOS depending on the criteria used 
to diagnose PCOS and NAFLD [65]. Currently, there is little evidence to suggest 
that NAFLD confers additional cardiovascular risk in women with PCOS. 
Dawson et al compared the cardiovascular risk profiles in women with PCOS and 
women with PCOS and NAFLD [144].  They did not find a difference in lipid 
profile, blood pressure, biomarkers of endothelial function or inflammatory markers 
between the two groups, despite the PCOS and NAFLD group being heavier. They 
suggested that no difference was found because insulin resistance is thought to 
contribute to the pathogenesis of both conditions.  Sprung et al studied endothelial 
function and body fat composition in women with PCOS.  The hepatic intracellular 
triaclyglycerol pools did not account for the endothelial dysfunction and the authors 
concluded that PCOS women with NAFLD do not have additional cardiovascular 
risk compared to women with PCOS alone [145]. 
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1.4 PCOS and Cardiovascular Disease 
With the increased prevalence of cardiovascular risk factors in women with PCOS, it 
would be reasonable to expect an increase in cardiovascular events such as 
myocardial infarction or stroke.  Three large prospective cohort studies have found 
an increased risk of cardiovascular events in women reporting clinical features of 
PCOS [70-72] and this was discussed in more detail in section 1.1.7.2.  
A meta-analysis in 2011 found the relative risk for coronary heart disease or stroke 
was 2.02 comparing women with PCOS to women without PCOS.  This increased 
relative risk was reduced to 1.55 following adjustments for BMI [73].  However, a 
large community-based, controlled study of young women with PCOS failed to find 
an increased risk of large vessel disease [67].  This may have been because the 
population was young and yet to develop cardiovascular events.  A further meta-
analysis in 2014 examined non-fatal cardiovascular events in women with PCOS.  In 
women over 45 years, the risk of non-fatal stroke was significantly increased but this 
became non-significant after matching for BMI [146].  In the group as a whole there 
was no increased risk of non-fatal stoke or non-fatal coronary heart disease [146]. 
Two studies with 21 and 23 years of follow-up found no difference in cardiovascular 
events between PCOS women and controls [74,147].  However, a 20 year 
retrospective cohort study found (age-group-specific) odds ratios for the prevalence 
of MI and angina in women with PCOS compared to the local female population 
ranged between 2.6 (95%CI 1.0, 6.3) and 12.9 (95% CI 3.4, 48.6) with the highest 
ratio being for MI in the over 65 year age group [148].  In this study there were 
significant correlations with age, history of hypertension and smoking.    
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There is thus no evidence presently of increased cardiovascular events in young 
women with PCOS.  There may be an excess of cardiovascular events in older 
women with PCOS but it is not possible to ascertain the mechanism from these 
studies.   
 
1.5 PCOS and Subclinical Cardiovascular Disease 
Clinical cardiovascular events, such as MI and stroke, do not appear to be increased 
in young women with PCOS but are possibly increased in older women with the 
syndrome.   It would be preferable to determine whether women with PCOS are at 
increased risk of developing cardiovascular events before they happen.  Coronary 
atherosclerosis was found in 50% of young men (mean age 22 years) killed in the 
Vietnam War [149].  Is it therefore possible to identify cardiovascular disease in 
young asymptomatic women with PCOS?  
1.5.1 Subclinical Cardiovascular Disease 
Risk factors for cardiovascular disease identify people at higher risk of 
cardiovascular events but do not assess their individual burden of disease.  They are 
useful therapeutic targets but do not identify an individual’s risk of sustaining an 
event.  Cardiovascular events are preceded by the development of atherosclerosis, 
endothelial and myocardial dysfunction, which may serve as useful surrogate 
measures of disease risk. 
Atherogenesis begins at sites of injury to the endothelium (the inner layer of the 
arterial vessel wall), often caused by local shear forces.  This is exacerbated by high 
levels of LDL-cholesterol, low levels of HDL-cholesterol, smoking, diabetes, 
hypertension, oxidative stress and systemic inflammatory states.  These factors 
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decrease the endothelial cell production of nitric oxide (NO).  This vasodilatory 
molecule inhibits key events in the development of atherosclerosis such as leukocyte 
adhesion and migration, smooth muscle cell proliferation, platelet adhesion and 
aggregation.   When NO production is decreased, the vasodilatory capacity of the 
blood vessel is reduced and the normal protective function of the vascular 
endothelium is lost.  LDL-cholesterol can then infiltrate into the subendothelial space 
where it is oxidised.  The dysfunctional endothelial cells also express adhesion 
molecules (such as vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1)) that promote the binding of circulating monocytes 
to the endothelium.  The monocytes migrate into the carotid intima where they 
differentiate into macrophages.  The macrophages internalise the oxidised LDL-
cholesterol and become lipid-laden foam cells.  Inflammatory mediators invade this 
lesion and promote the formation of a fibrous cap.  Ongoing inflammatory response 
in the vascular wall promotes the accumulation of more LDL-cholesterol and the 
growth of the lesion.  The fibrous cap can rupture, resulting in platelet aggregation 
and coagulation leading to the formation of thrombus.  The thrombus can partially or 
totally occlude a vessel resulting in a cardiovascular event [150-152]. 
Subclinical cardiovascular disease is the identification of these early changes in 
asymptomatic individuals, before the progression to significant narrowing of the 
blood vessels and symptomatic disease.  This is important to improve risk 
stratification and prevent clinical disease.  For example, one study has demonstrated 
that identifying subclinical cardiovascular disease improves medication adherence in 
asymptomatic individuals [153]. 
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1.5.2 Assessment of Subclinical Cardiovascular Disease 
There are several non-invasive and invasive methods to identify subclinical 
cardiovascular disease.  These include assessment of endothelial function and 
measuring the burden of arterial calcification and plaques, carotid artery intima-
media thickness, arterial stiffness and diastolic function of the heart.   
Peripheral endothelial function can be measured using plethysmography of the 
forearm circulation, flow-mediated vasodilatation (FMD) of the brachial artery and 
finger plethysmography [152].  The former is limited by the need for arterial 
puncture and the latter is a relatively new method.  The most commonly used method 
is the FMD technique.  This involves placing an occluding cuff over an artery 
immediately proximal or distal to the site to be imaged, for 5 minutes.  In response to 
the ischaemia, endothelial nitric oxide is released during the reactive hyperaemia 
(flow-mediated) causing dilatation of the artery.  Measurements of the artery 
diameter are taken pre and post cuff inflation.  When endothelial dysfunction is 
present, FMD is reduced.  Biochemical indices of endothelial function can also be 
measured including total nitric oxide, nitrite and nitrate.   
Coronary artery calcification (CAC) can be assessed using electron-beam computed 
tomography (EBCT). Coronary calcium reflects the atherosclerotic plaque burden, 
because calcium deposits are related to the lipid and apoptotic remnants of the 
plaque [154].  The advantage of this technique is that it is non-invasive, however 
there is exposure to a small amount of radiation and no information on the 
susceptibility of plaques to rupture is gained [152]. 
Carotid intima-media thickness (CIMT) is measured in the common carotid artery, 
using B-mode ultrasonography.  It reflects the diffuse thickening of the intimal layer 
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during atherosclerosis.  This non-invasive technique does not expose a subject to 
radiation and is highly reproducible.  However, as with EBCT CAC measurement, it 
does not give an indication of susceptibility of plaques to rupture [152].  High 
resolution magnetic resonance imaging is a non-invasive method which does not 
expose an individual to radiation and is able to measure plaque volume, composition 
and susceptibility to rupture [152].  However, this is not widely available and is 
expensive.  Coronary angiography allows direct visualisation of the plaque burden 
and degree of luminal narrowing of the coronary arteries but is invasive. 
Arterial stiffening occurs when the arterial wall becomes less elastic or distensible 
resulting in a reduction of the capacity of the vessel to accommodate volume 
changes throughout the cardiac cycle.  Atherosclerosis is thought to contribute to 
arterial stiffening [155,156].  Possible mechanisms of arterial stiffening include 
derangement of the elastic laminae with increasing age [157]; hypertension induced 
structural changes such as hypertrophy and changes in the extracellular matrix [158]; 
disruption of the nitric oxide pathway in the endothelium affecting the vascular tone 
and elastic properties of the arterial wall [159] and a direct effect of insulin on the 
vessel wall or elevated glucose levels resulting in collagen cross linking due to non-
enzymatic glycation [160].  Arterial stiffness can be measured non-invasively using 
applanation tonometry and this technique is discussed in more detail in Chapter 2.  
The principal measurement recorded is the pulse wave velocity (PWV); the stiffer 
the arteries the higher the PWV. 
There are two aspects of diastolic heart function; relaxation and stiffness, which 
describe different properties of the myocardium.  The relaxation phase (a dynamic 
and energy consuming phase) begins at the end of systolic contraction and continues 
throughout isovolumic relaxation and early diastolic filling.  Impairment of this 
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phase is due to regional dyssynchrony or a reduction in energy supply such as 
myocardial hypertrophy or ischaemia.  Diastolic stiffness is measured at the end of 
diastole and reflects passive ventricular motion; it is dependent on left atrial 
contractility and the viscoelastic properties of the left ventricle. Changes in stiffness 
result from changes in the composition of the myocardium such as interstitial 
fibrosis or left ventricular hypertrophy [161].  Diastolic function may by assessed by 
pulsed myocardial velocity imaging of the lateral and septal mitral annulus averaged 
over three consecutive cycles.  Early diastolic (e’) and atrial (a’) myocardial 
velocities are recorded.  The e’ reflects passive filling and a’ reflects filling related to 
atrial contraction.  In a compliant ventricle, most of the filling occurs passively and 
e’ is larger than a’.  In impaired relaxation, diastolic dysfunction, e’ declines and a’ 
increases as atrial contraction contributes more to diastolic filling.  
1.5.3 Endothelial Dysfunction 
Endothelial dysfunction measured by FMD has been shown to correlate with 
coronary artery endothelial function [162] and be an independent predictor of 
coronary artery disease [163].   Endothelial dysfunction in women with PCOS, 
assessed by reduced FMD, has been demonstrated in some [164,165] but not all 
[166,167] studies.  A recent meta-analysis has found that the pooled mean FMD was 
3.4% lower in women with PCOS compared to controls and that the difference was 
not influenced by BMI or age [168].   
A few studies have measured total nitric oxide in women with PCOS and controls 
and not found any differences between the groups [169, 170].  Work in our own 
group has confirmed this using more sensitive methods to assess nitric oxide and its 
metabolites [171].    
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1.5.4 Coronary Artery Calcification 
A meta-analysis of 30 prospective studies in asymptomatic subjects found that the 
presence of CAC was associated with an increased risk of cardiovascular and all-
cause mortality [172].   The American College of Cardiology Foundation and the 
American Heart Association have provided pooled data for outcome with CAC 
scores [173].  In the absence of CAC, there was a low risk of cardiovascular events.  
However, the relative risk of cardiovascular events in those with intermediate and 
high levels of CAC scores compared to those with low levels were 4.3 and 7.2 
respectively.    
The Dallas heart study did not find an increase in CAC in pre-menopausal women 
with PCOS compared to controls despite the PCOS group having a greater 
prevalence of cardiovascular risk factors and higher BMI and blood pressure [174].  
However, other studies have found an increased prevalence of CAC in pre-
menopausal women with PCOS [175-177] and post-menopausal women with PCOS 
[178].  
1.5.4 Carotid Intima Media Thickness 
A systematic review and meta-analysis of CIMT and cardiovascular events found an 
increase in CIMT thickness of 0.10mm predicted a 15% increased risk of myocardial 
infarction and an 18% increased risk of stroke [179].   
Some studies have demonstrated an increase in CIMT in young women with PCOS 
compared to BMI and age matched controls [180-185] but not others [166, 186].  
One study demonstrated a difference in CIMT in older PCOS subjects only [187].   
The mean difference in CIMT among women with PCOS compared to controls was 
found to be 0.072 mm (95% CI 0.04-0.105, P<0.0001) in a meta-analysis of high 
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quality studies, however there was no significant difference in studies with fair or 
lower quality [188].   
1.5.5 Arterial Stiffness 
Augmentation Index and PWV, both measures of arterial stiffness, independently 
predict cardiovascular events and/or mortality in the general population [189, 190], 
the elderly [191, 192] and in disease states including end-stage renal disease [193, 
194], hypertension [195, 196] and impaired glucose tolerance/diabetes [197].  
Arterial stiffness has also been associated with cardiovascular risk factors including 
hypercholesterolaemia [198] and smoking [199].   
In women with PCOS some studies have found evidence of increased arterial 
stiffness [201-203].  One study found evidence of increased arterial stiffness in the 
brachial artery but not the aorta of women with PCOS [204].   
1.5.6 Diastolic Dysfunction 
Risk factors for the development of preclinical diastolic dysfunction include 
coronary artery disease, diabetes, hypertension, hyperlipidaemia and the metabolic 
syndrome [205].  Diastolic dysfunction has been shown to progress to heart failure 
and is an independent risk for all-cause mortality [206,207].   
Impaired diastolic function has been reported in some studies comparing PCOS 
women with age and BMI matched controls [180, 208] but not all [209]. 
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1.6 Me chanisms of Cardiovascular Disease in PCOS 
The potential mechanisms of cardiovascular disease in PCOS are discussed below. 
1.6.1 Obesity 
Traditionally, adipose tissue has been seen as an inert store of energy but has 
recently been identified as a metabolically active endocrine organ which secretes 
adipose-tissue derived substances such as adipocytokines affecting a range of body 
functions.  Excess adipose tissue results in obesity, a chronic, low-grade pro-
inflammatory state in which the hyperplasia and hypertrophy of adipose cells causes 
a disturbance of adipokine secretion [210].   The systemic inflammation and 
abnormal production of adipocytokines have been identified as important factors in 
the formation and progression of atherosclerosis [211]. 
1.6.1.1 Adipose Tissue Distribution 
The distribution of adipose tissue is important as visceral adiposity is an independent 
risk factor for cardiovascular disease [112, 113, 114] and there are obese people who 
appear to be metabolically healthy and not at increased risk for cardiovascular events 
[212, 213].  Waist circumference is a stronger risk factor than BMI for 
cardiovascular disease [113, 214, 215] and waist circumference correlates well with 
visceral adipose tissue volume [216].  This has been proposed as a reason for men 
having higher rates of cardiovascular disease than women as they are more likely to 
accumulate fat around the abdomen (android obesity) than women who are more 
likely to accumulate fat around the lower body (gynoid obesity) [217].  The 
Framingham study found that 40% of men and women had increased visceral fat 
despite modestly elevated BMI of 27 kg/m
2 
in women and 28 kg/m
2 
in men [218].  
The adipose tissue expandability theory, mentioned previously, could explain this 
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finding.  In a state of positive energy balance, once an individual has reached the 
limit of their capacity to store fat in the subcutaneous tissues a lipotoxic state 
develops and one of the consequences is accumulation of fat in ectopic deposits.  Not 
all individuals increase visceral fat when overfed, only those with a defective 
regulation of lipid-storing genes in subcutaneous fat [219].   
Women with PCOS may have greater central adiposity than BMI-matched controls 
in both non-obese and obese subjects [56, 118].   Whether obesity or central 
adiposity are independent risk factors for cardiovascular risk/disease in PCOS is yet 
to be established.  
As part of the adipose tissue expandability hypothesis, an unfavourable 
adipocytokine profile is suggested and this may provide a link between visceral fat 
and cardiovascular disease and will be discussed further below. 
1.6.1.2 Adipocytokines 
Adipocytokines are peptides secreted by adipose tissue. Adipokines (adiponectin, 
leptin, visfatin, apelin, chemerin and acute-phase serum amyloid A) are secreted 
from the adipocytes whereas cytokines (TNFα and interleukins) are secreted from 
the stromovascular cells.  Resistin is an adipocytokine secreted from both adipocytes 
and stromovascular cells. 
Adiponectin has anti-inflammatory, anti-atherogenic and anti-diabetic effects, and 
promotes good endothelial function [220].  Weight loss and insulin-sensitising drugs 
increase plasma adiponectin levels [221]; pro-inflammatory cytokines reduce the 
secretion of adiponectin from cultured adipocytes [222] which provides evidence to 
support the link between inflammation and insulin resistance and obesity.  Plasma 
adiponectin levels appear to be reduced in people with insulin resistance and 
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coronary artery disease [223].  A systematic review and meta-analysis has found that 
adiponectin levels are significantly lower in PCOS women compared to BMI-
matched controls [224].  Low levels of adiponectin were associated with insulin 
resistance and PCOS severity but not with testosterone in the PCOS group [224].  
However, a recent randomised controlled trial in women with PCOS found no effect 
of metformin on adiponectin levels despite weight loss and an improvement in 
insulin resistance [225].  
Leptin promotes insulin resistance, hypertension, atherosclerosis, vascular 
inflammation, oxidative stress and endothelial dysfunction but may reduce infarct 
size and decrease hypoxic damage in cardiomyocytes [220].  Leptin levels rise with 
increasing body fat and may be a link between obesity and cardiovascular disease.  
In the general population leptin is associated with cardiovascular disease but this is 
dependent on BMI [226].  In women with PCOS, some studies have found no 
association of leptin with PCOS after accounting for BMI [227, 228] but others have 
noted increased leptin levels independent of obesity [229, 230].  One study has found 
that secretion of leptin is altered in women with PCOS compared to normal women 
[231]. 
Visfatin is mainly produced in visceral fat and may reduce infarct size and reduce 
hypoxic-induced damage.  However, high levels of visfatin are associated with 
endothelial inflammation, plaque destabilisation, increased oxidative stress and 
increased pro-inflammatory cytokine levels [220].  One study has suggested that 
visfatin may be an important link between intra-abdominal obesity and diabetes 
[232] but others have disputed this [233, 234].  Visfatin increases insulin secretion 
and insulin receptor phosphorylation in mouse pancreatic β-cells [235] and increases 
with progressive β-cell deterioration in Type 2 Diabetes [236].  In women with 
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PCOS, circulating visfatin levels are positively associated with BMI [237-239], 
fasting insulin levels [239] and blood pressure [238]. 
Apelin reduces atherogenesis, macrophage inflammation, cardiomyocyte 
contractility and heart failure and increases serum adiponectin levels and decreases 
leptin levels [220].  Significantly lower levels of apelin have been demonstrated in 
women with PCOS compared to BMI matched controls [240, 241].   
Chemerin is thought to reduce endothelial cell inflammation and promote 
angiogenesis [220].  It also plays a role in adipocyte differentiation, glucose 
homeostasis and lipolysis in adipose tissue [242].  Plasma levels are positively 
correlated with BMI, blood pressure and circulating triglycerides [243].  It has been 
found to be associated with arterial stiffness, after adjustment for other 
cardiovascular risk factors [244] but does not predict coronary atherosclerosis [245].   
In women with PCOS, chemerin levels are increased and metformin has been shown 
to reduce levels whereas insulin increases the levels [246]. 
Acute-phase serum amyloid A (ASAA) is a pro-inflammatory adipokine that is 
increased in obese and insulin-resistant people.  It is also elevated in the plasma and 
adipose tissue (visceral and subcutaneous depots) in women with PCOS.  Treatment 
with metformin for six months reduces the level of ASAA [247]. 
Adiponectin and leptin, two of the first adipokines to be discovered, have been more 
extensively researched than the others.  Adiponectin and apelin appear to have a 
protective role and be anti-inflammatory and anti-atherogenic whereas leptin and 
ASAA are pro-inflammatory and pro-atherogenic.  Chemerin and visfatin are less 
clear-cut.  Adipokines have a role in the metabolic abnormalities seen in PCOS but 
whether they are a cause or consequence of the syndrome is yet to be determined. 
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Resistin is secreted by macrophages and is associated with endothelial dysfunction 
(promotes adhesion molecules and proliferation), insulin resistance and increases 
secretion of pro-inflammatory cytokines [220].  It has been shown to be predictive of 
5 year mortality in people who have had an atherothrombotic stroke [248].  There is 
no difference in resistin serum levels between PCOS subjects and matched controls 
but messenger RNA levels were twice as high in omental adipocytes from PCOS 
women [249].   
Interleukins and TNF-α were discussed in section 1.2.6. 
1.6.2 Insulin Resistance 
Insulin resistance is present in both obese and non-obese women with PCOS [84] 
and could provide a link between PCOS and cardiovascular disease independently of 
BMI.  Insulin resistance itself increases the risk for coronary artery disease [250]. 
Endothelial cells, vascular smooth muscle cells and macrophages all involved in the 
development of atherosclerosis, express insulin receptors which are down-regulated 
in hyperinsulinaemia [251].  The PI3K and MAPK insulin signalling pathways 
regulate endothelial NO production and secretion of endothelin-1 (a vasoconstrictor) 
respectively, and the balance of these determines the response of the vessel to 
insulin.  In insulin resistance the PI3K pathway is down regulated but the MAPK 
pathway remains intact [252].   This results in a reduction in available NO and 
therefore a relative increase in endothelin-1 both of which contribute to endothelial 
dysfunction and the development of atherosclerosis, as demonstrated in mice [251].   
In humans, IR has been shown to alter large artery compliance [253] and affect 
endothelial function [254].  Insulin is not able to reduce aortic stiffness in insulin-
resistant subjects and this correlates with whole-body insulin resistance [255].  These 
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studies provide further evidence to support a link between insulin resistance and 
subclinical cardiovascular disease. 
1.6.3 Hyperglycaemia 
Insulin resistance and a failure of pancreatic β cells to secrete enough insulin results 
in hyperglycaemia.  There is evidence that lowering glucose levels results in a 
reduction in cardiovascular events in Type 1 and Type 2 Diabetes [256-258].   An 
association between glucose level 2 hours after a 75 gram glucose load and 
cardiovascular disease has been demonstrated in the general population [259, 260].  
These findings suggests that there could be a link between hyperglycaemia and 
cardiovascular disease.   
Hyperglycaemia results in increased leucocyte adhesion to endothelial cells, an 
initial step in atherogenesis, likely mediated by increased expression of adhesion 
molecules such as VCAM-1 and ICAM-1 and increased oxidative stress [261].   
Hyperglycaemia-induced advanced glycation end products (AGEs) formed by non-
enzymatic reaction of glucose with proteins and lipids and can occur intra- or extra-
cellularly [262].  These bind to the receptor for AGEs (RAGE) which promotes 
VCAM-1 expression [263].  Blocking of RAGE has been shown to prevent 
atherosclerosis in a mouse model [263].  High intracellular glucose concentrations 
also activate protein kinase C (PKC) which results in generation of reactive oxygen 
species [264] which are discussed below and are implicated in atherogenesis. 
1.6.4 Oxidative Stress 
Excessive production of oxidants in the presence of limited antioxidants results in 
oxidative stress and this has been proposed as a unifying mechanism for the 
development of endothelial dysfunction resulting from a number of cardiovascular 
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risk factors such as diabetes, hypertension and smoking [265].   Oxidants include 
reactive oxygen species (ROS), products of normal cellular metabolism derived from 
oxygen and reactive nitrogen species (RNS) derived from nitrogen oxide.  At low 
levels, ROS and RNS have a beneficial role including defence against infections. At 
high levels, they damage DNA and cellular lipids and proteins [266].  Antioxidants 
such as glutathione peroxidase and paroxanase, dispose of or prevent formation of 
oxidants.   
ROS have been implicated in the formation of the fatty streak in atherosclerosis 
through to plaque rupture [265].  In humans, ROS production is significantly higher 
in unstable angina versus stable angina, suggesting a role in modulating plaque 
stability [267].  Nicotinamide adenine dinucleotide phosphate oxidase (NAD(P)H) 
and Xanthine Oxidase (XO) are enzymes in vascular cells which generate ROS, and 
these have been shown to be activated in coronary arteries of patients with coronary 
artery disease [268].  
Oxidant levels are increased in obesity [269, 270] and are decreased in response to 
weight loss and calorie restriction [271, 272]. Contributors to oxidative stress in 
obesity include hyperglycaemia, hyperlipidaemia, hyperleptinaemia and chronic 
inflammation [272].   
A meta-analysis has found increased circulating levels of homocysteine and 
asymmetric dimethylarginine (both increase ROS production) in women with PCOS 
compared to controls [273].  Circulating glutathione, and paroxonase-1 activity (both 
anti-oxidants) were decreased in women with PCOS compared to control women 
[273].  These findings persisted when studies which BMI and age matched women in 
PCOS and control groups were examined [273]. This is an important finding as 
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obesity itself is associated with increased oxidative stress and obesity is common in 
PCOS.  Oxidative stress may have a role in vascular dysfunction in women with 
PCOS independently of weight. 
1.6.5 Androgens 
Before the age of 75, the incidence of heart disease is lower in women than men.  It 
has been postulated that androgens may have a detrimental effect on cardiovascular 
health and/or that oestrogens are protective.  In support of this, adolescent boys have 
higher blood pressure than age-matched girls when androgen levels are increasing 
[274] and in rat models, castrated male rats and males rats treated with flutamide 
have blood pressures equivalent to female rats and significantly lower than untreated 
males [275].  It has been speculated that androgens cause an increase in renin 
activity, resulting in an increase in angiotensin II.  This results in hypertension via 
oxidative stress causing renal vasoconstriction and by increasing sodium 
reabsorption [276].   
However, there is an increasing amount of data suggesting that low testosterone 
levels in men are associated with an increase in cardiovascular mortality and 
morbidity [277-281].  Low testosterone may reflect poor health; obesity and Type 2 
Diabetes are associated with low testosterone levels, which are risk factors for 
cardiovascular disease themselves and therefore possibly confounding factors.  If 
testosterone was detrimental to cardiovascular health, it would be expected that 
female to male transsexual patients treated with testosterone would have 
significantly increased cardiovascular disease events, but this has not been found 
[281].   Testosterone replacement to physiological levels has been shown to improve 
risk factors for atherosclerosis including reduction of central adiposity and insulin 
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resistance, improvement of lipid and inflammatory profiles and vascular function 
[282].   Animal studies have shown that castration accelerates aortic plaque 
development whilst testosterone replacement significantly reduced plaque formation, 
also suggesting a link between testosterone and atherosclerosis [283].  Testosterone 
may exert an anti-atherogenic effect by causing vasodilatation; reducing pro-
inflammatory cytokine production; reducing adhesion molecule expression and 
inhibiting the formation of foam cells [284].  It is not clear whether androgens are 
beneficial or detrimental in health.  
In women with PCOS there are also conflicting results regarding cardiovascular 
disease and androgens. Compared to healthy controls, CIMT was increased in 
women with PCOS independently of obesity but related directly to androgen excess 
[185].  In a different study, treatment with spironolactone (an anti-androgen) 
improved endothelial function to the same extent as healthy controls but without a 
change in androgen levels [285].  However, one study found that 
dehydroepiandrosterone sulphate was a strong negative predictor of CIMT in women 
with PCOS, suggesting a protective effect of androgens [184]. 
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 1.7 Thesis Aims 
PCOS is a common endocrine disorder of young women associated with many 
cardiovascular disease risk factors.  Whether this collection of risk factors results in 
an increase in cardiovascular events is debated.  Large cohort studies have suggested 
an increase in non-fatal and fatal cardiovascular events in women who reported 
irregular menstruation [70-72]. One meta-analysis found that women with PCOS 
were twice as likely to have a cardiovascular event compared to controls, however 
the odds ratio was reduced to 1.55 after adjustment for BMI [73].  Other studies have 
failed to demonstrate an increase in cardiovascular events in pre- or post-menopausal 
women with PCOS [67, 147, 148].  
Markers of subclinical cardiovascular disease may be increased in young and middle 
aged women with PCOS including endothelial dysfunction [164-166], carotid 
intima-media thickness [180-185], arterial stiffness [164, 166, 200] and myocardial 
dysfunction [180, 208].  However, it is difficult to determine how much of this is due 
to PCOS per se or to obesity which is common in PCOS and is itself a risk factor for 
cardiovascular disease.  One study has found no difference in large artery 
distensibility in women with PCOS compared to controls, but did find that it was 
inversely related to adiposity [201]. 
 
Hypothesis: Cardiovascular risk (measured by arterial stiffness, common carotid 
intima-media thickness and myocardial dysfunction) is increased in young women 
with PCOS independently of obesity compared to healthy volunteers. 
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Aims 
1. Determine whether cardiovascular risk is increased in young women with 
PCOS independently of obesity. 
2. Explore the relationship between regional body composition and markers of 
subclinical cardiovascular disease in young women with PCOS. 
3. Explore the relationship between insulin sensitivity and markers of 
subclinical cardiovascular disease in young women with PCOS. 
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CHAPTER 2: METHODS 
 
 
2.1 Outline of Study 
2.1.1 Study Approval 
The study was approved by the Research and Development department at the 
University Hospital of Wales (UHW) (Ref 08/RPM/4276) and the South East Wales 
Research Ethics Committee (Ref 08/WSE04/53), before it commenced.  The study 
was sponsored by Cardiff University (CU) (Ref SPON CU 523-08).  
2.1.2 Recruitment 
  
Patients aged between 16 and 45 years of age were recruited from local 
endocrinology, dermatology and gynaecology clinics.  They were provided with an 
information sheet giving details about the study (Appendix 1).  The initial contact 
was followed up with a telephone call to determine interest and confirm eligibility. 
Healthy volunteers (HVs) aged between 16 and 45 years, were recruited from UHW 
and CU using poster advertisements and intranet postings (Appendix 2). Further 
recruitment of HVs was achieved by advertising in the local paper (Appendix 3). All 
interested, eligible women were provided with an information sheet (Appendix 4) 
and were telephoned a week later to determine if they wished to participate or not. 
2.1.3 Inclusion and Exclusion Criteria of Study Participants 
 
Patients who met the Rotterdam criteria for diagnosis of PCOS were included [6].  
Congenital adrenal hyperplasia, Cushing’s syndrome, androgen-secreting tumours, 
hyperprolactinaemia and thyroid dysfunction were excluded by biochemical testing.  
Women were excluded from participation if they were pregnant, breastfeeding or if 
they had a history of diabetes, hypertension or hyperlipidaemia.  Potential 
participants who were taking, or had taken in the previous 3 months, anti-
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hypertensive agents, lipid-lowering agents, glucose lowering agents, weight reducing 
agents or glucocorticoids were also excluded. 
The healthy state of the volunteers was established by history, physical examination 
and biochemical testing. They were included if they had regular menstrual cycles 
(every 27-32 days) and excluded if there was a family history of PCOS, evidence of 
hyperandrogenism or if they had a history of hypertension, hyperlipidaemia or 
impaired glucose metabolism.    
All women were investigated during the follicular phase of their menstrual cycle if 
they had mild oligomenorrhoea or eumenorrhoea. No restrictions were applied to 
women with severe oligomenorrhoea or amenorrhoea. 
2.1.4 Consent 
All participants gave written informed consent prior to entering the study 
(Appendices 5 and 6). 
2.1.5 Protocol 
Participants attended the Clinical Research Facility (CRF), UHW at 8am following 
an overnight fast.  All subjects had a pregnancy test to confirm that they were not 
pregnant before a clinical assessment, venepuncture and oral glucose tolerance test 
were undertaken. Computed tomography (CT) and dual energy x ray absorptiometry 
(DEXA) scans were performed at the Medical Physics Department in UHW, carotid 
ultrasound and echocardiography at The Wales Heart Institute, UHW and 
applanation tonometry at the CRF.  The information acquired was recorded on case 
report forms (Appendices 7 and 8). 
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2.2 Clinical Assessment 
The clinical assessment was undertaken by me. 
2.2.1 History and Examination 
Details of past medical history, medication taken currently and in the previous 3 
months, contraceptive use, smoking history, family history and menstrual history 
were recorded.  A routine physical examination was performed. 
2.2.2 Blood Pressure Measurement 
After five minutes of rest in a seated position, three blood pressure recordings were 
taken from the right brachial artery using a validated semi-automated oscillometric 
device (Omron 7051T; Omron Corporation, Tokyo, Japan). The mean of these 
recordings was used in this study. 
 
2.3 Biochemical and Metabolic Measurements 
The blood sampling was undertaken by me. 
2.3.1 Sample Collection and Storage 
With the subject at rest, an intravenous cannula or butterfly needle was inserted into 
a suitable vein in the antecubital fossa or forearm and secured.  Blood was obtained 
directly into blood bottles via a vaccutainer or via a syringe and then decanted into 
blood bottles.  The cannula or butterfly needle was then flushed with 5 millilitres 
(mls) of normal saline. The bottles were marked with the subject number and 0 
minutes.  The subject then received a drink containing 113 mls of Polycal® with 187 
mls of water.  Thirty, 60, 90 and 120 minutes later further blood samples were 
collected and marked with the subject number and time. The first 5 mls of blood at 
each collection were discarded and the cannula was flushed with 5 mls of normal 
saline after the sampling was completed.  The cannula or butterfly needle was 
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removed after the 120 minutes sample was taken.  Samples were centrifuged at 4000 
rpm for 8 minutes and stored at -30°C prior to analysis. 
2.3.2 Assays 
Serum total cholesterol, high density lipoprotein cholesterol (HDL) and triglycerides 
were assayed using an Aeroset automated analyser (Abbott Diagnostics, Berkshire, 
UK); LDL cholesterol (LDL) was calculated using Friedewald’s formula.  Insulin 
was measured using an immunometric assay specific for human insulin (Invitron, 
Monmouth, UK) and glucose was measured using the Aeroset chemistry system 
(Abbott Diagnostics, Berkshire, UK).  High sensitivity C-reactive protein (hsCRP) 
was assayed by nephelometry (BN™ II system, Dade Behring, Milton Keynes, UK) 
and total testosterone was measured by liquid chromatography-tandem mass 
spectrometry (Quattro™ Premier XE triple quadruple tandem mass spectrometer, 
Waters Ltd, Watford, UK).  High molecular weight (HMW) adiponectin was 
measured by ELISA (EMD Millipore, Billerica, MA).  The intra- and inter-assay 
coefficients of variation were all less than 9%. 
2.3.3 Estimations of Insulin Sensitivity and Insulin Resistance 
The hyperinsulinaemic-euglycaemic clamp is the gold standard method to measure 
insulin sensitivity [286].   Insulin is infused intravenously at a constant rate in 
subjects who have fasted overnight.  Blood glucose levels are measured every 5 to 
10 minutes and 20% dextrose is given intravenously at a variable rate to maintain 
euglycaemia.  It is assumed that the hyperinsulinaemic state suppresses hepatic 
gluconeogenesis.  After several hours of constant insulin infusion, steady state 
conditions are achieved for plasma insulin, blood glucose and glucose infusion.  As 
there is no net change in glucose, the glucose infusion rate equals glucose disposal 
rate (GDR) in the subject. To generate an estimate of insulin sensitivity, GDR is 
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normalised to body weight or fat free mass (FFM).  Alternatively, an insulin 
sensitivity index is calculated using the formula: 
SIClamp = M/(G x ∆I)  
where M = glucose infusion rate, G = steady state blood glucose concentration and 
∆I = difference between fasting and steady-state insulin concentrations. Tam et al 
have determined that an individual with an M or GDR value of 
<5.6mg/kgFFM+17.7∙min has an 80% chance of being insulin resistant [287]. The 
main advantage of this method is that whole body glucose disposal is measured 
directly at a defined level of hyperinsulinaemia.  However, the method is labour-
intensive, time consuming and expensive and for these reasons was not used as there 
were large numbers of subjects recruited to the study. 
Alternative methods have been established to overcome the limitations of the 
hyperinsulinaemic-euglycaemic clamp.  Two well described and widely published 
methods are the homeostatic model assessment (HOMA) [288] and the quantitative 
insulin sensitivity check index (QUICKI) [289].  HOMA-IR is a paradigm model 
derived from a mathematical assessment of the interaction between β-cell function 
and IR and is calculated using the formula: 
HOMA-IR = (FPI x FPG)/22.5  
where FPI = fasting plasma insulin (mU/l) and FPG = fasting plasma glucose 
(mmol/l).  QUICKI uses a log transform of the insulin-glucose product and therefore 
correlates to HOMA-IR.  These methods require a single fasting insulin and fasting 
glucose measurement and are therefore ideal for studies involving large numbers of 
subjects. HOMA-IR was used in this study for these reasons and because it correlates 
highly (Rs=0.88, P<0.0001) with the hyperinsulinaemic-euglycaemic clamp [288].  
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The above methods do not measure insulin sensitivity in a dynamic state.  An OGTT 
enables assessment of glucose tolerance and insulin secretion in response to a 
glucose challenge.  Insulin measurements at 0, 30, 60, 90 and 120 minutes after a 75 
grams glucose challenge allow calculation of area under curve (AUC) insulin.  The 
AUC insulin will be greater in an insulin resistant subject than a normal subject, as 
more insulin will be secreted in response to the glucose load.  This is clinically 
important and has been associated with cardiovascular mortality [290].  Post-
challenge insulin levels have also been shown to improve the performance of 
visceral fat adiposity in identifying subjects with metabolic disease [291].  Glucose 
levels 2 hours after an oral glucose challenge have also been associated with 
cardiovascular mortality [292, 293]. 
 
2.4 Body Composition Measurements 
2.4.1 Anthropometric Measurements 
The anthropometric measurements were taken by me.  
Height was measured to the nearest 0.1 centimetre (cm) using a stadiometer and 
recorded in metres (m).  Measurements were taken with the subject’s footwear 
removed. Their head, back, buttocks and heels were placed against the wall and they 
were asked to look straight ahead.  The headboard was then moved until firmly 
pushing on the vertex. 
Weight was measured to the nearest 0.5 kilogram using digital weighing scales 
(Omron Monitor BF500, Omron Corporation, Japan).  Subjects wore light clothing 
and had footwear removed. 
Body Mass Index (BMI) was calculated as weight (kg) divided by height (m) 
squared. 
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Waist circumference was measured at minimal respiration to the nearest 0.5 cm by 
positioning a tape parallel to the floor and immediately above the superior iliac 
crests.  Hip circumference was measured to the nearest 0.5 cm by positioning a tape 
parallel to the floor and at the greatest protrusion of the buttocks. 
2.4.2 Dual Energy X Ray Absorptiometry 
A whole body image was obtained (Hologic Discovery A absorptiometer) with the 
subject in the supine position.  Body composition was determined using Auto Whole 
Body Fan Beam software version 13.3.0.1:3 by a single operator, Dr Sarah 
Darlington who was blind to the subject status. An example of the image recorded is 
shown in Figure 2.1.  The image was subdivided into different regions by adjusting 
the white lines on the image to ensure all tissues were enclosed.  Fat mass, lean mass 
and percentage fat were determined for regional areas and in total.  An example of 
the output generated is shown in Figure 2.2. 
 
Figure 2.1 An Example of the DEXA Image Acquired 
 
 
Adipose tissue 
Lean tissue 
Line subdividing body into regions 
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Figure 2.2 An Example of the Body Composition Results 
 
 
 
2.4.3 Computed Tomography 
With the subject in the supine position, one cross-sectional scan was obtained by CT 
(Hawkeye, GE Medical Systems) using standard acquisition parameters (140kV, 
2.5mA, 10mm slice width, 13.6 s rotation time, 256
2 
pixel matrix) at the level of the 
fourth and fifth lumbar spines.  The image was imported into MATLAB (Maths 
Works) and analysed by a single operator, Dr Helen Blundell who was blind to 
subject status.  The image was segmented into areas of non-adipose tissue and 
adipose tissue using a fixed range of CT numbers (-120 to -80 to represent fat) 
derived from a previously published study [294].  The visceral adipose tissue area 
and total adipose tissue areas were calculated by segmenting an intra-peritoneal 
region and the whole image respectively as shown in Figure 2.3.  Subcutaneous 
adipose tissue area was calculated by subtracting the visceral fat area from the total 
fat area. 
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Figure 2.3 Cross-sectional CT Scan Image 
 
2.5 Vascular Measurements 
Arterial stiffness and carotid intima thickness were measured to assess the vascular 
status of the subjects. The methods used were applanation tonometry and carotid 
ultrasound, respectively.  These methods were chosen because they are non-invasive 
and highly reproducible and therefore ideal for studies involving large numbers of 
subjects. 
2.5.1 Applanation Tonometry 
The Sphygmocor® apparatus (AtCor Medical, Sydney, Australia) was used to 
measure peripheral arterial wave forms from which measures of arterial stiffness 
were derived.  A highly sensitive pressure transducer (tonometer) was placed over 
the point of maximal palpable pulsation of the radial, carotid or femoral artery. 
Gentle downward pressure was applied to the sensor to partially compress the artery 
beneath underlying structures, as shown in Figure 2.4.  The sensor detected dynamic 
Intraperitoneal region enclosed within the yellow line. 
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pressure and volume changes in the artery and generated a peripheral arterial 
waveform. 
 
 
The tonometer interfaces with the software to record the peripheral pressure 
waveforms.  These waveforms are a composite of the forward pressure wave created 
by ventricular contraction, the first peak, and the reflection back of this wave from 
peripheral resistance vessels, the second peak as shown in Figure 2.5. 
 
 
 
 
 
 
 
 
 
Bone
Radial artery
Tonometer
Figure 2.4 Applanation Tonometry Schematic 
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Fig. 2.5 Radial Peripheral Waveform Recorded by Applanation Tonometry  
(adapted from Oliver et al 2003 [295]) 
 
 
The Sphygmocor® software derives a central pressure waveform, as shown in Figure 
2.6, from 20 recorded and averaged peripheral waveforms using a validated, 
generalised transfer function [296]. Augmentation index (Ai) (the difference between 
the first and second systolic peaks (∆P) expressed as a percentage of the pulse 
pressure (PP)), is a measure of arterial stiffness and can be derived from the central 
pressure waveform.  
 
 
 
 
 
 
 
 
 
Primary systolic peak
Secondary systolic peak
Time (milliseconds) 
Blood 
pressure 
(mmHg) 
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Figure 2.6 Central Aortic Waveform Derived From Peripheral Wave Form 
using a Generalised Transfer Factor (adapted from Oliver et al 2003 [295]) 
 
P1 First systolic peak 
P2 Second systolic peak 
∆P Difference between first and second systolic peaks 
PP Pulse pressure 
TF Foot of wave 
TR Time between TF and inflection 
 
Before clinical cardiovascular events occur, arterial walls becomes less elastic or 
distensible resulting in a reduction of the vessel capacity to accommodate volume 
changes throughout the cardiac cycle.  Higher systolic pressures are generated as the 
aorta distends less well, maintenance of the pulse pressure is impaired due to reduced 
elastic recoil and pressure waves and their reflections from peripheral resistance 
vessels are transmitted at higher velocities.  Therefore, in stiffer arteries the reflected 
wave is seen earlier and if it appears before aortic valve closure will add to or 
augment the pressure produced by the initial wave resulting in higher central arterial 
pressures and a higher Ai.  
Ai and pulse wave velocity (PWV), measures of arterial stiffness, independently 
predict cardiovascular events and/or mortality in the general population [189, 190], 
P1
P2
∆P
TR
PP
TF
incisura
Time (milliseconds) 
 
Blood 
pressure 
(mmHg) 
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the elderly [191, 192] and in disease states including end-stage renal disease [193, 
194], hypertension [195, 196] and impaired glucose tolerance/diabetes [197].  
Arterial stiffness has also been associated with cardiovascular risk factors including 
hypercholesterolaemia [198] and smoking [199].   
Measurements were taken by me in accordance with international recommendations 
[297].   
Formal training was undertaken for pulse wave analysis using the sphygmocor at the 
‘Arterial Stiffness Theory and Practice’ course at the Vascular Research Unit in 
Addenbrooke’s Hospital.  Prior to commencement of the study, intra-operator 
variability was established by performing pulse wave analysis on 15 volunteers at 
two time points, ten minutes apart.  The mean difference and the standard deviation 
of the difference between the readings were calculated for augmentation index and 
aortic pulse wave velocity and were 2.93% and 1.98% and 0.35m/s and 0.29m/s 
respectively, as shown in Table 2.1.  This is comparable with previously published 
data which found the intra-operator standard deviation of the difference between 
readings to be 5.37% for augmentation index and 1.09 m/s for aortic pulse wave 
velocity [298]. 
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Table 2.1 Intra-operator Variability for Pulse Wave Analysis 
Age AIx 1 AIx 2 Difference 
AIx 1 & 2 
aPWV 1 aPWV 2 Difference 
aPWV 1 
&2 
22 3.0 2.0 1 5.9 5.6 0.3 
39 0.0 2.0 2 7.6 6.8 0.8 
36 16 11 5 5.7 5.8 0.1 
34 10 10 0 7.7 7.5 0.2 
34 23 25 2 6.5 5.8 0.7 
26 -6.0 -8.0 2 6.5 6.5 0.0 
45 30 30 0 6.1 7.0 0.9 
40 35 30 5 7.4 6.7 0.7 
42 16 13 3 8.6 8.7 0.1 
38 5.0 10 5 8.3 8.4 0.1 
27 22 27 5 5.2 5.3 0.1 
40 7.0 13 6 6.8 7.2 0.4 
21 0.0 -3.0 3 5.7 5.4 0.3 
25 -4.0 -5.0 1 5.7 5.9 0.2 
36 14 10 4 6.9 6.6 0.3 
Mean    2.93   0.35 
SD   1.98   0.29 
AIx, Augmentation Index; aPWV, aortic pulse wave velocity 
 
2.5.1.1 Pulse Wave Analysis 
Peripheral pressure wave forms were recorded from the right radial artery with the 
subject at rest for 10 minutes, as described above.  Ai and central aortic pressure 
were derived from analysis of the central waveform.  Ai was adjusted to a heart rate 
of 75 beats per minute. 
2.5.1.2 Pulse Wave Velocity 
During pressure wave recordings for PWV, the subject had continuous 3 lead ECG 
recording allowing gating of the pressure wave to the peak of the R wave on the 
ECG.  This allowed the time for the pressure wave to move from the ascending aorta 
to the peripheral pulse to be calculated. Measurements were taken from the carotid 
notch to the carotid, radial and femoral pulses to determine distance. From these 
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measurements, brachial (determined from recordings at the carotid and radial pulses) 
and aortic (determined from recordings at the carotid and femoral) pulse wave 
velocities were calculated as the distance/time in metre per second. 
2.5.2 Carotid Ultrasound 
Ultrasound imaging (Aloka Prosound SSD-5500, 7.5MHz linear array transducer) 
was undertaken by a single investigator, Mrs Emma Rees, who was blind to the 
subject status.  An image was recorded of the right and left common carotid artery 
with the subject lying supine after 5 minutes of rest. 
2.5.2.1 Carotid Intima Media Thickness 
Measurements of carotid intima-media thickness (CIMT) were taken off-line, from a 
one centimetre segment of the common carotid artery proximal to the bifurcation, 
using automated-tracking and analysis software (Carotid Analyzer, Medical Imaging 
Applications).  A mean of left and right sided values was used to calculate CIMT. 
The coefficient of variance for the right and left common carotid arteries were 5% 
and 6% respectively.  These were calculated on a sample of 20 subjects selected with 
a random number generator, from repeated analysis of the raw Digital Imaging and 
Communications in Medicine (DICOM) files for a single session. 
  
2.6 Cardiac Measurements 
Echocardiography (Vivid 7, GE Medical Systems, Horten, Norway, with a 2.5MHz 
transducer and harmonic imaging) was undertaken by Mrs Emma Rees who was 
blind to subject status.  Images were acquired at passive end-expiration where 
possible. Standard echocardiographic measurements and calculations were 
performed during off-line analysis using EchoPAC PC software version 110.0.0 (GE 
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Healthcare) according to the recommendations of the European Association of 
Echocardiography [299].   
2.6.1 Myocardial Function 
Longitudinal systolic function (s’) and diastolic function ( e’, a’ and e’:a’ ratio) were 
assessed by pulsed Doppler myocardial velocity imaging. The e’ and a’ are measures 
of left ventricular myocardial velocity related to passive filling and the component of 
filling related to atrial contraction, respectively. Reproducibility for resting 
myocardial velocities are well defined in the Wales Heart Research Institute (WHRI) 
echo laboratory and are all <10%, this was not repeated for the PCOS data.  All 
echocardiograms in this study were undertaken in the WHRI echo laboratory. 
 
2.7 Statistical Analyses 
Statistical analyses were undertaken with the help of Professor Frank Dunstan, 
statistician, Institute of Primary Care and Public Health, Cardiff University. 
2.7.1 Sample Size Calculation 
The planned sample size was 80 in each group. This would give 80% power for 
detecting a difference of 0.45m/sec in aortic PWV or one of 0.25 in e’:a’.  I regarded 
these differences in PWV and e’:a’ as being aetiologically significant. The likely 
power for the regression analyses was harder to estimate without detailed knowledge 
of the relationships but estimated to be 80% for detecting partial correlation 
coefficients of around 0.25. 
2.7.2 Regression Analyses 
Comparisons between patients with PCOS and controls, both unadjusted and 
adjusted, were performed by using linear models when distributions of variables 
were approximately normally distributed and using bootstrapping when this was not 
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the case.  Relationships with age and BMI were checked for linearity using graphical 
methods and examining residuals.   
Relationships between fat measures and arterial stiffness parameters were also 
estimated using linear modelling.  Fat measures were first converted into z-scores to 
facilitate comparison between models; a regression coefficient associated with a fat 
measure could then be interpreted as the effect on the outcome of a change of one 
standard deviation of the fat measure.  Models were adjusted for age, central pulse 
pressure and, where there was evidence that body size was a confounder, for height.  
Interaction terms between PCOS status and the explanatory factors were included in 
the models to test if the relationships varied between PCOS subjects and controls. 
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CHAPTER 3: Demographic, Metabolic and Anthropometric Results 
 
3.1. Introduction 
Risk factors for cardiovascular disease include impaired glucose tolerance (IGT), 
Type 2 diabetes, an adverse lipid profile, elevated high sensitivity C reactive protein 
(hsCRP), obesity, visceral adiposity, hypertension and smoking.  Factors which may 
explain the mechanisms of cardiovascular disease include the distribution of adipose 
tissue, adipocytokines, insulin resistance, hyperglycaemia, oxidative stress and 
androgens.  This chapter will explore many of these risk factors and potential 
mediators of cardiovascular disease in our study population.  As discussed in the 
introduction, the best method for screening PCOS women for dysglycaemia is 
debated and in a subgroup of the PCOS cohort we measured fasting glucose, 
glycated haemoglobin (HbA1C) and performed an oral glucose tolerance test to 
determine the best method in our local population. 
The aims of this chapter are to: 
1. Present the data on study recruitment 
2. Present the age and BMI distribution of the population and explain what 
adjustments were needed 
3. Present the ethnicity, smoking status and medications taken by the subjects 
4. Explore any differences between the PCOS group and HV groups in terms of 
metabolic factors; glucose tolerance, insulin area under the curve (AUC), 
glucose AUC, lipid profile, hsCRP, adiponectin and testosterone 
5. Examine the different screening methods for identifying dysglycaemia in 
PCOS 
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6. Explore any differences between the PCOS group and HV group in terms of 
anthropometric data; waist and hip circumferences, waist to hip ratio, total 
body fat, total lean mass and trunk fat measured by dual energy x ray 
absorptiometry (DEXA); and total fat, visceral fat and subcutaneous fat as 
measured by Computed Tomography (CT) 
 
3.2 Study Recruitment  
From the departmental database and outpatient clinics at the University Hospital of 
Wales, women of the correct age with a presentation of hirsutism, 
oligo/amenorrhoea, infertility, biochemical hyperandrogenaemia or obesity were 
identified.  Of these, 229 had an alternative diagnosis to PCOS or failed to meet the 
inclusion/exclusion criteria.  A further 257 were not contactable or declined to 
participate.  From local advertisement, 269 expressed an interest in being a healthy 
volunteer.  One hundred and seventy four were excluded as they did not meet the 
inclusion and exclusion criteria. Please see Figure 3.1. 
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Figure 3.1 Study Recruitment Flow Diagram 
 
 
3.3 Demographic Data 
The numbers of subjects in each group, their age, BMI, smoking status, ethnicity and 
medications taken are presented below.  The PCOS group was analysed with respect 
to the three different diagnostic criteria for PCOS. 
3.3.1 Number of Subjects 
Eighty-four women with PCOS and 95 healthy volunteers participated in the study. 
3.3.2 PCOS Subjects and Different Diagnostic Criteria  
The Rotterdam criteria were used in the recruitment of PCOS subjects.  The NIH 
criteria are the least inclusive requiring a diagnosis of hyperandrogenism and chronic 
anovulation. The AE-PCOS criteria are broader including hyperandrogenism and 
ovulatory dysfunction (olig- or an-ovulation or polycystic ovaries) and the 
PCOS 
570 
Alternative Diagnosis 
Failed inclusion/exclusion 
criteria 
229 
Not contactable 
Declined to participate 
257 
Included  
84 
HV 
269 
Failed to meet 
inclusion/exclusion criteria  
174 
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Rotterdam are the most inclusive as a diagnosis of hyperandrogenism is not needed.  
This is reflected in the numbers of women in this study meeting the different 
diagnostic criteria as shown in Table 3.1.  
Table 3.1 Polycystic Ovary Syndrome Subjects in Different Diagnostic Criteria 
Groups 
Diagnostic 
Criteria 
NIH Rotterdam AE-PCOS 
Number of subjects 66 84 75 
 
3.3.3 Age and BMI Distribution 
During recruitment it was noticed that the HV group had a lower mean BMI than the 
PCOS group.   To address this, an advert was placed in the local paper for healthy 
volunteers with a dress size of 16 or more (Appendix 3).   Dress size was used to 
reflect a larger BMI, as it was thought most women would know their dress size but 
may not know their BMI.  The mean age and standard deviation (SD) of the PCOS 
and HV groups were 29.8 years ± 6.7 and 32.6 years ± 7.9 respectively, which was 
significantly higher in the HV group (p=0.01).  The mean BMI and SD of the PCOS 
and HV groups were 33.3 kg/m
2
 ± 7.8 and 27.6 kg/m
2
 ± 6.3 respectively, which was 
a significant difference (p<0.001).  Results are displayed in Table 3.2. 
Table 3.2 Age and Body Mass Index of Study Population  
 PCOS 
Mean (SD) 
HV 
Mean (SD) 
Difference 
(PCOS-HV) 
95% CI p-value 
Age (years) 29.8 (6.7) 32.6 (7.9) -2.9 -5.0, -0.7 0.01 
BMI (kg/m
2
) 33.3 (7.8) 27.6 (6.3) 5.7 3.6, 7.8 <0.001 
SD, standard deviation 
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3.3.3.1 Adjustments for Age and BMI 
Matching for BMI and age within the study group resulted in a reduction in the 
number of subjects, under-powering the study. As these were possible important 
confounding factors for cardiovascular disease, further analyses were undertaken 
taking age and BMI into account.  Linear regression models were used to assess 
measurements. Subject status, age and BMI were put into the model as 
explanatory/independent variables and the measurement of interest was the 
outcome/dependent variable.  This made the assumption that relationships were 
linear and this was checked using scatter plots. 
3.3.4 Ethnicity 
The majority of the study population were Caucasian; 89% of the total study 
population, 82% of the PCOS group and 94.7% of the healthy volunteers.  There was 
a significant difference in the number of Caucasians in each group (p=0.009).  
Further details of ethnicity are provided in Table 3.3. 
Table 3.3 Ethnicity of Study Population 
Ethnicity PCOS  
Number (%) 
Healthy Volunteers 
Number (%)  
Asian 7 (8.3) 3 (3.2) 
Arab 2 (2.4) 0 (0.0) 
Afro-Caribbean 4 (4.8) 1 (1.1) 
Caucasian 69 (82) 90 (94.7) 
Mixed Race 2 (2.4) 1 (1.1) 
 
3.3.5 Smoking Status 
A third of the PCOS group (32%) and a third of the healthy volunteer (31%) were 
current or ex-smokers.  There was no significant difference in the number of ex- and 
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current smokers compared to non-smokers in each group (p=1.0).  Results are 
displayed in Table 3.4. 
Table 3.4 Smoking Status of Study Population 
Smoking Status PCOS  
Number (%) 
Healthy Volunteers 
Number (%) 
Non-smoker 57 (68) 65 (68) 
Ex-smoker 12 (14) 19 (20) 
Smoker 15 (18) 11 (12) 
 
3.3.6 Medication 
As this was a study of young women, ladies taking contraceptive pills were included.  
Recruitment would have been more difficult if this was an exclusion criterion as they 
are widely used in this age group.  Twenty-eight (29.5%) of the HVs and 19 (22.6%) 
of the PCOS group were taking a contraceptive pill; there was no significant 
difference between the two groups, p=0.3.  Twelve of the PCOS group and 8 of the 
HVs were taking antidepressants.  Two PCOS women were taking a proton-pump 
inhibitor and one of the HVs.  One of the HVs was taking acetazolamide and three 
others were taking antihistamines as required.  
 
3.4 Metabolic Characteristics of Study Population 
The glucose tolerance status, measures of insulin resistance, glucose AUC, lipid 
profile, hsCRP, testosterone and high molecular weight (HMW) adiponectin data are 
presented in this section.  Data on screening for dysglycaemia in PCOS are also 
presented. 
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3.4.1 Glucose Tolerance Status 
All women had a 75 gram oral glucose tolerance test (OGTT); samples from two 
healthy volunteers were lost in the lab and one PCOS subject did not complete the 
OGTT.  None of the subjects had any known pre-existing diabetes or pre-diabetes 
states.  There was an abnormality of the OGTT in 16% of the PCOS subjects 
compared to 4% of the HVs, which was significantly higher (p=0.02).  Details are 
shown in Table 3.5. 
Table 3.5 Glucose Tolerance Status of Study Population 
 Normal 
Number (%) 
Diabetes 
Number (%) 
IGT 
Number (%) 
IFG 
Number (%) 
PCOS 70 (84) 5 (6) 8 (10) 0 (0) 
HV 89 (96) 0 (0) 4 (4) 0 (0) 
IGT- Impaired glucose tolerance, IFG – Impaired fasting glycaemia.  
3.4.1.1 Screening for Glucose Intolerance in PCOS 
In a subgroup of PCOS subjects (n=34), HbA1c was measured along with the 
OGTT.  Seven women were identified as having abnormal glucose tolerance on one 
or more of the three screening tests and the results are displayed in table 3.6.  If an 
OGTT had not been performed, 5 diagnoses of IGT or diabetes would have been 
missed (subject numbers 1-5).  The HbA1c identified subject number 6 as having 
diabetes who had a normal fasting glucose and OGTT by World Health Organisation 
(WHO) diagnostic criteria, although if the American Diabetes Association (ADA) 
criteria were applied she would have been defined as having impaired fasting 
glycaemia.  Subject number 7 was identified as having diabetes by all three 
screening tests.  All subjects except subject number 6, who was identified by HbA1c 
alone, had a BMI>37 kg/m
2
.   
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Table 3.6 Outcome of Screening tests for Diabetes and Dysglycaemia in Polycystic Ovary Syndrome 
Subject 
Number 
Diagnosis HbA1c 
(mmol/mol) 
FPG 
(mmol/l) 
2 hour glucose 
(mmol/l) 
BMI 
(kg/m
2
) 
Age 
(years) 
Ethnicity 
1 IGT 29 4.4 8.2 43 30 Caucasian 
2 Diabetes 36 4.8 11.6 37.5 37 Caucasian 
3 Diabetes 37 5.6 11.3 37 40 Caucasian 
4 IGT 39 5.6 7.9 45.7 22 Caucasian 
5 IGT 40 5.6 8.0 42.7 35 Caucasian 
6 Diabetes 48 5.6 4.9 27.8 24 Arab 
7 Diabetes 54 8.7 14.1 42.7 29 Caucasian 
FPG, fasting plasma glucose; BMI, body mass index; IGT, impaired glucose tolerance 
Diabetes: WHO/ADA HbA1c ≥ 48 mmol/mol or FPG ≥7.0mmol/l or 2 hour glucose OGTT ≥11.1mmol/l 
Impaired glucose tolerance: WHO/ADA FPG <7.0mmol/l and 2 hour glucose OGTT ≥ 7.8mmol/l 
Impaired fasting glycaemia: WHO FPG ≥ 6.1 mmol/l and <7.0 mmol/l, ADA FPG ≥5.6 mmol/l and < 7.0 mmol/l 
High risk of diabetes: WHO HbA1c 42-47mmol/mol, ADA 39mmol/mol-47mmol/mol 
 
Results displayed in red are abnormal as per WHO criteria 
Results displayed in blue are abnormal according to ADA criteria; this is also the cut off for an oral glucose tolerance test according to NICE 
guidelines
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3.4.2 Insulin Resistance and Glucose Area Under the Curve 
Insulin resistance was assessed by measuring insulin AUC and homeostatic model 
assessment for insulin resistance (HOMA-IR).  The mean insulin AUC in the PCOS 
and HV groups was 101000 pmol min/l and 50900 pmol min/l respectively which 
was significant before (p<0.001) and after adjustment (p<0.001) for age and BMI, as 
shown in Table 3.7.  The mean HOMA-IR in the PCOS and HV groups was 4.94 and 
2.33 respectively, which was also significant before (p<0.001) and after adjustments 
(p=0.003) for age and BMI, as shown in Table 3.7.  The mean glucose AUC was 
higher in the PCOS group than the HV group, 812 mmol min/l and 699 mmol min/l 
respectively, which was significant before (p<0.001) and after (p=0.005) adjustments 
for age and BMI, as shown in Table 3.7.  Adjusting for age only, resulted in little 
change in the mean difference between the two groups for IAUC, HOMA-IR and 
glucose AUC but the p value remained significant.  Adjusting for BMI only, resulted 
in a greater change in the mean difference between the two groups for IAUC, 
HOMA-IR and glucose AUC and this was also significant.  BMI was having a 
greater influence on the difference between the two groups, although after 
adjustment for age and BMI there remained a significant difference between the two 
groups. 
3.4.3 Lipid Profile 
The mean total cholesterol was 4.80 mmol/l and 4.63 mmol/l in the PCOS and HV 
groups, respectively.  In the PCOS group the mean HDL-cholesterol was 1.32 
mmol/l and in the HV group 1.39 mmol/l.  The mean LDL-cholesterol was 2.97 
mmol/l in the PCOS group and 2.79 mmol/l in the HV group. There were no 
significant differences in total cholesterol, HDL-cholesterol or LDL-cholesterol 
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between the two groups before or after adjustment for age and BMI. The mean 
triglycerides in the PCOS group was 1.11 mmol/l compared to 0.96 mmol/l in the 
HV group.  This was significant before adjustment for age and BMI (p=0.031) but 
not after the adjustment was made (p=0.841).  These results are presented in Table 
3.7.  BMI accounted for the difference in triglycerides between the two groups. 
3.4.4 High Sensitivity C Reactive Protein 
The mean hsCRP was 4.67 mg/l in the PCOS group and 2.49 mg/l in the HV group.  
This was significantly higher in the PCOS group in the unadjusted analysis 
(p=0.002) but not after adjustments for age and BMI (p=0.553), please see Table 3.7.  
Adjustments for age only and BMI only were done. Adjusting for BMI only, the 
difference became non-significant suggesting that BMI was contributing to the 
difference rather than age.  
3.4.5 Testosterone 
The mean testosterone was 1.39 nmol/l in the PCOS group and 0.77 nmol/l in the 
HV group.  Testosterone was significantly higher in the PCOS group in unadjusted 
(p<0.001) and adjusted (p<0.001) analyses.  Please see Table 3.7.   
3.4.6 High Molecular Weight Adiponectin 
In the PCOS group the mean HMW adiponectin was 10.5 µg/ml and in the HV 
group 10.1 µg/ml.  There was no significant difference in unadjusted analyses 
(p=0.723) but mean HMW adiponectin became higher in the PCOS group after 
adjustment (p=0.02).   Please see Table 3.7.  When the adjustment for BMI only was 
done, the adiponectin was significantly higher in the PCOS group suggesting that 
BMI was contributing to the difference.
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Table 3.7 Metabolic Characteristics of the Study Population Unadjusted and Adjusted for Age and Body Mass Index 
 
 
  Unadjusted   Adjusted   
 
PCOS 
Mean (SD) 
HV 
Mean (SD) 
Difference 
(PCOS-HV) 
95% CI P-value Difference 
(PCOS-HV) 
95% CI P-value 
Insulin AUC 
(pmol min/l) 
101000 
(66000) 
50900   
(34700) 
50000 32800, 68400 <0.001 35900 19900, 52600 <0.001 
HOMA-IR 4.94 (4.15) 2.33   (1.45) 2.61 1.71, 3.52 <0.001 1.33 0.45, 2.21 0.003 
Glucose 
AUC (mmol 
min/l) 
812 (250) 699 (134) 113 54, 169 <0.001 78.4 26.9, 131.6 0.005 
TC (mmol/l) 4.80   (0.75) 4.63   (0.83) 0.17 -0.06, 0.41 0.152 0.19 -0.06, 0.45 0.139 
HDL-C 
(mmol/l) 
1.32  (0.35) 1.39   (0.33) -0.07 -0.17, 0.03 0.166 0.07 -0.04, 0.17 0.196 
LDL-C 
(mmol/l) 
2.97   (0.68) 2.79   (0.78) 0.18 -0.04, 0.40 0.115 0.11 -0.13, 0.35 0.346 
TG (mmol/l) 1.11   (0.47) 0.96   (0.45) 0.15 0.01, 0.29 0.031 0.01 -0.13, 0.16 0.841 
hsCRP (mg/l) 4.67 (5.92) 2.49 (3.04) 2.18 0.81, 3.55 0.002 0.41 -0.95, 1.78 0.553 
Testosterone 
(nmol/l) 
1.39   (0.81) 0.77   (0.38) 0.61 0.43, 0.80 <0.001 0.57 0.36, 0.78 <0.001 
Adiponectin 
(µg/ml) 
10.5   (8.9) 10.1   (7.0) 0.4 -1.98, 2.84 0.723 3.01 0.49, 5.53 0.020 
 
AUC, area under the curve; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglycerides; hsCRP, high 
sensitivity C reactive protein 
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3.5 Anthropometric Characteristics of Study Population 
The waist and hip circumferences, waist to hip ratio measurements and body 
composition as assessed by DEXA and CT are presented below. 
3.5.1 Waist and Hip Circumference 
The mean waist circumferences were 98.1cm and 85.4 cm in the PCOS and HV 
groups, respectively. The mean hip circumferences were 117.5 cm and 105.5 cm in 
the PCOS and HV groups, respectively.  The mean waist to hip ratio was 0.83 and 
0.81 in the PCOS and HV groups.  All parameters were significantly higher in the 
PCOS group in the unadjusted analyses (waist circumference, p<0.001; hip 
circumference p<0.001 and waist hip ratio, p<0.03) but differences were not 
significant after adjustments (waist circumference, p=0.101; hip circumference, 
p=0.91 and waist to hip ratio, p=0.09).  Please see Table 3.8.  Adjusting for age and 
BMI separately, suggested that BMI was contributing to the difference between the 
two groups.   
3.5.2 Total Body Fat, Regional Body Fat and Lean Mass Assessed by DEXA 
The Hologic Discovery A absorptiometer was not always available due to servicing 
or awaiting repairs, therefore only 146 women had a DEXA scan.  The mean total 
lean mass, mean total body fat and mean trunk fat in the PCOS group were 46477 
grams, 41281 grams and 20574 grams respectively.  In the HV group, the mean total 
lean mass, mean total body fat and mean trunk fat were 40937 grams, 29058 grams 
and 13130 grams respectively.   PCOS women had a higher lean mass, total body fat 
and trunk fat mass compared to HVs (p<0.001 for all parameters) but after 
adjustments for age and BMI there were no significant differences (p=0.513, p=0.401 
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and p=0.515 respectively).  Please see Table 3.8.  Adjusting for age and BMI 
separately, suggested that BMI was contributing to the difference.  
3.5.3 Subcutaneous and Visceral Fat Measurement Assessed by CT 
In the PCOS group, the mean total fat, subcutaneous fat and visceral fat areas were 
361 cm
2
, 322 cm
2
 and 39.1 cm
2
 respectively.  In the HV group, the mean total fat, 
subcutaneous fat and visceral fat areas were 286 cm
2
, 257 cm
2
 and 28.5 cm
2
 
respectively.  Before adjustments for age and BMI, the mean of all parameters were 
higher in the PCOS group compared to the HV group (p=0.001 for total fat and 
subcutaneous fat and p=0.007 for visceral fat).  After adjustment there were no 
differences between the two groups for total fat (p=0.904), subcutaneous fat 
(p=0.783) or visceral fat (p=0.529). Please see Table 3.8.  Adjusting for age and BMI 
separately, suggested that BMI was contributing to the difference.  
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Table 3.8 Anthropometric Characteristics of the Study Population Unadjusted and Adjusted for Age and Body Mass Index 
 
 
  Unadjusted   Adjusted   
 
PCOS 
Mean (SD) 
HV 
Mean (SD) 
Difference 
(PCOS-HV) 
95% CI P-value Difference 
(PCOS-HV) 
95% CI P-value 
WC (cm) 98.1 (17.9) 85.4 (13.8) 12.7 8, 17.4 <0.001 1.65 -0.33, 3.62 0.101 
HC (cm) 117.5 (18.0) 105.5 (14.4) 12.1 7.3, 16.9 <0.001 -0.09 -1.66, 1.48 0.91 
Waist: Hip 
ratio 
0.83 (0.05) 0.81 (0.05) 0.02 0.01, 0.04 <0.003 0.02 -0.002, 0.03 0.09 
DEXA total 
lean mass (g) 
46477 (9700) 40937 (5551) 5540 2839, 8082 <0.001 -630 -2371, 1130 0.513 
DEXA total 
body fat (g) 
41281 
(15811) 
29058 
(11934) 
12222 7747, 
17041 
<0.001 -620 -2250, 738 0.401 
DEXA trunk 
fat (g) 
20574 (9232) 13130 (6766) 7444 4861, 
10204 
<0.001 273 -643, 1182 0.515 
CT Total fat 
(cm
2
) 
361 (126) 286 (130) 75 30.6,110.8 0.001 -1.6 -27.3, 24.1 0.904 
CT SC fat 
(cm
2
) 
322 (110) 257 (115) 65 25.2, 96.1 0.001 -3.4 -27.7, 20.9 0.783 
CT Visceral 
fat (cm
2
) 
39.1 (28.2) 28.5 (19.5) 10.6 2.7, 17.4 0.007 1.8 -3.9, 7.5 0.529 
 
WC, waist circumference; HC, hip circumference; SC, subcutaneous 
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3.6 Summary of Demographic, Metabolic and Anthropometric Results 
All PCOS women met the Rotterdam criteria, 66 met the NIH criteria and 75 met the AE-
PCOS criteria.  Women with PCOS were significantly heavier and younger than the HVs, so 
adjustments were made for these in further analyses as they were potential confounding 
factors for cardiovascular disease.  The majority of women were Caucasian, however there 
were significantly more Caucasians in the HV group compared to the PCOS group.  There 
were no significant differences between the two groups with respect to numbers of 
smokers/exsmokers and the number of women taking the contraceptive pill.   
In the PCOS group, 5 women were found to have diabetes and 8 IGT compared to 4 HVs 
having IGT.  There was a significant difference between the two groups in the numbers of 
women having an abnormal OGTT.  In a subgroup of PCOS women, HbA1c was not able to 
identify all women with an abnormal OGTT result.  Markers of insulin resistance (HOMA-IR 
and insulin AUC), glucose AUC and testosterone were significantly higher in the PCOS 
group before and after adjustment.  There were no significant differences in cholesterol 
measurements.  Triglycerides and hsCRP were significantly higher in the PCOS group before 
adjustment but there were no differences after adjustment.  High molecular weight (HMW) 
adiponectin did not differ between the groups in the unadjusted analyses but became 
significantly higher in the PCOS group after adjustment. 
All anthropometric measurements were significantly higher in the PCOS group in unadjusted 
analyses, but none were significant after adjustments for age and BMI.  Not surprisingly, 
adjusting for BMI alone, resulted in no significant difference between the two groups. 
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3.7 Discussion 
All women with PCOS met the Rotterdam criteria for diagnosis of PCOS as this was part of 
the inclusion criteria for the study.  The AE-PCOS criteria were met by more women than the 
NIH criteria, the latter has the strictest criteria for the diagnosis of PCOS.  This was not 
surprising and reflects the prevalence of PCOS by the different criteria in the general 
population; the prevalence of PCOS diagnosed by the Rotterdam criteria being the highest 
and the prevalence of PCOS diagnosed by the NIH criteria being the lowest [50, 51].   This 
study was not designed to determine if there were any differences in cardiovascular risk 
between the different diagnostic groups.  It has been suggested that non-NIH PCOS may 
present with a less adverse cardiometabolic profile than women with PCOS diagnosed by 
NIH criteria [52, 301].  A study examining vascular function in the different categories of 
PCOS found elevated asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide 
production, in both NIH-PCOS and non-NIH PCOS patients which were significantly higher 
than controls; however, there were no differences between NIH PCOS and non-NIH PCOS 
and controls for other measures of vascular health including central aortic pulse wave 
velocity and endothelial function [302]. 
The BMI of the PCOS group was significantly higher than the HV group in our study.  This 
reflects the high levels of obesity in women with PCOS [56]. As obesity is associated with 
hypertension and dysgylcaemia, this may have contributed to difficulty in recruiting ‘healthy’ 
volunteers who are obese and well.  It may be that obese women are less likely to be 
volunteers in research studies than women of a normal weight.  The HV group were older 
than the PCOS group and this could have occurred as older women may be more concerned 
about their health than younger women and more likely to volunteer in a study investigating 
cardiovascular risk. 
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The majority of women in the study were Caucasian but there were more ethnic minorities 
represented in the PCOS group.  Asians and Arabs are at higher risk of developing glucose 
intolerance than Caucasians and this could have affected the results but the numbers involved 
are small and are unlikely to have made a big difference. 
Smoking is a risk factor for cardiovascular disease but there were no significant differences in 
history of smoking between the PCOS and HV groups in our study and so unlikely to have 
affected our results.  However, the total smoking pack year history was not ascertained and 
the effect of this on cardiovascular risk was not determined.  The prevalence of smokers or 
ex-smokers in this study was 32% which is similar to that of work done by own group 
looking at a large community-database when the prevalence was 39% [67]. 
There is some evidence to suggest that oral contraceptive pills containing higher levels of 
ethinyl estradiol, are associated with impaired glucose tolerance and insulin resistance in the 
general population [303], increasing cardiovascular risk.   However, a review suggests that 
the risk of cardiovascular events is minimal particularly in women who do not smoke and are 
not hypertensive [304]. A systematic review and meta-analysis of oral contraceptive use in 
women with PCOS also failed to find any clinically significant adverse metabolic profiles 
[305].  In our study there were no differences in oral contraceptive use between the PCOS 
group and HV group and therefore any increased cardiometabolic risk from the oral 
contraceptive pill, if present, is unlikely to have affected our results. 
More IGT and diabetes were found in the PCOS group than in the healthy volunteers.  This is 
not surprising as women with PCOS are at increased risk of developing glucose intolerance 
and diabetes [67, 100].  The prevalence rates of diabetes and IGT in PCOS are 1.6-10% [75-
82] and 9.4-35% [75-82] respectively.  The prevalence rates I found in my study were 
similar, 6% had diabetes and 10% had IGT.  As known IGT and diabetes were exclusion 
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criteria in this study, the actual prevalence of IGT and diabetes in our local PCOS population 
may be higher.  The mean BMI was higher in the PCOS group and this may be a factor in 
explaining the higher prevalence of dysglycaemia in the PCOS group; however, the measures 
of insulin resistance and glucose AUC were higher in the PCOS group than the HV group 
even after BMI- and age-matching. Therefore differences in BMI are unlikely to contribute 
solely to the differences in the prevalence of diabetes/IGT between the two groups. 
The OGTT is the gold standard for diagnosing abnormalities of glucose metabolism.  
Alternatives are the fasting plasma glucose and the HbA1c which are more convenient, less 
costly and less labour intensive than the OGTT.  In our population, HbA1c was not able to 
identify all women with dysglycaemia and if this had been used alone, five out of six (83%) 
ladies with an abnormal OGTT would have been missed.  Therefore, in patients with PCOS 
HbA1c may not be an adequate screening test for diagnosing glucose intolerance and diabetes 
in PCOS.  This is in agreement with other studies [109-110].  Following the NICE guidance 
[107] would have identified all women in this subgroup with IGT/diabetes as all had a fasting 
plasma glucose ≥5.6 mmol or a BMI more than 30.  However, as the mean BMI in this 
population was 33.3 there may not be many women who would be excluded from having an 
OGTT.   
Markers of insulin resistance (HOMA-IR and Insulin AUC) were significantly higher in the 
PCOS group both before and after adjustments for age and BMI.  This is consistent with 
other studies.  Previous authors have also shown basal- and glucose- stimulated 
hyperinsulinaemia in women with PCOS compared to weight-matched controls [19] and IR is 
present in PCOS independently of obesity [58].   
This study found no differences in total or LDL-cholesterol between the two groups.  
Trigylcerides were higher in the PCOS group compared to the HV group in the unadjusted 
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analyses, but no differences were seen between the two groups after adjustment for age and 
BMI.  After adjustment for age alone, the difference remained significant; whereas adjusting 
for BMI alone negated the differences, implying that BMI was driving the difference between 
the two groups. The most common adverse lipid profile in PCOS is elevated triglycerides and 
decreased HDL-cholesterol and has been reported in up to 70% of American women with 
PCOS [134].  Our findings are not consistent with a meta-analysis which found adverse lipid 
profiles remained in PCOS women after BMI matching [60].  This study did not match for 
age and they found that women with PCOS diagnosed by NIH criteria had worse lipid 
profiles than women diagnosed by Rotterdam criteria; this may partially explain the 
differences with my results.  
A meta-analysis found that high sensitivity CRP was elevated in women with PCOS 
compared to controls, an observation which remained after studies with mismatches for BMI 
or prevalence of obesity were excluded [130].  Our study is not in agreement with this finding 
as there was no difference in hsCRP after matching for age and BMI.  The meta-analysis 
included studies using NIH criteria and Rotterdam criteria to diagnose PCOS and this may 
partly explain the differences between our study and the meta-analysis. 
Testosterone was significantly higher in the PCOS group before and after matching for age 
and BMI.  This was expected as hyperandrogenism is common in women with PCOS, 
although the diagnosis of PCOS using the Rotterdam criteria does not necessarily require 
biochemical hyperandrogenism to be present. 
A systematic review and meta-analysis found that adiponectin levels were significantly lower 
in PCOS women than BMI-matched controls [224].  However, some studies have not found 
any difference in adiponectin levels between PCOS and controls [306,307].   This study 
found no difference in HMW adiponectin between the two groups in unadjusted analyses; 
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after adjustment for age and BMI, HMW adiponectin was higher in the PCOS group 
(p=0.02).  In the meta-analysis, the majority of studies had measured total adiponectin and 
used NIH criteria for diagnosis of PCOS, whereas I measured HMW adiponectin and used 
Rotterdam criteria for diagnosis of PCOS which could be an explanation for the discrepancy 
in findings.  The PCOS women were more insulin resistant than the HVs in our study, even 
after adjustments for age and BMI, and therefore, it would be expected that the HMW 
adiponectin levels would be lower in the PCOS group as increasing insulin resistance has 
been associated with lower HMW adiponectin levels.  However, there is some evidence to 
suggest that the morphology of adipocytes in subcutaneous and visceral adipose tissue may 
be important in regulating the secretion of adiponectin.  One study has shown that 
hypertrophied adipocytes in subcutaneous adipose tissue secrete less adiponectin than smaller 
adipocytes and that the percentage of small fat cells in subcutaneous adipose tissue correlates 
with serum HMW adiponectin [308].  It could be that in our population, PCOS women had 
more small fat cells than the HVs explaining my finding of increased HMW adiponectin in 
the PCOS group. 
All anthropometric measures and assessments of body composition were significantly higher 
in the PCOS group in the unadjusted analyses but no differences were seen between the two 
groups after adjustment for age and BMI.   A meta-analysis found that women with PCOS 
had greater central adiposity than BMI-matched controls [56] and a further study found that 
non-obese PCOS women had greater accumulation of central fat mass than BMI-matched 
controls [118].  Neither of these studies matched for age and the former used waist 
circumference >80cm and waist:hip ratio >0.85 to define central obesity whilst the latter used 
ultrasound.  We adjusted for age and used CT to assess fat distribution which is a more 
accurate method.  A study using MRI (the gold standard along with CT) to assess body fat 
distribution did not find any differences in body fat distribution between PCOS patients and 
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controls [119] which is in agreement with our findings.  As higher BMI can reflect a greater 
lean mass, DEXA was used to assess lean and fat mass in our population.  A higher 
proportion of lean mass may protect against cardiovascular disease; however, there was no 
difference in lean mass after adjustment for age and BMI between the two groups. 
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CHAPTER 4: Cardiovascular Results 
 
4.1 Introduction 
Higher resting heart rate and hypertension are risk factors for cardiovascular disease 
and therefore resting heart rate and blood pressure were measured in our study 
population.  As we were investigating a young population who had no known 
cardiovascular disease, surrogate markers of cardiovascular disease were measured to 
identify any subclinical cardiovascular disease.  These included augmentation index 
(Ai), pulse wave velocity (PWV), common carotid intima-media thickness (ccIMT) 
and diastolic heart function.  Aortic PWV, ccIMT and diastolic heart function are all 
independent predictors of cardiovascular disease [179, 189, 190, 206, 207]. 
 The aims of this chapter are to: 
1. Present the data on resting heart rate and blood pressure  
2. Present the data on Ai, brachial PWV and aortic PWV 
3. Present the data on ccIMT measurements 
4. Present the data on echocardiogram measurements 
5. Compare the findings with other studies 
As significant differences between the age and body mass index (BMI) of the 
polycystic ovary syndrome (PCOS) group and healthy volunteer (HV) group were 
found (see Chapter 3), results are presented unadjusted and adjusted for age and BMI. 
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4.2 Resting Heart Rate 
The mean resting heart rate was higher in the PCOS group 74.6 beats per minute 
(bpm) compared to the HV group 70.1 bpm, p=0.009.  However, after adjustments 
the difference was no longer significant, p=0.250. Please see Table 4.1. After 
adjusting for age alone, there remained a significant difference in the results 
suggesting BMI was mediating the difference in heart rate in the unadjusted analyses.   
 
4.3 Blood Pressure 
The peripheral blood pressure and central blood pressure measurements are presented 
below.  The central blood pressure was derived from data collected during 
applanation tonometry. 
4.3.1 Peripheral Blood Pressure 
None of the subjects included in the study had a systolic blood pressure greater than 
or equal to 140 mmHg.  Four of the PCOS group (4.8%) and no-one in the HV group 
had a diastolic blood pressure greater than or equal to 90 mmHg (p=0.047).  The 
mean systolic pressure in the PCOS group was 114.4 mmHg and in the HV group 
112.1 mmHg, p=0.135.   After adjustments for age and BMI, there was no significant 
difference in mean systolic blood pressure between the two groups, p=0.313.  The 
mean diastolic blood pressure in the PCOS group was 67.2 mmHg and in the HV 
group 64.4 mmHg, which was significantly higher, p=0.047.  After adjustments for 
age and BMI this was no longer significant, p=0.480. Please see Table 4.1.  Adjusting 
for age alone, diastolic pressure remained higher in the PCOS group but no 
significant differences were found when adjusting for BMI alone; suggesting that 
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BMI exerted the main influence on the difference in diastolic blood pressure between 
the two groups.   
4.3.2 Central Blood Pressure 
Central systolic blood pressure was no different between the two groups before 
(p=0.381) and after adjustment for age and BMI (p=0.543).  Mean central diastolic 
blood pressure was higher in the PCOS group before adjustments, PCOS mean 68.6 
mmHg and HV mean 65.2 mmHg, p=0.02. After adjustment there was no difference, 
p=0.269. Please see Table 4.1.  Adjusting for age only, the significant difference in 
central diastolic blood pressure remained but not after adjusting for BMI alone; also 
suggesting that BMI was mediating the difference between the two groups in the 
unadjusted analyses.   
 
4.4 Augmentation Index 
The mean Ai, adjusted to a heart rate of 75 bpm, in the PCOS group was 3.72% and 
in the HV group 5.6%.  There were no differences between the two groups in the 
unadjusted (p=0.343) or age and BMI adjusted analyses (p=0.935).  Please see Table 
4.1.  Adjusting for BMI alone resulted in a lower mean Ai in the PCOS group 
whereas adjusting for age alone had no significant effect. 
 
4.5 Pulse Wave Velocity 
The mean aortic PWV in the PCOS group was 6.40 metres per second (m/s) and in 
the HV group 6.41 m/s and was no different before (p=0.921) or after full adjustment 
(p=0.334).  The mean brachial PWV in the PCOS group was 7.17 m/s and in the HV 
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group 7.16 m/s, which was also not different in unadjusted (p=0.976) or adjusted 
analyses (p=0.977). Please see Table 4.1.  Adjusting for age only, all parameters 
remained non-significant.  However, adjusting for BMI alone resulted in the aortic 
PWV just becoming significantly lower in the PCOS group compared to the controls 
(p=0.016).  
 
4.6 Carotid Intima Media Thickness 
The mean common carotid artery intima media thickness was 0.50 mm in the PCOS 
group and 0.51mm in the HV group.  There was no difference before (p=0.100) or 
after adjustment (p=0.133).  Please see Table 4.1.  Adjusting for BMI alone, the 
ccIMT was significantly lower in the PCOS group than the HV group.  There were no 
differences when adjusting for age alone.
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Table 4.1 Cardiovascular Characteristics of the Study Population Unadjusted and Adjusted for Age and Body Mass Index 
 
 
  Unadjusted   Adjusted   
 
PCOS 
Mean (SD) 
HV 
Mean (SD) 
Difference 
(PCOS-HV) 
  95% CI   P-value  Difference    
(PCOS-HV) 
     95% CI     P-value 
HR (bpm) 74.6 (11.0)  70.1 (10.9) 3.5 1.11, 7.80 0.009 2.10 -1.49,5.69 0.250 
Peripheral 
SBP (mmHg) 
114.4 (9.7) 112.1 (10.3) 2.3 0.71, 5.26 0.135 -1.50 -4.43, 1.43 0.313 
Peripheral 
DBP (mmHg) 
67.2 (9.5) 64.4 (9.1) 2.8 0.04, 5.60 0.047 1.02 -1.82, 3.85 0.480 
Central  
SBP (mmHg) 
97.3 (9.5) 95.9 (10.9) 1.4 -1.71, 4.45 0.381 -0.88 -3.74, 1.97 0.543 
Central   
DBP (mmHg) 
68.6 (9.6) 65.2 (9.4) 3.4 0.53, 6.21 0.02 1.63 -1.27, 4.52 0.269 
AI (75bpm) 3.72 (11.31) 5.69 (15.41) -1.97 -6.06, 2.12 0.343 0.15 -3.40, 3.69 0.935 
aPWV (m/s) 6.40 (1.03) 6.41 (0.97) -0.02 -0.32, 0.29 0.921 -0.13 -0.40, 0.14 0.334 
bPWV (m/s) 7.17 (1.05) 7.16 (1.31) 0.01 -0.35, 0.36 0.976 0.01 -0.37, 0.38 0.977 
ccIMT (mm) 0.50 (0.06) 0.51 (0.06) -0.01 -0.04, 0.00 0.100 -0.01 -0.03, 0.00 0.133 
 
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; AI, augmentation index; aPWV, aortic pulse wave velocity; bPWV, brachial 
pulse wave velocity; ccIMT, common carotid intima media thickness
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4.7 Echocardiographic Measures 
The mean of the following echocardiographic variables were no different between the 
PCOS group and HV group before or after adjustments for age and BMI; left 
ventricular (LV) posterior wall thickness, LV end-diastolic septal thickness, LV end-
diastolic dimension, LV end-diastolic volume, LV end-systolic volume, stroke 
volume and ejection fraction.  Fractional shortening was higher in the PCOS group 
prior to adjustment for age and BMI but not after. The echocardiographic measures 
that were particularly of interest, as they are independent predictors for cardiovascular 
mortality, were the longitudinal systolic myocardial velocity (s’), the early diastolic 
myocardial velocity and the early to late myocardial velocity ratio.  The mean early 
diastolic myocardial velocity was 14.71 cm/s in the PCOS group and 14.57 cm/s in 
the HV group.  The mean systolic myocardial velocity was 9.84 cm/s in the PCOS 
group and 9.83 cm/s in the HV group.  The mean early:late diastolic myocardial 
velocity ratio was 1.82 in the PCOS group and 1.76 in the HV group. There was no 
difference between the two groups for early diastolic myocardial velocity, systolic 
myocardial velocity or the early:late diastolic myocardial velocity ratio before 
adjustments (p=0.756, p=0.974 and p=0.586 respectively) or after adjustments 
(p=0.345, p=0.511 and p=0.860 respectively).  Please see Table 4.2. 
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Table 4.2 Echocardiographic Measures Unadjusted and Adjusted for Age and Body Mass Index 
 
  Unadjusted   Adjusted   
 
PCOS 
Mean (SD) 
HV 
Mean (SD) 
Difference 
(PCOS-HV) 
95% CI P-value Difference 
(PCOS-HV) 
95% CI P-value 
LV posterior wall 
thickness (cm) 
0.86 (0.14) 0.85 (0.13) 0.01 -0.03, 0.05 0.662 -0.04 -0.88 ,0.01 0.059 
LV end-diastolic 
septal thickness 
(cm) 
0.85 (0.14) 0.81 (0.13) 0.04 -0.01, 0.08 0.084 -0.01 -0.05, 0.03 0.578 
LV end-diastolic 
dimension (cm) 
4.65 (0.38) 4.63 (0.38) 0.03 -0.09, 0.15 0.634 -0.04 -0.17, 0.08 0.492 
Fractional 
shortening (%) 
35.4 (5.0) 33.6 (5.5) 1.8 0.17, 3.42 0.031 1.28 -0.47, 3.03 0.151 
LV end-diastolic 
volume (ml) 
85.8 (13.6) 84.7 (16.4) 1.0 -4.76, 6.79 0.729 -3.72 -9.14, 1.71 0.177 
LV end-systolic 
volume (ml) 
35.5 (6.9) 33.8 (6.8) 1.7 -0.95, 4.26 0.210 -0.63 3.16, 1.90 0.623 
Stroke volume (ml) 65.6 (12.9) 64.0 (11.1) 1.6 -2.03, 5.18 0.389 -0.15 -3.91, 3.61 0.936 
Ejection fraction 
(%) 
58.7 (4.0) 59.9 (4.5) -1.3 -2.92, -0.37 0.125 -0.78 -2.55, 1.00 0.387 
Early diastolic 
myocardial velocity 
(cm/s) 
14.71 (2.72) 14.57 (2.68) 0.14 -0.76, 1.05 0.756 0.42 -0.45, 1.29 0.345 
Systolic myocardial 
velocity (cm/s) 
9.84 
(1.64) 
9.83 
(1.78) 
0.01 -0.57, 0.59 0.974 -0.22 -0.88, 0.44 0.511 
Early:late diastolic 
myocardial velocity 
1.82 (0.57) 1.76 (0.58) -0.05 -0.25, 0.14 0.586 -0.01 -0.18, 0.15 0.860 
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4.8 Summary of Cardiovascular Results 
The resting heart rate, peripheral and central diastolic blood pressures were 
significantly higher in the PCOS group in the unadjusted analyses, but were not 
significant after adjustment for age and BMI.  Adjusting for BMI alone removed the 
differences between the two groups, suggesting that the difference in the unadjusted 
analyses was mediated by BMI.  There were no differences in the central and 
peripheral systolic blood pressures, Ai, aortic PWV, brachial PWV or ccIMT between 
the two groups before or after adjustments for age and BMI.  The measures of cardiac 
function were not different between the two groups before or after adjustments for 
age and BMI except for fractional shortening; this was significantly higher in the 
PCOS group in the unadjusted analyses but not after the adjustment for age and BMI 
was made. 
 
4.9 Discussion 
The resting heart rate was significantly higher in the PCOS group compared to the 
HV group before adjustments were made.  This is in agreement with another study 
which found significantly higher heart rate in women with PCOS compared to age-
matched controls [309].  However, this study had significant differences in BMI 
between the PCOS group and controls.  After adjustments for BMI there were no 
differences between the two groups in resting heart rate which is in agreement with 
other studies who have age- and BMI-matched their subjects [166, 204].  The 
difference between the unadjusted and adjusted analyses in my study is likely to be 
due to obesity.   
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Defining hypertension as a peripheral blood pressure greater than or equal to 140/90 
mmHg, the prevalence of hypertension was 4.8% in the PCOS group and 0% in the 
HV group.  This is much lower than the prevalence reported by a Chinese study, 
19.2% [131] and the Dallas heart study, 29.2% [174]. In the Dallas heart study, the 
PCOS group had a significantly higher BMI than the controls.  As women with 
hypertension and those on antihypertensive medications were excluded from 
participating in this study, it is not surprising that the prevalence rates were lower.  
The mean diastolic blood pressure was significantly higher in the PCOS group in the 
unadjusted analyses but not after adjustment.  Blood pressure is a continuous variable 
and increases with age and BMI.  The difference seen in the unadjusted analyses may 
be related to the higher BMI in the PCOS group which was a greater significant 
difference than the older age in the HV group.  The potential mechanisms causing 
hypertension in obesity include hyperinsulinaemia, activation of the renin-
angiotensin-aldosterone system, sympathetic nervous system stimulation and 
abnormal levels of leptin [310].   
Atcor medical, the company manufacturing the sphygmocor apparatus which was 
used in this study, have published mean values and reference ranges for Ai in a 
healthy population; for ages 20-, 30- and 40-years the mean Ai is -4.67%, 3.03% and 
10.73% respectively.  In the PCOS group the mean age was 29.8 years and the mean 
Ai was 3.72%.  In the HV group the mean age was 32.6 years and the mean Ai was 
5.69%.  Both the PCOS and HV groups had comparable results with the published 
age-specific mean Ai values.  In a healthy population the mean aortic PWV is 6.1 m/s 
in the under 30 year age group and 6.6 m/s in the 30-39 year age group [311].  In this 
study the mean aortic PWV was 6.4 m/s in the PCOS group and 6.41 m/s in the HV 
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group.  These both fall within the published normal range of 4.6-7.5 m/s for the under 
30 year olds and 4.4-8.1 m/s in the 30-39 year olds [311]. 
There was no evidence of increased arterial stiffness (measured by aortic and brachial 
PWV) in this population of PCOS women compared to healthy volunteers. This is in 
agreement with Muneyyirci-Deale et al [202], Ketel et al [201] and Moran et al [302] 
who found no relationship between arterial stiffness and PCOS after adjustment for 
BMI and age.  Ketel et al also used Rotterdam criteria to diagnose PCOS but had 
fewer subjects in their study than mine [201]. The mean aortic PWV was 6.31 m/s in 
the lean PCOS group and 6.82 m/s in the obese PCOS group [201] comparable with 
the mean 6.4 m/s in this study.  Moran et al included women diagnosed by NIH 
criteria and non-NIH criteria but found no differences between these groups [302].  
Cussons et al [203] also found no difference between non-obese PCOS and controls 
in arterial stiffness, as measured by PWV and Ai.  However, other studies have found 
evidence of increased arterial stiffness in women with PCOS [164, 166, 200].  Meyer 
et al also measured arterial stiffness by PWV but the mean age and BMI of their 
population were higher than this study which may partially explain the differences in 
findings [164].   Soares et al used carotid ultrasound to assess artery distensibilty and 
stiffness index, a different method to that used in this study [166]. 
There was no difference in ccIMT between the PCOS and HV groups.  This is in 
contrast with a meta-analysis which found that women with PCOS had ccIMT around 
0.08mm greater than matched controls [188].  The mean ccIMT of the PCOS patients 
included in the meta-analysis varied from 0.41 mm to 0.7 mm [188] and the mean 
ccIMT of PCOS patients in my study was 0.5 mm. The meta-analysis considered the 
potential confounders of age and obesity but included women who were diagnosed 
with PCOS using the three different criteria. This study included women with PCOS 
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diagnosed by the Rotterdam criteria and this may explain some of the difference in 
outcomes of the studies. Talbott et al [187] also failed to find a difference in ccIMT 
in PCOS patients under the age of 45 years.  As subjects were young in this study 
population, it may be that the metabolic alterations were not yet sufficient to result in 
measurable ccIMT changes; repeating the study in 15-20 years might conceivably 
yield different results.  
There were no differences in echocardiographic measures between the two groups 
before or after adjustment for age and BMI except for fractional shortening which 
was significant in the unadjusted but not the adjusted analysis.  One study has 
reported increased left ventricular posterior wall thickness and ejection fraction in 
women with PCOS compared to controls [180] whilst others have not [209, 312].  
Some studies have reported impaired diastolic function in women with PCOS 
compared to age- and BMI- matched controls [180, 208] while others have not [209, 
312].  The differences in results may be related, in part, to the lack of sensitivity of 
traditional left ventricular echocardiographic measures.   
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CHAPTER 5 – Associations of Metabolic Parameters and Body Composition 
with Cardiovascular Measures 
 
5.1 Introduction 
The previous two results chapters have compared the metabolic, anthropometric and 
cardiovascular data between the polycystic ovary syndrome (PCOS) group and 
healthy volunteer (HV) group, unadjusted and adjusted for age and body mass index 
(BMI).  Insulin resistance (a risk factor for cardiovascular disease) and testosterone 
(a possible protector against the development of cardiovascular disease) were 
significantly different between the two groups after adjustment for age and BMI.  
Adiponectin, which has anti-atherogenic properties, was significantly higher in the 
PCOS group in the adjusted analyses.  These metabolic variables were explored 
further to identify any influence on cardiovascular function.   
Obesity is common in PCOS and is itself a risk factor for cardiovascular disease.  
Studies to date have reported conflicting results on the risk of cardiovascular disease 
and cardiovascular events in women with PCOS.  Obesity could partly explain these 
differing results.  Body composition variables were explored further to determine 
any influence on cardiovascular measures in our population. 
As metabolic and body composition could be jointly contributing to cardiovascular 
outcomes these were explored in multivariable analyses.  The models were then 
adjusted to explore whether adiposity and insulin resistance affected cardiovascular 
function independently of each other. 
Three cardiovascular measures were selected for analyses: aortic pulse wave velocity 
(aPWV), common carotid intima-media thickness (ccIMT) and the ratio of early to 
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late diastolic mitral  velocity (e’:a’).  These were chosen as aPWV and ccIMT have 
the greatest validity as predictors of cardiovascular events in the general population 
[189, 190, 179].  The measure of diastolic function chosen was e’:a’ as this is less 
sensitive to change in pre-load [299], an important consideration because of the 
potential influence of obesity in this population, and because it is an independent 
predictor of death [206]. 
The aims of the chapter are to: 
1. Determine the effect of insulin resistance, testosterone and adiponectin on 
cardiovascular measures in women with PCOS. 
2. Determine the effect of BMI on cardiovascular measurements and metabolic 
parameters in women with PCOS. 
3. Explore any association between body composition and insulin resistance  
with cardiovascular function 
4. Explore any association between insulin resistance and cardiovascular 
function adjusted for visceral fat  
 
5.2 Metabolic Parameters and Cardiovascular Function in Women with PCOS 
The PCOS population were initially divided into four groups, according to quartiles 
of HOMA-IR, testosterone and adiponectin.  The mean and standard deviation for 
the chosen cardiovascular measures were calculated for each group.  Comparisons 
were then made between the quartiles. 
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5.2.1 Insulin Resistance 
With increasing quartiles of HOMA-IR, there was an increase in the mean aortic 
PWV, 6.00 m/s, 6.10 m/s, 6.50 m/s and 7.10 m/s.  However, the mean ccIMT was 
similar across the quartiles, 0.49 mm, 0.50 mm, 0.51 mm and 0.50 mm for quartiles 
1 to 4 respectively.  The mean e':a' ratio was lower in quartiles 3 and 4 (1.43 and 
1.56 respectively), than 1 and 2 (1.67 and 1.71 respectively).  Quartiles 1 and 2 had a 
significantly lower aortic PWV when compared to quartile 4, p=0.007 and p=0.014 
respectively.  There were no significant differences across the quartiles with respect 
to ccIMT and diastolic function.  Please see Table 5.1. 
 
Table 5.1 Effect of Insulin Resistance on Cardiovascular Measures in Women 
with PCOS 
Quartile of 
HOMA-IR 
Aortic PWV (m/s) ccIMT (mm) Early:late diastolic 
myocardial velocity 
(e’:a’) 
1 6.00 (0.6) 0.49 (0.06) 1.67 (0.4) 
2 6.10 (0.7) 0.50 (0.08) 1.71 (0.4) 
3 6.50 (0.9) 0.51(0.07) 1.43 (0.4) 
4 7.10 (1.4) 0.50 (0.05) 1.56 (0.4) 
    
1 versus 4 -1.1 (-1.4 – -0.74); 
p=0.007 
-0.01 (-0.008 – -0.01); 
p=0.594 
0.11 (0.082 – 0.093); 
p=0.412 
2 versus 4 -1.0 (-1.3 – -0.7); 
p=0.014 
0.00 (-0.01 – 0.01); 
p=0.775 
0.15 (0.13 – 0.17); 
p=0.308 
3 versus 4 -0.6 (-0.9 – -0.2); 
p=0.151 
0.01 (0.016 – 0.02); 
p=0.375 
-0.13 (-0.17 – - 0.19); 
p=0.363 
Summary measures by quartile are expressed as mean (Standard Deviation).  Comparisons between 
each quartile and the most insulin resistant quartile are expressed as mean and confidence intervals for 
the difference. PWV, pulse wave velocity; ccIMT common carotid intima media thickness 
 
 
5.2.2 Testosterone 
The mean aortic PWV increased within the first three quartiles, 5.90 m/s, 6.41 m/s 
and 6.66 m/s respectively. However, there appeared to be no relationship between 
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testosterone quartile and mean ccIMT or mean e':a'.  There were no significant 
relationships between quartiles of testosterone and the cardiovascular markers.  
Please see Table 5.2. 
 
Table 5.2 Effect of Testosterone on Cardiovascular Measures in Women with 
PCOS 
Quartile of 
Testosterone 
Aortic PWV (m/s) ccIMT (mm) Early:late diastolic 
myocardial velocity 
(e’:a’) 
1 5.90 (0.6) 0.51 (0.07) 1.71 (0.4) 
2 6.41 (1.4) 0.46 (0.11) 1.60 (0.5) 
3 6.66 (1.1) 0.51 (0.07) 1.45 (0.4) 
4 6.62 (1.4) 0.50 (0.06) 1.61 (0.4) 
    
1 versus 4 -0.72 (-1.1 – -0.4); 
p=0.08 
0.01 (0.01 – 0.02); 
p=0.327 
0.1 (0.09 – 0.12); p=0.490 
2 versus 4 -0.21 (-0.22 – -0.20); 
p=0.585 
-0.04 (-0.01 – -0.06); 
p=0.061 
-0.01 (-0.04 – 0.04); 
p=0.493 
3 versus 4 0.04 (-0.9 – 0.17); 
p=0.927 
0.01 (0.007 – 0.02); 
p=0.536 
-0.16 (-0.17 – -0.15); 
p=0.226 
Summary measures by quartile are expressed as mean (standard deviation).  Comparisons between 
each quartile and the highest testosterone quartile are expressed as mean and confidence intervals for 
the difference.  PWV, pulse wave velocity; ccIMT common carotid intima media thickness. 
 
 
5.2.3 Adiponectin 
With increasing quartiles of adiponectin, mean aortic PWV decreased; quartile one, 
6.74 m/s, quartile two, 6.49 m/s, quartile 3, 6.34 m/s and quartile 4, 6.06 m/s.  This 
reached statistical significance for quartile 1 versus quartile 4. The mean ccIMT 
decreased across the four quartiles; quartile one, 0.51mm, quartile two 0.51 mm, 
quartile 3, 0.50 mm and quartile 4, 0.47mm but none of these reached significance.  
There appeared to be no relationship with quartile of adiponectin and e':a' with the 
exception of quartile 3 which was significantly lower than quartile 4.  Please see 
Table 5.3. 
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Table 5.3 Effect of Adiponectin on Cardiovascular Measures in Women with 
PCOS 
Quartile of 
Adiponectin 
Aortic PWV (m/s) ccIMT (mm) Early:late diastolic 
myocardial velocity 
(e’:a’) 
1 6.74 (1.1) 0.51 (0.07) 1.56 
2 6.49 (1.1) 0.51(0.06) 1.56 
3 6.34 (1.0) 0.50 (0.07) 1.46 
4 6.06 (0.8) 0.47 (0.07) 1.77 
    
1 versus 4 0.68 (0.56 – 0.81); 
p=0.053 
0.04 (0.036 – 0.042); 
p=0.067 
-0.21 (-0.23 – -0.19); 
p=0.163 
2 versus 4 0.43 (0.29 – 0.57); 
p=0.198 
0.04 (0.03 – 0.04); 
p=0.087 
-0.21 (-0.25 – -0.17); 
p=0.433 
3 versus 4 0.28 (0.21 – 0.36); 
p=0.534 
0.03 (0.019 – 0.025); 
p=0.285 
-0.31 (-0.37 – -0.25); 
p=0.028 
Summary measures by quartile are expressed as mean (SD).  Comparisons between each quartile and 
the highest adiponectin quartile are expressed as mean and confidence intervals for the difference 
 
 
5.3 Body Mass Index and Metabolic and Cardiovascular Measures in Women 
with PCOS 
Women with PCOS were divided into four groups according to quartile of BMI.  
Mean and standard deviation for each metabolic parameter (HOMA-IR, testosterone 
and adiponectin) and cardiovascular measure (aortic PWV, ccIMT and e’:a’) were 
calculated for each group. Comparisons were made between the lower BMI quartiles 
and the most obese BMI quartile. 
5.3.1 Body Mass Index and Metabolic Parameters 
The mean HOMA-IR increased with increasing quartile of BMI; 3.13, 3.21, 5.68 and 
7.87 for quartiles one to four respectively.  There appeared to be no relationship with 
testosterone and quartile of BMI and this was confirmed when comparing the mean 
difference between quartiles.  Mean adiponectin decreased with increasing quartiles 
of BMI; 17.2 µg/ml, 10.9 µg/ml, 9.1 µg/ml and 4.6 µg/ml.  The lower two quartiles 
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compared to quartile 4 for HOMA-IR and adiponectin revealed significant 
relationships.  The lowest two BMI quartiles were less insulin resistant than the 
highest quartile (p=0.001 for both) and had higher levels of adiponectin (p<0.001 
and p=0.003). A comparison of quartiles 3 and 4 for adiponection also reached 
statistical significance.  Please see Table 5.4. 
 
Table 5.4 Effect of Body Mass Index on Metabolic Parameters in Women with 
PCOS 
Quartile of 
BMI 
HOMA-IR Testosterone 
(nmol/l) 
Adiponectin 
(µg/ml) 
1 3.13 (3.3) 1.58 (0.7) 17.2 (11.3) 
2 3.21 (3.2) 1.62 (0.7) 10.9 (8.2) 
3 5.68 (4.2) 2.37 (1.2) 9.1 (6.2)  
4 7.87 (5.1) 1.99 (0.9) 4.6 (2.5) 
    
1 versus 4 -4.74 (-5.50 – -4.70); 
p=0.001 
-0.41 (-50 – -0.33); 
p=0.166 
12.6 (8.8 – 16.5); p<0.001 
2 versus 4 -4.66 (-6.37 – -2.92); 
p=0.001 
-0.37 (-0.40 – -0.30), 
p=0.219 
6.3 (3.9 – 8.9); p=0.003 
3 versus 4 -2.19 (-2.58 – -1.80); 
p=0.150 
0.38 (0.25 – 0.50); 
p=0.291 
4.5 (2.9 – 6.2); p=0.006 
Summary measures by quartile are expressed as mean (SD).  Comparisons between each quartile and 
the most obese are expressed as mean and confidence intervals for the difference 
 
5.3.2 Body Mass Index and Cardiovascular Function  
With increasing quartiles of BMI there was an increase in mean aPWV; quartile one, 
5.86 m/s; quartile two, 6.09 m/s; quartile three, 6.41 m/s and quartile four, 7.30 m/s.  
Mean ccIMT measurements also increased with increasing quartile; first quartile, 
0.47mm; second quartile, 0.49 mm; third quartile, 0.51 mm and fourth quartile, 0.52 
mm.  Mean e’:a’ ratios decreased with increasing quartile; quartile 1, 2.16;quartile 2,  
1.78; quartile 3, 1.68 and quartile 4, 1.35. 
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Comparisons were made between each quartile and the most obese quartile to see if 
the relationships were significant.  Adjustments were made for age and central pulse 
pressure as these were potential confounding factors.  The lowest three quartiles had 
a significantly lower aPWV than the most obese quartile; quartile 1 versus 4 mean 
difference -1.27 (p<0.001), quartile 2 versus 4 mean difference -1.14 (p<0.001) and 
quartile 3 versus 4 mean difference -0.79 (p=0.009).  There were no significant 
differences between the quartiles when ccIMT was investigated; quartile 1 versus 4 
mean difference -0.25 (p=0.167), quartile 2 versus 4 mean difference -0.11 
(p=0.560) and quartile 3 versus 4 mean difference -0.01 (p=0.947).  The lower two 
quartiles had a significantly higher e’:a’ than the most obese quartile and there was 
no difference between quartiles 3 and 4; quartile 1 versus 4 mean difference 0.72 
(p<0.001), quartile 2 versus 4 mean difference 0.36 (p=0.035) and quartile 3 versus 4 
mean difference 0.30 (p=0.112).  Please see Table 5.5. 
 
Table 5.5 Effect of BMI on Cardiovascular Measures in Women with PCOS 
Quartile of 
BMI 
Aortic PWV (m/s) ccIMT (mm) Early:late diastolic 
myocardial velocity (e’:a’) 
1 5.86 (0.72) 0.47 (0.06) 2.16 (0.54) 
2 6.09 (0.64) 0.49 (0.04) 1.78 (0.61) 
3 6.41 (1.04) 0.51 (0.07) 1.68 (0.43) 
4 7.30 (1.10) 0.52 (0.07) 1.35 (0.34) 
    
1 versus 4 -1.27 (-1.85, -0.70); 
p<0.001 
-0.25 (-0.62, 0.11); 
p=0.167 
0.72 (0.36, 1.08); p<0.001 
2 versus 4 -1.14 (-1.71, -0.57); 
p<0.001 
-0.11 (-0.46, 0.25); 
p=0.560 
0.36 (0.03, 0.69); p=0.035 
3 versus 4 -0.79 (-1.38, -0.21); 
p=0.009 
-0.01 (-0.37, 0.35); 
p=0.947 
0.30 (-0.07, 0.67); p=0.112 
Summary measures by quartile are expressed as mean (SD).  Comparisons between each quartile and 
the most obese are expressed as mean and confidence intervals for the difference  
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5.4 Association of Body Composition and Insulin Resistance with 
Cardiovascular Measures 
Multivariable analyses were undertaken to examine the relationships between 
obesity and insulin resistance with cardiovascular function.  Potential confounders of 
age, height, central pulse pressure and LDL cholesterol were controlled for.  
Interaction terms between PCOS status and the explanatory factors were included in 
the models to see if the relationships varied between PCOS subjects and controls.  
The standardised regression coefficient, 95% confidence interval, p value and the 
percentage variation explained in the models were calculated. 
Body composition markers (log visceral fat area and BMI) were strongly associated 
with diastolic function (e’:a’) and aortic PWV (p<0.0001 for all relationships). There 
was no association between log visceral fat area and BMI with ccIMT (p=0.382 and 
p=0.101 respectively).  The markers of insulin resistance (HOMA-IR and Insulin 
AUC) were strongly associated with diastolic function (e’:a’) and aortic PWV 
(p<0.0001 for all relationships).  The interaction terms were not significant 
suggesting that the relationships between the cardiovascular risk factors and the 
explanatory variables were similar in both the PCOS and HV groups.  There was no 
significant overall association with HOMA-IR and ccIMT (p=0.750).  However, the 
association between insulin AUC and ccIMT varied in the two groups with no 
association seen in the PCOS group (p=0.650) but a strong association in the HV 
group (p=0.009).  Please see Table 5.6. 
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Table 5.6 Associations of Measures of Body Composition and Insulin Resistance with Diastolic Function, Aortic Pulse Wave Velocity 
and Common Carotid Intima-Media Thickness 
 Standardised regression 
coefficient 
95% CI P-value Percentage variation 
explained 
Log visceral fat area     
   E’:a’ -0.386 -0.536, -0.236 <0.0001 48.4 
   Aortic PWV 0.291 0.153, 0.434 <0.0001 32.4 
   Common carotid IMT 0.067 -0.084, 0.217 0.382 31.1 
BMI     
   E’:a’ -0.449 -0.584, -0.315 <0.0001 48.8 
   Aortic PWV 0.383 0.253, 0.513 <0.0001 38.9 
   Common carotid IMT 0.114 -0.022, 0.251 0.101 30.3 
HOMA-IR     
   E’:a’ -0.311 -0.452, -0.171 <0.0001 41.6 
   Aortic PWV 0.298 0.164, 0.432 <0.0001 34.1 
   Common carotid IMT -0.022 -0.159, 0.115 0.750 30.2 
Insulin AUC     
   E’:a’ -0.466 -0.609, -0.323 <0.0001 47.7 
   Aortic PWV 0.304 0.159, 0.449 <0.0001 33.9 
   Common carotid IMT 
   PCOS 
-0.047 -0.252, 0.158 0.650 37.3 
  Common carotid IMT HV 0.323 0.084, 0.562 0.009 31.6 
Percentage variation explained includes age, height, central pulse pressure and LDL cholesterol. E’:a’, early:late mitral velocity ratio; PWV, pulse wave velocity; IMT, 
intima media thickness
104 
 
5.5 Association of Insulin Resistance with Cardiovascular Measures Adjusted 
for Log Visceral Fat 
Further analyses were undertaken to see if adiposity and insulin resistance affected 
cardiovascular function independently of each other.  The results were adjusted on 
insulin sensitivity for log visceral fat.  This adjustment reduced the strength of the 
associations between HOMA-IR and aortic PWV, and insulin AUC and aortic PWV 
which nevertheless remained significant (p=0.015, and p=0.015 respectively). There 
was no longer a significant association between HOMA-IR and diastolic function 
after adjustment for log visceral fat area (p=0.063) but the association between 
insulin AUC and e':a' remained highly significant (P<0.0001).  The associations 
between HOMA-IR and ccIMT, and between insulin AUC and ccIMT in the PCOS 
group remained non-significant (p=0.270 and p=0.548).  The association between 
insulin AUC and ccIMT in the HV group remained, but was less significant 
(p=0.028).  Please see Table 5.7. 
 
Table 5.7 Associations of Markers of Insulin Resistance with Cardiovascular 
Measures Adjusted for Log Visceral Fat Area 
 Standardised 
regression 
coefficient 
95% CI p-value 
HOMA-IR    
   E’:a’ -0.099 -0.180, 0.005 0.063 
   Aortic PWV 0.214 0.043, 0.385 0.015 
   Common carotid IMT -0.099 -0.274, 0.077 0.270 
Insulin AUC    
   E’:a’ -0.173 -0.266, -0.080 <0.0001 
   Aortic PWV 0.214 0.042, 0.385 0.015 
   Common carotid IMT 
PCOS 
-0.076 -0.329, 0.176 0.548 
   Common carotid IMT  
HV 
0.314 0.035, 0.593 0.028 
E’:a’, early:late mitral velocity ratio; PWV, pulse wave velocity; IMT, intima media thickness 
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5.6 Summary of Results 
In the PCOS group, there was a significant relationship between HOMA-IR and 
aortic PWV, but no relationship between testosterone and adiponectin with 
cardiovascular measures.  This would suggest that worsening insulin resistance was 
associated with arterial stiffness.  With increasing quartiles of BMI, mean HOMA-IR 
increased and adiponectin decreased suggesting that, as expected, more obese 
women with PCOS are more insulin resistant and have lower levels of adiponectin.  
There appeared to be no clear relationship with testosterone and BMI in PCOS 
women.   
Mean aortic PWV and ccIMT increased with increasing quartiles of BMI in the 
PCOS group suggesting that obesity was associated with worse cardiovascular 
function.  Diastolic function decreased with increasing quartiles of BMI.  There was 
a significant difference across the lower three quartiles with the most obese quartile 
for aortic PWV and diastolic function (except quartile 3 compared to quartile 4 for 
diastolic function) but no significant differences between the groups with respect to 
ccIMT.  Increasing BMI in women with PCOS appeared to be associated with stiffer 
arteries and worse diastolic function but there was no effect on ccIMT. 
In multivariable analyses, body composition and insulin resistance measures were all 
significantly associated with aortic PWV and diastolic function, after controlling for 
the potential confounding influences of age, height, central pulse pressure and LDL-
cholesterol.  There was no association between log visceral fat, BMI, HOMA-IR and 
ccIMT.  Insulin AUC was associated with ccIMT in the healthy volunteers but not in 
the PCOS group.   
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Further adjustments for log visceral fat area revealed that the strengths of the 
associations between measures of insulin resistance and both aortic PWV and 
diastolic function were reduced but remained significant. This suggests that insulin 
resistance may be contributing to increased arterial stiffness and diastolic 
dysfunction independently of visceral fat.   
 
5.7 Discussion 
In this study, central arterial stiffness and diastolic dysfunction were associated with 
insulin resistance and abdominal obesity in young women.  It is likely that insulin 
resistance and abdominal obesity exert effects on cardiovascular function that are at 
least in part mediated independently of each other.  PCOS does not appear to confer 
any additional cardiovascular risk in young women.  Adiponectin and testosterone do 
not appear to be conferring any protection against cardiovascular risk in young 
women with PCOS. 
Some studies have demonstrated that women with PCOS have stiffer arteries [164, 
166, 200] than controls whereas others, like mine, have found no difference in 
arterial stiffness between women with PCOS and controls [201, 202, 203].  These 
differing results may be due to small numbers of subjects, failure to adjust fully for 
obesity, or estimating stiffness in a single arterial territory.  Previous studies have 
used simple anthropometric measures to assess adiposity whereas in this study CT 
was incorporated, a more accurate and precise measure of regional fat distribution.  
DEXA was also used to assess lean mass and fat mass, as a higher BMI can reflect a 
greater lean mass as well as increased fat.  This study has demonstrated that central 
obesity is associated with arterial stiffness in women with PCOS but this is not 
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affected by the syndrome itself.  This is in agreement with Ketel et al [201] who 
used waist circumference as an indicator of central obesity whereas this study used 
CT.  Ketel et al did not make an assessment of insulin resistance in their study [201] 
whereas this study did and found that insulin resistance was having an independent 
effect on arterial stiffness.  Cussons et al, in agreement with my study, found no 
difference in arterial stiffness (assessed by PWV and Ai) between PCOS women and 
controls but did find that flow-mediated dilatation (FMD) was reduced in the PCOS 
group [203].  This group did not demonstrate any difference in markers of insulin 
resistance between the PCOS women and controls but did find elevated androgens in 
the PCOS group and attributed the difference in FMD to the androgens [203].  
Meyer et al found that women with PCOS had stiffer arteries and were more insulin 
resistant than controls; they demonstrated that in women with PCOS, insulin 
resistance was making an independent contribution to the variance in PWV [164].  In 
this study, the PCOS group were significantly more insulin resistant and had higher 
testosterone levels that the HV group. Insulin resistance was independently 
associated with arterial stiffness but testosterone had no significant association with 
arterial stiffness. 
There was no significant difference in ccIMT between the PCOS group and HVs in 
adjusted or unadjusted analyses.  These results are in agreement with those of Talbott 
et al [187] whose PCOS population had a mean testosterone of 1.6mmol/l similar to 
our own.   Studies reporting a greater ccIMT in PCOS women had higher mean 
testosterone values [180-182] than this study, but had used less sensitive methods 
than the mass spectrometry method adopted here to measure testosterone.  
Vryonidou et al have suggested that hyperandrogenism partly attenuates the 
difference in ccIMT that they found between PCOS women and controls [184].  
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However, I did not find any association between ccIMT and testosterone.  The mean 
testosterone level was higher in the Vryonidou et al study but they used less 
sensitive methods to measure testosterone than I did.   No association was found 
between insulin resistance or body composition with ccIMT in my study, except for 
insulin AUC in the HV group.  This is in agreement with Soares et al who also failed 
to demonstrate a difference in ccIMT between PCOS women and healthy controls 
and found no difference in markers of insulin resistance between the two groups 
[166].   Vryonidou et al found no association between insulin resistance and ccIMT 
but did with BMI and ccIMT [184].   
There were no difference in echocardiographic measures between PCOS women and 
HVs in this study. However, diastolic function was associated with insulin resistance 
and central adiposity.  Kosmala et al [312] also found that impaired systolic and 
diastolic function were associated with insulin resistance in young, obese women 
with PCOS.  In this study, lean women with PCOS were also included and therefore 
adds knowledge to the Kosmala et al study.  Yarali et al also found that fasting 
insulin level correlated negatively with e’:a’ ratio and have suggested that there is an 
association between insulin resistance and diastolic dysfunction in women with 
PCOS [208].   
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CHAPTER 6: Discussion 
 
6.1 Background 
Polycystic ovary syndrome (PCOS) is characterised by hyperandrogenism, ovarian 
dysfunction and polycystic ovaries.  The pathogenesis is debated but insulin 
resistance is thought to play a role.  It is a common condition, affecting 4-20% of 
pre-menopausal women depending on criteria used for diagnosis and ethnicity.   
Many cardiovascular risk factors have been documented to occur in the PCOS 
population including hypertension [61], dyslipidaemia [59, 60, 134], insulin 
resistance [57, 83, 84], type 2 diabetes [67, 75-82, 100] and impaired glucose 
tolerance [75-82].  Due to the presence of these cardiovascular risk factors, it is 
expected that women with PCOS are at greater risk of cardiovascular disease than 
women without the syndrome.   
Three large prospective cohort studies have found an increased risk of cardiovascular 
events in women reporting a history of clinical features of PCOS [70-72].  A 
retrospective cohort study found increased odds ratio for the prevalence of 
myocardial infarction (MI) and angina in women with PCOS compared to the local 
female population; this was highest in women over the age of 65 years [148].  A 
meta-analysis in 2011, found the relative risk for coronary heart disease or stroke 
was 2.02 in women with PCOS compared to female controls [73]; this was reduced 
to 1.55 following adjustments for BMI [73]. However, two long-term follow-up 
studies failed to find a difference in the number of cardiovascular events between 
women with PCOS and controls [41, 147]. Work by our own group looked at a large 
community-based database and found no increased risk of large vessel disease in 
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women with PCOS [67].  A meta-analysis in 2014, found an increased risk of non-
fatal stroke in women over 45 years but this observation did not remain after 
adjustment for BMI [146]; there was no significant increased risk of MI [146].   
There may be an excess of cardiovascular events in older women with PCOS but 
there is no evidence currently of increased cardiovascular events in young women 
with PCOS.  
Subclinical cardiovascular disease can be assessed by measuring endothelial 
dysfunction, carotid intima-media thickness (cIMT), arterial stiffness and myocardial 
dysfunction.  Some [164, 165, 168] but not all [166, 167, 169-171] studies have 
found evidence of endothelial dysfunction in women with PCOS.   Evidence of 
increased cIMT in women with PCOS has been demonstrated in some studies [180-
185, 188].  However, others have failed to find any increased cIMT in women with 
PCOS [166, 186]; one study only found evidence of increased cIMT in older women 
with PCOS [187].   Arterial stiffness in women with PCOS has been demonstrated in 
some studies [164, 166, 200] but not in others [201-203].  Some studies have 
reported impaired diastolic function in women with PCOS compared to controls 
[180, 208] but others have not [209, 312]. 
Obesity is common in women with PCOS [56] and is itself a risk factor for 
cardiovascular disease.  It is difficult to determine whether any cardiovascular risk in 
young women with PCOS is due to the syndrome itself or to obesity.  Some people 
with obesity appear to be metabolically healthy and not at increased risk for 
cardiovascular disease [212, 213] whilst others are metabolically unhealthy and are 
at increased risk for cardiovascular disease.  The distribution of body fat is important 
as visceral adiposity is an independent risk factor for cardiovascular disease [112-
114].  There is some evidence to suggest women with PCOS may have greater 
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central adiposity than controls [56, 118]; however, Barber et al, using magnetic 
resonance imaging (MRI), the gold standard for measuring fat distribution, failed to 
find any evidence of increased visceral fat in women with PCOS compared to 
matched controls [119].   
Possible mechanisms by which obesity contributes to cardiovascular disease are 
unclear but secretion of adipocytokines may play a role.  Some adipocytokines have 
been associated with endothelial dysfunction and oxidative stress which contribute to 
the development of atherosclerosis [220].  Hyperinsulinaemia and insulin resistance 
have also been associated with altered adipocytokine secretion [235, 220].  Insulin 
resistance itself increases the risk for coronary artery disease [250] and has been 
shown to alter large artery compliance [253] and affect endothelial function [254].    
Although obesity is common in PCOS it is not universal [56].  Insulin resistance is 
also common in PCOS [57, 83, 84] and is present in non-obese and obese women 
with PCOS [84].    
In light of these considerations, this study sought to determine whether there was 
increased cardiovascular risk in young women with PCOS which was independent of 
obesity.  The relationships between insulin resistance and cardiovascular function, 
and body composition and cardiovascular function were also explored. 
 
6.2 Discussion of Results 
This study has shown that arterial stiffness, carotid intima-media thickness and 
diastolic function are not increased in young women with PCOS compared to 
healthy volunteers, after careful adjustment for age and BMI.  In this population, 
there was a positive association between insulin resistance and visceral adipose 
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tissue with central arterial stiffness and an inverse association of these measures with 
diastolic function.  The association was reduced but still remained significant for 
insulin resistance and both central arterial stiffness and diastolic dysfunction after 
adjusting for log visceral fat.  This suggests that insulin resistance and visceral fat 
were mediating an effect on the cardiovascular measures, independently of each 
other.  
Some studies have demonstrated that women with PCOS have stiffer arteries [164, 
166, 200] than controls whereas others, like mine, have found no difference in 
arterial stiffness between women with PCOS and controls [201-203].  These 
differing results may be due to small numbers of subjects, failure to adjust fully for 
obesity, or estimating stiffness in a single arterial territory.  Previous studies have 
used simple anthropometric measures to assess adiposity whereas this study 
incorporated CT, a more accurate and precise measure of regional fat distribution.  
This study has demonstrated that central obesity is associated with arterial stiffness 
in women with PCOS but arterial stiffness is not affected by the syndrome itself.  
This is in agreement with Ketel et al [201] who used waist circumference as an 
indicator of central obesity.  Central adiposity is a risk factor for cardiovascular 
disease in other populations [112-114]. Central adiposity has also been shown to be 
associated with increasing arterial stiffness in the elderly [313] and in healthy 
children [314].  Possible mechanisms for central adiposity to cause arterial stiffness 
include an unfavourable adipocytokine profile and/or insulin resistance. 
In this study population, insulin resistance was associated with arterial stiffness 
independently of visceral fat. Markers of insulin resistance, HOMA-IR and insulin 
area under the curve (IAUC), were significantly higher in the PCOS group after 
adjustments for age and BMI.  This is consistent with other studies in the literature 
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[19, 58, 84].  Insulin resistance disrupts insulin signalling pathways [252], resulting 
in a reduction in nitric oxide and a relative increase in endothelin-1.  Both of these 
alterations may contribute to the development of atherosclerosis, as demonstrated in 
mice [251].  Hyperinsulinaemia has been shown to promote smooth muscle cell 
growth, endothelial dysfunction, oxidative stress and activate the sympathetic 
nervous system [315] which could all contribute to increased arterial stiffness.  The 
finding that insulin resistance persists in women with PCOS compared to HV after 
adjustment for BMI and age, is potentially an important finding as it could provide a 
link between PCOS and cardiovascular disease independently of BMI.   
There was no significant difference in ccIMT between the PCOS group and HVs in 
adjusted or unadjusted analyses.  These results are in agreement with those of Talbott 
et al [187] whose PCOS population had a mean testosterone of 1.6mmol/l similar to 
our own.   It is unclear whether testosterone is protective or detrimental to 
cardiovascular health.  When quartiles of testosterone were examined in the PCOS 
group, there were no significant relationship with cardiovascular measures and 
therefore in this group testosterone does not appear to be playing a role in 
cardiovascular risk in women with PCOS.  There was no association between insulin 
resistance or body composition with ccIMT. 
This study did not demonstrate any differences in echocardiographic measures 
between PCOS and HVs.  Some studies have reported impaired diastolic function in 
women with PCOS compared to age- and BMI- matched controls [180, 208] while 
others have not [209].  Differing results may be in part due to the lack of sensitivity 
of traditional left ventricular echocardiographic measures used.  There was an 
association with insulin resistance and visceral adiposity with diastolic heart function 
in my study.  Kosmala et al [312] also found that impaired systolic and diastolic 
114 
 
function were associated with insulin resistance in young, obese women with PCOS.   
Hyperinsulinaemia could potentially cause cardiac hypertrophy through myocyte 
growth and interstitial fibrosis, resulting in cardiac dysfunction. Obesity results in 
increased blood volume and blood pressure which can lead to compensatory cardiac 
hypertrophy and in time to cardiac dysfunction.                          
                                                          
6.3 Study Limitations 
There are a number of limitations in this study.  The study was cross-sectional in 
design; therefore the possibility that the association seen between fat distribution, 
hyperinsulinaemia and cardiovascular dysfunction was mediated by an unmeasured 
common underlying factor cannot be discounted. This study does not give insight 
into the mechanisms causing cardiovascular dysfunction; it could be postulated that 
insulin resistance and central adiposity were influencing cardiovascular dysfunction 
independently of each other and therefore there may be more than one mechanism 
involved. 
Selection bias may have influenced our results.   Recruitment of PCOS women who 
by chance were healthier than non-enrolled PCOS women (bias towards the null) 
may have happened.  This is because women with a history of diabetes, 
hypertension, dyslipidaemia or medication for these were excluded from 
participating.  If women with these cardiovascular risk factors had been included, a 
difference in cardiovascular function between the two groups may have been found.  
The more inclusive Rotterdam criteria for diagnosis of PCOS were used in this study 
and may have resulted in the recruitment of women with milder phenotypes of the 
syndrome.  A ‘healthy worker’ effect (bias away from the null) may have occurred 
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as some of the volunteers were recruited from medical staff and students at our 
institution. Due to the nature of their studies and work, they may have been more 
likely to have increased knowledge and awareness of cardiovascular disease than the 
general population.  If this knowledge was put into practice then they may have been 
healthier than the general population.  
The intention was to age- and BMI-match PCOS subjects with HVs but this was not 
achieved; however, these potential confounding factors were adjusted for carefully in 
statistical analyses to avoid any influence they may have had on cardiovascular 
outcome measures. Obesity itself is associated with hypertension, dyslipidaemia, 
diabetes and impaired glucose tolerance and therefore may have contributed to the 
difficulty of recruiting obese, ‘healthy’ volunteers.  Obese women may be less likely 
to volunteer to participate in research studies than women with a normal BMI 
whereas obese women with PCOS may be more likely to participate as they have a 
medical diagnosis and hope to benefit their own health.  Initially, healthy volunteers 
were recruited from our institution. Young students participated and there was no 
difficulty in age-matching at that time, although there was difficulty in BMI-
matching.  As recruitment was widened to the local community, the age of healthy 
volunteers increased.  It may be that older women were more likely to take part as 
they had concerns about their health and were less likely to be responsible for the 
care of young children.  As young women with PCOS were included in this study, 
the findings cannot be extrapolated to older women with PCOS. 
The majority of women enrolled in the study were Caucasian; however, significantly 
more ethnic minority groups were represented in the PCOS group.  Asian and 
Middle Eastern populations are more at risk of developing diabetes than Caucasians.  
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This could have influenced the outcome of the study but the numbers were relatively 
small and therefore analyses were not undertaken excluding these women. 
The amount of physical activity undertaken by the subjects was not assessed and this 
could have been a confounding factor.  It is possible that women with PCOS were 
more physically active than the HVs thus offering them some cardiovascular 
protection. 
A basic smoking history was taken to ascertain whether the subjects were current or 
ex-smokers as smoking is a risk factor for cardiovascular disease.  Smoking pack 
year history was not assessed; this is a weakness in the study as some women may 
have had a greater lifetime exposure to cigarette smokers than others.  
Women were identified to have diabetes or impaired glucose tolerance in both the 
PCOS group and HV group.  This was unknown pathology and the women were not 
excluded from analyses.  It could be that this affected the results, especially as there 
was a significant difference between the two groups.  However, as there was no 
difference in cardiovascular function between the two groups it is unlikely to have 
had a significant effect. The models exploring body composition and insulin 
resistance markers with cardiovascular function did not find any differences between 
the groups except for insulin area under the curve and cIMT in the HVs.   
It is not possible to completely exclude an association between PCOS and arterial 
stiffness or diastolic function because of the sample size.  However, this is one of the 
largest studies on cardiovascular function in PCOS ever conducted, suggesting that 
any effects of the syndrome on these cardiovascular measures independent of 
obesity, if present, are likely to be small. 
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6.4 Implication of Results on Clinical Practice 
This study has shown that a diagnosis of PCOS itself does not increase 
cardiovascular risk in young women with PCOS.  Further studies are needed to 
confirm this, but it is reassuring information for the healthcare provider to give to the 
patient.  However, this study has shown that central obesity and insulin resistance are 
associated with cardiovascular risk in young women, and patients should be 
counselled regarding this. 
Obesity and central adiposity can be easily measured in clinic by measuring BMI 
and waist circumference.  These are of low cost and do not expose the patient to 
radiation.  They can be repeated to assess the effectiveness of any interventions.  
Insulin resistance is harder to assess in the clinical setting.  A fasting glucose and 
fasting insulin sample are needed to calculate HOMA-IR and although this is 
feasible it does require patients to be fasted.  Assessing patients for the development 
of diabetes and impaired glucose tolerance is most easily done by measuring 
glycated haemoglobin.  However, this study and others [109, 110] have shown that 
this misses a significant number of cases and the clinician needs to be aware of the 
limitations of this test.  An oral glucose tolerance test (OGTT) is the best method but 
is inconvenient and costly for the healthcare provider and patient.  OGTTs should be 
performed at diagnosis and in high risk groups in the PCOS population as suggested 
in the NICE guidelines [107].  Women with PCOS should be strongly advised and 
encouraged to maintain a normal BMI (less than 25 in Caucasians and less than 23 in 
Asians) and waist circumference (less than 80 centimetres). 
Interventions to assist weight loss, reduce central adiposity and improve insulin 
resistance in women with PCOS include lifestyle measures (diet and exercise) and 
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medication such as orlistat, glucagon-like peptide-1 (GLP-1) mimetics and 
metformin.  Lifestyle intervention is recommended as the first line treatment for 
prevention of cardiovascular disease by the AE-PCOS society [316].  Calorie 
restriction can reduce BMI, abdominal obesity and insulin resistance in women with 
PCOS [317-319].  A 24 week structured exercise program consisting of three 
supervised 30 minute sessions on a bicycle ergometer with a target of 60-70% of 
maximal oxygen consumption resulted in reduction in weight, BMI, waist 
circumference and an improvement in insulin resistance indices in obese PCOS 
women [319].  However, Hutchinson et al found no change in weight or waist 
circumference with their exercise intervention program (12 weeks of three 
supervised, intensive one hour training sessions) but did find a significant 
improvement in insulin resistance, a reduction in visceral fat mass and triglycerides 
in obese PCOS women [320].  Two systematic reviews and meta-analyses have 
confirmed that lifestyle intervention in women with PCOS reduces weight and waist 
circumference and improves insulin resistance [321, 322].  Sprung et al found an 
improvement in endothelial function (measured by flow-mediated dilatation) in 
overweight and obese women with PCOS using a 16 week moderate-intensity 
aerobic exercise training program which was independent of improvements in body 
composition and insulin resistance [323].  They also found that compared to obese 
controls, women with PCOS had defective microvascular function which improved 
with a supervised 16 week moderate-intensity aerobic exercise program via the up 
regulation of nitric oxide [324].  In addition to the benefits to cardiovascular health 
outlined above, regular exercise also improves reproductive function [319] and 
cardiorespiratory fitness [325].  Women with PCOS should be strongly encouraged 
to undertake regular aerobic exercise even if weight loss is not achieved. 
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Orlistat and Liraglutide are the only licensed medications for weight loss in the UK.  
Orlistat is an established medication and has been shown to reduce weight in women 
with PCOS [326].  Liraglutide, a glucagon-like peptide-1 (GLP-1) mimetic, has very 
recently received a licence for weight loss in the UK.  Several studies have 
demonstrated that liraglutide is effective in reducing weight in women with PCOS.  
One observational study of 84 obese and overweight PCOS women, who had failed 
to lose weight with metformin and lifestyle intervention, found a mean weight loss 
of 9 kilograms when treated with liraglutide [327].  A further observational study of 
36 obese PCOS women treated with liraglutide for 12 weeks, found a mean weight 
loss of 3.8 kilograms and significant improvement in uncontrolled eating and 
emotional eating scores [328].  Liraglutide in combination with metformin resulted 
in greater weight loss and reduction in waist circumference than metformin or 
liraglutide alone in a randomised open-label study in obese PCOS women [329].  Six 
months treatment with liraglutide has also been shown to significantly reduce 
procollagen type III amino-terminal peptide (PIIINP), an early marker of liver 
fibrosis, in obese women with PCOS [330]. These women had also lost weight and 
therefore the reduction in PIIINP may have been related to the weight loss or the 
liraglutide treatment or a combination of the two.  There is a potential risk of 
developing medullary thyroid cancer with liraglutide treatment, careful discussion 
with the patient should be undertaken before prescribing it for weight loss in women 
with PCOS.  Exenatide, another GLP-1 has also been shown to reduce weight in 
women with PCOS [331] but does not have marketing authorisation for weight loss 
in the UK. 
Metformin has been shown to reduce weight and/or waist circumference in women 
with PCOS in some [332, 333] but not all studies [334].  Work, by our own group 
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and Diamanti-Kandarakis et al found that metformin reduces arterial stiffness and/or 
improves endothelial function in women with PCOS [332, 335].  Metformin has also 
been shown to revert some women with PCOS and IGT to normal glucose tolerance 
[336] and reduce circulating CRP [337].  Metformin is safe in pregnancy and 
consideration should be given to prescribing this for PCOS women at higher risk of 
cardiovascular disease. 
Attention should also be given to other modifiable cardiovascular risk factors; PCOS 
patients should be discouraged from smoking; blood pressure and lipid profiles 
should be assessed regularly and treated as needed.   
 
6.5 Future Studies 
This study looked at young women with PCOS and it could be that the population 
had yet to develop subclinical cardiovascular disease.  Increasing age is associated 
with increased cardiovascular risk.  In order to establish if cardiovascular events are 
affected in older women with PCOS, a sample of older women with PCOS and HVs 
should be investigated.  Alternatively, this cohort of patients and healthy volunteers 
should be followed up in the future but results would not be available for many 
years.  Larger and prospective longitudinal studies would also be useful to confirm if 
the findings of this study are reflected in an ongoing absence of an increase in 
cardiovascular risk.    
As PCOS is a heterogeneous disorder, larger studies, sufficiently powered to look at 
subgroups within the PCOS population, are needed to identify who is most likely to 
develop cardiovascular risk factors and disease. This would help clinicians stratify 
who was at greatest risk and who would benefit most from intervention.  This is 
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particularly important as PCOS is very common and potentially poses a large burden 
on the National Health Service.   
Testosterone could be protective or detrimental in cardiovascular health and a study 
specifically designed to examine whether women with PCOS are offered some 
cardiovascular protection or not from testosterone should be undertaken.   
 
6.6 Conclusion 
This is the first study to comprehensively assess the relationships between carotid 
intima-media thickness, arterial stiffness, myocardial function, metabolic 
abnormalities and regional fat distribution in women with PCOS.  It demonstrates 
that central arterial stiffness and diastolic dysfunction are not increased in young 
women with PCOS compared to healthy volunteers, after adjustment for age and 
BMI.  Insulin resistance and visceral adipose tissue are associated with arterial 
stiffness and diastolic dysfunction in young women and are likely to exert their 
effects on cardiovascular risk independently of each other.  This extends the 
understanding of cardiovascular risk in young women with PCOS.  Further studies 
are needed to establish whether young women with PCOS are protected from 
cardiovascular dysfunction by an unknown factor related to the syndrome.  Central 
obesity and insulin resistance are modifiable risk factors for cardiovascular disease 
in young women with PCOS, and lifestyle measures which target weight loss remain 
crucially important in disease management. 
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Appendix 1 
 
 
VISCERAL FAT AND VASCULAR RISK IN POLYCYSTIC OVARY SYNDROME 
 
PATIENT INFORMATION SHEET 
(Version 2 September 2008) 
 
1. Title of study 
 
Stratification of cardiometabolic risk in Polycystic Ovary 
Syndrome: is visceral fat a major player? 
 
2. Introduction 
 
You are being invited to take part in a clinical research study. 
This study will also form part of a higher degree (MD) 
educational qualification. Before you decide whether you wish to 
become involved it is important that you understand why the 
research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with 
others if you wish. Please do not hesitate to ask us if there is 
anything that is not clear or if you would like more information. 
Take time to consider whether or not you would wish to take 
part. 
 
Thank you for reading this. 
 
3. What is the purpose of this study? 
 
Polycystic ovary syndrome (PCOS) is the commonest hormone 
condition in women of reproductive age, affecting up to 10% of 
the premenopausal population. In addition to its well-recognised 
effects on weight gain, excessive hair growth and infertility, it is 
becoming increasingly clear that PCOS is associated with long-
term health risks including diabetes and arterial (blood 
vessel)/heart muscle disease, both of which are related to 
impaired action of insulin throughout the body, also known as 
insulin resistance.  
 
There is increasing evidence that a major underlying cause of 
insulin resistance is a build up of a particular type of fat around 
the bowel called visceral fat. There have not been any studies on 
the relationship between visceral fat and arterial disease (or 
‘stiffness’) or heart muscle function in young women with PCOS, 
but this may be an important area to study as research in 
middle-aged women with PCOS has shown that visceral fat is 
associated with increased ‘furring’ of the arteries in the neck, 
which is a marker for early heart disease. 
  
We aim to measure visceral fat area in women with PCOS and 
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relate this to arterial stiffness and heart muscle function.  
 
This study will involve two visits to the Clinical Research Facility 
and the Welsh Heart Research Institute at the Heath hospital, 
each lasting 2-3 hours or one visit lasting 6 hours.  
 
4. Why have I been chosen? 
 
You have been chosen for this study as your doctor has 
identified you as having PCOS. A total of 100 patients and 100 
healthy volunteers will be studied. 
  
5. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide 
to take part you will be given this information sheet to keep and 
be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. 
A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive.   
 
6. What will happen to me if I take part? 
 
The study will take place at the Clinical Research Facility and the 
Welsh Heart Research Institute at the University Hospital of 
Wales. You will be asked to attend in the morning having only 
had water to drink (i.e. no breakfast, tea or coffee) on 2 separate 
days. Each visit will last approximately 2-3 hours. If you are a 
smoker we request that you avoid smoking on each morning. 
 
We will firstly require you to have a pregnancy test before 
carrying out any measurements. 
 
We will then measure your weight, height, blood pressure, waist 
circumference, hip circumference and take a brief clinical history. 
We will take blood samples (approximately four tablespoons) to 
check levels of ‘fat’ proteins (called adiponectin, PAI-1 and RBP-
4), blood vessel proteins (called BNP, ICAM-1, VCAM-1 and 
TBARS) and to measure cholesterol, insulin, glucose and CRP 
(a marker of inflammation in the body). We will also measure a 
urine sample for a substance called 8-epi-PGF2, which is a 
marker of cholesterol damage.  
 
Next we will measure the amount of visceral fat in your body by 
three techniques: the BIA (bioimpedance) method, DEXA and 
CT scanning. The BIA technique is a simple, rapid and non-
invasive technique which is used routinely in clinical practice to 
measure a patient’s percentage body fat. It sends a very small 
electrical current through the body and measures the body’s 
resistance to this current to determine the amount of fat, muscle 
and water present. The amount of electrical current is so small 
that you will be unable to feel it. The DEXA scan is also a simple, 
rapid and non-invasive technique which is used routinely in 
clinical practice. This scan does involve a very small dose of 
radiation, equivalent to what you would be exposed to simply by 
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living in Cardiff for 1 day. A CT scan will then be performed. 
Unlike CT scans used in medical practice this will be a single 
image (or ‘slice’) only, taken at the level of your lower spine. This 
will give us enough information to measure the amount of 
visceral fat present, while minimising your exposure to radiation. 
The amount of radiation you will receive is very small and similar 
to what you would be exposed to simply by living in Cardiff for 1 
week. 
 
We will then measure the stiffness of your blood vessels and 
your heart muscle function. The ‘arterial stiffness’ test will be 
performed using an item of equipment called a ‘Sphygmocor’ 
machine. This technique, which is completely painless and ‘non-
invasive’, consists of a small pencil-like probe placed over the 
wrist, which measures the waveform of the pulse. Further 
measurements will be obtained over pulses in the neck (the 
carotid artery) and top of the leg (femoral artery). The ‘heart 
muscle’ test will be performed at the Welsh Heart Research 
Institute using a technique called echocardiography. This is a 
painless non-invasive ultrasound technique used routinely in 
clinical practice to give pictures of the heart muscle and 
chambers within the heart. It uses a very high frequency sound 
which cannot be heard, but can be emitted and detected by 
special machines. 
 
Finally we will ask you to attend the Clinical Research Facility on 
a second morning for an oral glucose tolerance test (OGTT). 
This will assess how good your body is at handling sugar 
(termed ‘insulin resistance’). We request that you attend in the 
morning having only had water to drink (i.e. no breakfast, tea or 
coffee). We will take a blood test from you (roughly one 
tablespoon) then we will ask you to take a drink containing a 
measured amount of glucose. Further blood samples (at 30, 60 
and 90 minutes) will be taken during the test and a final test is 
taken at two hours. Each blood sample will be roughly one 
tablespoon.       
 
If you wish we will be able to reimburse any travelling expenses / 
car parking fees incurred while attending for the study visits. 
 
7. What do I have to do? 
 
It is important that you take your regular medication in the 
normal way without altering the dose or timing of these. You 
should inform us of any dose adjustments.  
 
There are no lifestyle or dietary restrictions and you can continue 
your daily activities normally. We request that you report any 
illnesses to us as they may influence the timing of your test visit.  
 
You should inform us if there is any possibility of you being 
pregnant and this will be tested for in all participants. If you are 
pregnant you will not be able to participate in this study.  
 
For the study visits, we ask that you attend the Clinical Research 
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Facility at 8 o’clock in the morning having fasted from midnight 
the previous night. You can drink water freely up to this point.  
 
8.  What are the possible disadvantages and risks of taking 
part? 
 
Other than possible discomfort (temporary pain, swelling, 
bruising and rarely infection) caused by the collection of blood, 
no other side effects are anticipated from the study procedures, 
though as outlined above, a ‘single slice’ CT scan and DEXA 
scan do involve exposure to a small amount of radiation. In 
addition the CT scan could by chance pick up an unsuspected 
abnormality in your abdomen, in which case you will be given an 
opportunity to discuss these findings further with Dr Aled Rees. 
Similarly, the echocardiogram and blood tests may pick up 
unsuspected abnormalities in which case you will again be given 
an opportunity to discuss these findings further with Dr Rees. 
 
 
9. What are the potential benefits of taking part? 
 
There are unlikely to be any direct benefits for you but the study 
may provide us with important information in determining 
whether visceral fat could be important in the development of 
arterial disease and heart muscle dysfunction in women with 
PCOS. It may therefore be possible in future to use treatments 
which reduce visceral fat to prevent the development of arterial 
disease in patients with PCOS. 
 
10.  Will I be able to have the results of my tests? 
 
We will contact you if there are any unsuspected abnormalities in 
your test results and you will be given an opportunity to discuss 
these findings with Dr Aled Rees.  If you wish to have all your 
test results (including normal results), we will be able to provide 
these for you on your request. 
 
11.  What if something goes wrong? 
 
This study is being indemnified by Cardiff University. If you are 
harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated during the course of 
this study, the normal National Health Service complaints 
mechanisms should be available to you.  
 
12. Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of 
the research will be kept strictly confidential. Any information 
about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it. With 
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your permission your GP will be informed of your participation in 
this study. With your permission we may also look at sections of 
your medical notes which are relevant to the research study.  
 
13. What will happen to the results of the research study? 
 
The results of the research study will be prepared for publication 
in appropriate medical journals together with presentation at 
medical conferences. Patients participating in the study will be 
able to obtain a copy of the results after they have been 
published in the relevant journal(s). Patients will not be identified 
in any report/publication.  
  
14. Who is organising and funding the research? 
 
The study is being organised by Dr Aled Rees (the Principal 
Investigator) and Dr Rosie Hocking (Research Registrar) from 
the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. Funding for the study is provided 
from funds within the Centre for Endocrine and Diabetes 
Sciences at the University Hospital of Wales. The doctors 
conducting the research are not being paid for including and 
looking after patients in the study. 
 
15. Who has reviewed the study? 
 
The study has been reviewed by the Cardiff and Vale NHS Trust 
Research and Development Office and by the South Wales 
Research Ethics Committee. 
 
 
16. Contact for further information 
 
Should you have any further queries regarding this research 
study, then please do not hesitate to contact me on 02920 
742341. You can also contact me via e-mail on 
reesda@cf.ac.uk.  Or you can contact Dr Rosie Hocking by 
email hockingrk1@cardiff.ac.uk or on 02920748251 or 
07866771280. 
 
Thank you for considering taking part in this study. 
 
 
 
Dr Aled Rees 
Senior Lecturer in Endocrinology 
 
 
You will be given a copy of this Patient Information Sheet and a 
signed consent form to keep 
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Appendix 3: Healthy Volunteer with Higher BMI Recruitment Advert 
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Appendix 4 
 
 
VISCERAL FAT AND VASCULAR RISK IN POLYCYSTIC OVARY SYNDROME 
 
 
HEALTHY VOLUNTEER INFORMATION SHEET 
(Version 4 March 2010) 
 
1. Title of study 
 
Stratification of cardiometabolic risk in Polycystic Ovary Syndrome: 
is visceral fat a major player? 
 
2. Introduction 
 
You are being invited to take part in a clinical research study. This 
study will also form part of a higher degree (MD) educational 
qualification.  Before you decide whether you wish to become 
involved it is important that you understand why the research is 
being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you 
wish. Please do not hesitate to ask us if there is anything that is not 
clear or if you would like more information. Take time to consider 
whether or not you would wish to take part. 
 
Thank you for reading this. 
 
3. What is the purpose of this study? 
 
Polycystic ovary syndrome (PCOS) is the commonest hormone 
condition in women of reproductive age, affecting up to 10% of the 
premenopausal population. In addition to its well-recognised 
effects on weight gain, excessive hair growth and infertility, it is 
becoming increasingly clear that PCOS is associated with long-
term health risks including diabetes and arterial (blood vessel) 
disease, both of which are related to impaired action of insulin 
throughout the body, also known as insulin resistance.  
 
There is increasing evidence that a major underlying cause of 
insulin resistance is a build up of a particular type of fat around the 
bowel called visceral fat. There have not been any studies on the 
relationship between visceral fat and arterial disease (or ‘stiffness’) 
or heart muscle function in young women with PCOS, but this may 
be an important area to study as research in middle-aged women 
with PCOS has shown that visceral fat is associated with increased 
‘furring’ of the arteries in the neck, which is a marker for early heart 
disease. 
  
We aim to measure visceral fat area in women with PCOS and 
relate this to arterial stiffness and heart muscle function. In order 
for us to investigate this we need to see how normal healthy 
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individuals, like yourself, who don’t have PCOS, respond to the 
same tests to see if there is a difference with our study patients. 
 
This study will involve two visits to the Clinical Research Facility 
and the Welsh Heart Research Institute at the Heath hospital, each 
lasting 2-3 hours or one visit lasting 6 hours.  
 
4. Why have I been chosen? 
 
You have been chosen for this study as you are healthy and similar 
in terms of age to the patients with PCOS. A total of 100 patients 
and 100 healthy volunteers will be studied. 
  
5. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide to 
take part you will be given this information sheet to keep and be 
asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time and without giving a reason.  
 
6. What will happen to me if I take part? 
 
The study will take place at the Clinical Research Facility and the 
Welsh Heart Research Institute at the University Hospital of Wales. 
You will be asked to attend in the morning having only had water to 
drink (i.e. no breakfast, tea or coffee) on 2 separate days. Each 
visit will last approximately 2-3 hours. If you are a smoker we 
request that you avoid smoking on each morning. 
 
We will firstly require you to have a pregnancy test before carrying 
out any measurements. 
 
We will then measure your weight, height, blood pressure, waist 
circumference, hip circumference and take a brief clinical history. 
We will take blood samples (approximately six tablespoons) to 
check levels of your hormones (testosterone, thyroid function, 
prolactin and 17-hydroxyprogesterone), ‘fat’ proteins (called 
adiponectin, PAI-1 and RBP-4), blood vessel proteins (called BNP, 
ICAM-1, VCAM-1 and TBARS) and to measure cholesterol, insulin, 
glucose and CRP (a marker of inflammation in the body). We will 
also measure a urine sample for a substance called 8-epi-PGF2, 
which is a marker of cholesterol damage.  
 
Next we will measure the amount of visceral fat in your body by 
three techniques: the BIA (bioimpedance) method, DEXA and CT 
scanning. The BIA technique is a simple, rapid and non-invasive 
technique which is used routinely in clinical practice to measure a 
patient’s percentage body fat. It sends a very small electrical 
current through the body and measures the body’s resistance to 
this current to determine the amount of fat, muscle and water 
present. The amount of electrical current is so small that you will 
be unable to feel it. The DEXA scan is also a simple, rapid and 
non-invasive technique which is used routinely in clinical practice. 
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This scan does involve a very small dose of radiation, equivalent to 
what you would be exposed to simply by living in Cardiff for 1 days. 
A CT scan will then be performed. Unlike CT scans used in 
medical practice this will be a single image (or ‘slice’) only, taken at 
the level of your lower spine. This will give us enough information 
to measure the amount of visceral fat present, while minimising 
your exposure to radiation. The amount of radiation you will receive 
is very small and similar to what you would be exposed to simply 
by living in Cardiff for 1 week. 
 
We will then measure the stiffness of your blood vessels and your 
heart muscle function. The ‘arterial stiffness’ test will be performed 
using an item of equipment called a ‘Sphygmocor’ machine. This 
technique, which is completely painless and ‘non-invasive’, 
consists of a small pencil-like probe placed over the wrist, which 
measures the waveform of the pulse. Further measurements will 
be obtained over pulses in the neck (the carotid artery) and top of 
the leg (femoral artery). The ‘heart muscle’ test will be performed at 
the Welsh Heart Research Institute using a technique called 
echocardiography. This is a painless non-invasive ultrasound 
technique used routinely in clinical practice to give pictures of the 
heart muscle and chambers within the heart. It uses a very high 
frequency sound which cannot be heard, but can be emitted and 
detected by special machines. Also at the Welsh Heart Research 
Institute we will examine the main artery in the neck (the carotid 
artery) using a special ultrasound probe. This is also a painless, 
non-invasive technique. 
  
Finally we will ask you to attend the Clinical Research Facility on a 
second morning for an oral glucose tolerance test (OGTT). This will 
assess how good your body is at handling sugar (termed ‘insulin 
resistance’). We request that you attend in the morning having only 
had water to drink (i.e. no breakfast, tea or coffee). We will take a 
blood test from you (roughly one tablespoon) then we will ask you 
to take a drink containing a measured amount of glucose. Further 
blood samples (at 30, 60 and 90 minutes) will be taken during the 
test and a final test is taken at two hours. Each blood sample will 
be roughly one tablespoon.       
 
If you wish we will be able to reimburse any travelling expenses / 
car parking fees incurred while attending for the study visits.  We 
will also give you a single payment of £50 to reimburse you for 
your time spent on the study. 
 
7. What do I have to do? 
 
It is important that you take any regular medication in the normal 
way without altering the dose or timing of these. You should inform 
us of any dose adjustments.  
 
There are no lifestyle or dietary restrictions and you can continue 
your daily activities normally. We request that you report any 
illnesses to us as they may influence the timing of your test visit.  
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You should inform us if there is any possibility of you being 
pregnant and this will be tested for in all participants. If you are 
pregnant you will not be able to participate in this study.  
 
For the study visit, we ask that you attend the Clinical Research 
Facility at 8 o’clock in the morning having fasted from midnight the 
previous night. You can drink water freely up to this point.  
 
8.  What are the possible disadvantages and risks of taking 
part? 
 
Other than possible discomfort (temporary pain, swelling, bruising 
and rarely infection) caused by the collection of blood, no other 
side effects are anticipated from the study procedures, though as 
outlined above, a ‘single slice’ CT scan and DEXA scan do involve 
exposure to a small amount of radiation. In addition the CT scan 
could by chance pick up an unsuspected abnormality in your 
abdomen, in which case you will be given an opportunity to discuss 
these findings further with Dr Aled Rees. Similarly, the 
echocardiogram and blood tests may pick up unsuspected 
abnormalities in which case you will be given an opportunity to 
discuss these findings with Dr Rees. 
  
9. What are the potential benefits of taking part? 
 
There are unlikely to be any direct benefits for you but the study 
may provide us with important information in determining whether 
visceral fat could be important in the development of arterial 
disease in women with PCOS. It may therefore be possible in 
future to use treatments which reduce visceral fat to prevent the 
development of arterial disease in patients with PCOS. 
 
10. Will I be able to have the results of my tests? 
 
We will contact you if there are any unsuspected abnormalities in 
your test results and you will be given an opportunity to discuss 
these findings with Dr Aled Rees.  If you wish to have all your test 
results (including normal results), we will be able to provide these 
for you on your request. 
 
11. What if something goes wrong? 
 
This study is being indemnified by Cardiff University. If you are 
harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you 
may have to pay for it. Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be 
available to you.  
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12. Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of 
the research will be kept strictly confidential. Any information about 
you which leaves the hospital will have your name and address 
removed so that you cannot be recognised from it. With your 
permission your GP will be informed of your participation in this 
study. With your permission we may also look at sections of your 
medical notes which are relevant to the research study.  
 
13. What will happen to the results of the research study? 
 
The results of the research study will be prepared for publication in 
appropriate medical journals together with presentation at medical 
conferences. Patients participating in the study will be able to 
obtain a copy of the results after they have been published in the 
relevant journal(s). Patients will not be identified in any 
report/publication.  
 
14. Who is organising and funding the research? 
 
The study is being organised by Dr Aled Rees (the Principal 
Investigator) and Dr Rosie Hocking (Research Registrar) from the 
Centre for Endocrine and Diabetes Sciences at the University 
Hospital of Wales. Funding for the study is provided from funds 
within the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. The doctors conducting the research 
are not being paid for including and looking after patients in the 
study. 
 
15. Who has reviewed the study? 
 
The study has been reviewed by the Cardiff and Vale NHS Trust 
Research and Development Office and by the South Wales 
Research Ethics Committee. 
 
16. Contact for further information 
 
Should you have any further queries regarding this research study, 
then please do not hesitate to contact me on 02920 745002. You 
can also contact me via e-mail on reesda@cf.ac.uk or Dr Rosie 
Hocking by email hockingrk1@cardiff.ac.uk or 07866771280. 
 
Thank you for considering taking part in this study. 
 
 
 
 
Dr Aled Rees 
Senior Lecturer in Endocrinology 
 
You will be given a copy of this Information Sheet and a signed 
consent form to keep 
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Appendix 5 
 
 
VISCERAL FAT AND VASCULAR RISK IN POLYCYSTIC OVARY SYNDROME  
 
    Patient Identification Number for this study: 
 
PATIENT CONSENT FORM 
(Version 2, September 2008) 
 
 
Title of Study:  Stratification of cardiometabolic risk in Polycystic Ovary 
Syndrome: is visceral fat a major player? 
  
Name of Researchers:  Dr Aled Rees, Dr Rosie Hocking    
       
         Please initial box 
 
1. I confirm that I have read and understood the information sheet dated  
September 2008 (version 2) for the above study and have had the 
opportunity to ask questions.         
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to 
have access to my records. 
 
4. I consent to my GP being informed of my participation in the Study. 
 
 
5. I consent to a pregnancy test.                                  
 
 
6. I agree to take part in the above study. 
 
 
__________________________  _____________  ____________ 
Name of patient    Date    Signature 
 
_________________________  _____________  _____________ 
Researcher     Date    Signature 
 
_______________________  _____________  ______________ 
Name of person taking consent  Date    Signature 
(if different from researcher) 
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix 6 
 
 
VISCERAL FAT AND VASCULAR RISK IN POLYCYSTIC OVARY SYNDROME  
 
     Subject Identification Number for this study: 
 
HEALTHY VOLUNTEER CONSENT FORM 
(Version 4 March 2010) 
 
 
Title of Study:  Stratification of cardiometabolic risk in Polycystic Ovary 
Syndrome: is visceral fat a major player? 
  
Name of Researchers:  Dr Aled Rees, Dr Rosie Hocking    
        
         Please initial box 
 
1. I confirm that I have read and understood the information sheet dated 
March 2010(version 4) for the above study and have had the opportunity to 
ask questions.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to have 
access to my records. 
 
4. I consent to my GP being informed of my participation in the Study. 
 
 
5. I consent to a pregnancy test.                               
 
 
6. I agree to take part in the above study. 
 
 
__________________________  _____________ ____________________ 
Name of volunteer    Date    Signature 
 
__________________________  _____________ ____________________ 
Researcher     Date    Signature 
 
__________________________  _____________ ______________ 
Name of person taking consent  Date    Signature 
(if different from researcher) 
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes 
Subject Number: 
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VISCERAL FAT AND VASCULAR RISK IN PCOS: CASE 
REPORT FORM FOR PATIENTS 
 
Patient Details 
 
Enrolment Number ………………………………………………………………….. 
 
Age   …………………………………………………………………. 
 
Date of Visit  ………………………………………………………………….. 
 
Inclusion Criteria 
 
Diagnosis of PCOS (2 out of 3) 
[   ] Ovulatory dysfunction (<6 cycles year) 
 [   ] Androgen excess (clinical or biochemical) 
 [   ] Polycystic ovaries on ultrasound 
 
[   ] Age 16-45  
 
Exclusion Criteria 
 
[   ] Pregnancy     [   ] CAH    
[   ] Breastfeeding     [   ] Cushings  
[   ] Hypertension     [   ] Hyperprolactinaemia  
[   ] Diabetes      [   ] Thyroid disease  
[   ] Glucocorticoids (current/last 3 mnth)  [  ] Androgen secreting tumour 
[   ] Lipid lowering agents (current/last 3 mnth) [   ] Glucocorticoid resistance 
[   ] Antihypertensives (current/last 3 mnth) 
[   ] Antidiabetic agents (current/last 3 mnth) 
[   ] Antiobesity agents (current/last 3 mnth) 
 
Consent 
[   ] Discuss Information Sheet and obtain informed consent 
 
 
Pregnancy Test 
 
[   ] Negative  [   ] Positive 
 
Batch No…………… Expiry Date………………… 
 
Performed by……………. Witnessed by……………………. 
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Medical History 
……………………………………………………………………………………………
……………………………………………………………………………………………
………………………………………………………………………………………….. 
 
Smoking Status 
 
Nonsmoker Y/N   Exsmoker (details)……………………………. 
Smoker (details)………………………………. 
 
Drug History 
Drug...................................................................................................................... 
Dose...................................................................................................................... 
Duration.................................................................................................................
Allergies…………………………………………………………………………………. 
Contraception…………………………………………………………………………... 
 
 
Family History 
……………………………………………………………………………………………
……………………………………………………………………………………………
…………………………………………………………………………………………… 
 
Menstrual History 
Age at Menarche……………………………………………………………………... 
Eumenorrhoeic cycle length…………………… Day no…………………. 
Oligomenorrhoeic LMP……………………………………………………………. 
Amenorrhoeic LMP……………………………………………………………. 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________ 
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Clinical Examination 
BMI   Height (m)…………..Weight (kg)…………BMI……………. 
 
Body composition Fat mass (kg)………...Fat %................... 
 
Waist:Hip  Waist (cm)…………..Hip (cm)…………..ratio…………….. 
 
Cardiovascular HS  
   Murmurs 
   BP 1…….. 2…….  3…….  Av………. 
 
Abdominal     Respiratory 
 
Oral Glucose Tolerance Test Date……………………. 
Time (mins) 0 30 60 90 120 
Glucose      
Insulin      
 
Other Laboratory Investigations 
 Blood Result Action if abnormal 
Overnight Dexamethasone Test 
(<50nmol/L) 
  
17-hydroxyprogesterone (2-
6nmol/L) 
  
TSH/FT4 (mU/L/pmol/L)   
Prolactin (50-560mU/L)   
Testosterone (<3noml/L)   
Androstenidone (4-10.2 nmol/L)   
 hs CRP   
 Total cholesterol (mmol/L)   
 Triglycerides(<2mmol/L)   
 LDL-cholesterol (mmol/L)   
 HDL-cholesterol (mmol/L)   
 adiponectin   
 Plasminogen activator-1   
 Retinol binding protein 4   
 Brain natriuretic peptide   
 Intercellular adhesion molecule 1   
 Vascular cell adhesion molecule 1   
Thiobarbituric acid reactive 
substance 
0min 
120 min    
 
Urine   
8-epi-prostaglandin-F2α   
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Medical Physics Department 
 
CT Abdomen  Date………………………………. 
 
Total fat Subcutaneous fat Visceral fat 
   
 
 
DEXA scan  Date………………………………….. 
 
  
Absolute total body fat (kg)  
Relative total body fat (%)  
Absolute total lean mass (kg)  
Relative total lean mass (%)  
Absolute total abdominal fat (kg)  
Relative total abdominal fat (%)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________ 
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Welsh Heart Research Institute  Date………………….. 
 
Augmentation Index and Pulse Wave Velocity 
 
Distance      Blood Pressure 
 
SSN to carotid pulse………………..mm  A………………………..mmHg 
 
SSN to radial pulse…………………mm  B………………………..mmHg 
 
       C………………………..mmHg 
 
SSN to femoral pulse………………mm  Average……………….mmHg 
 
 
Augmentation Index 
 
 
 
A B Average 
Augmentation Index 
(%) 
   
Central aortic 
pressure (mmHg) 
   
Time to return of 
reflected wave Tr (ms) 
   
Heart Rate (bpm)    
 
 
Pulse Wave Velocity 
 
 
 
A B Average 
Carotid-radial (m/s) 
 
   
Carotid-femoral (m/s) 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________ 
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Carotid Intima 
 
 mm mm 
Right carotid   
Left carotid   
Wave intensity   
 
 
 
Echocardiogram 
 
  
Systolic fn – long axis fn  
Diastolic fn – e’   
Diastolic fn – a’  
Diastolic fn – e’:a’ ratio  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________ 
 
Subject Number: 
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End of Study 
 
Study completed:  Yes [  ] Date……………………… 
    No   [  ] Date………………………. 
 
If No, reason study not completed  [  ] subject withdrawal of consent 
      [  ] Other………………………...... 
……………………………………………………………………………………………
……………………………………………………………………………………… 
 
Adverse Events 
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________ 
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VISCERAL FAT AND VASCULAR RISK IN PCOS: CASE 
REPORT FORM FOR HEALTHY VOLUNTEERS  
Version 1 Oct 2008 
 
Volunteer Details 
 
Enrolment Number ………………………………………………………………….. 
 
Age   ………………………………………………………………….. 
 
Date of Visit  ………………………………………………………………….. 
 
 
Inclusion Criteria 
 
[   ] Age 16-45  
[   ] Regular menstruation (27-32 days) 
 
 
Exclusion Criteria 
 
[   ] Pregnancy     [   ] Family history of PCOS 
[   ] Breastfeeding     [   ] Hirsutism  
[   ] Glucocorticoids (current/last 3 mnth)  [   ] Hypertension  
[   ] Lipid lowering agents (current/last 3 mnth) [   ] Diabetes 
[   ] Antihypertensives (current/last 3 mnth) 
[   ] Antidiabetic agents (current/last 3 mnth) 
[   ] Antiobesity agents (current/last 3 mnth) 
      
     
Consent 
 
[   ] Discuss Information Sheet and obtain informed Consent 
 
 
Pregnancy Test 
 
[   ] Negative  [   ] Positive 
 
Batch No:………… Expiry Date………… 
 
Performed by…………………………… Witnessed by………………………… 
 
 
 
 
 
 
 
_____________________________________________________________ 
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Medical History 
……………………………………………………………………………………………
……………………………………………………………………………………………
………………………………………………………………………………………….. 
 
Smoking Status 
 
Nonsmoker Y/N   Exsmoker (details)……………………………. 
Smoker (details)………………………………. 
 
Drug History 
Drug.................................................................................................................... 
Dose.................................................................................................................... 
Duration.............................................................................................................. 
Allergies……………………………………………………………………………….. 
Contraception………..………………………………………………………………... 
 
 
Family History 
……………………………………………………………………………………………
……………………………………………………………………………………………
…………………………………………………………………………………… 
 
Menstrual History 
Age at Menarche……………………………………………………………………... 
Eumenorrhoeic cycle length…………………… Day no…………………. 
Oligomenorrhoeic LMP……………………………………………………………. 
Amenorrhoeic LMP……………………………………………………………. 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________ 
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Clinical Examination 
 
BMI   Height (m)…………..Weight (kg)…………BMI……………. 
 
Body composition Fat mass (kg)………...Fat %................... 
 
Waist:Hip  Waist (cm)…………..Hip (cm)…………..ratio…………….. 
 
 
Cardiovascular HS     
   Murmurs 
   BP 1…….. 2………. 3………. Average………. 
 
Abdominal      Respiratory 
 
 
Oral Glucose Tolerance Test Date…………………. 
 
Time (mins) 0 30 60 90 120 
Glucose (mmol/L)      
Insulin      
 
Other Laboratory Investigations 
 Blood Results Action taken if 
abnormal 
17-hydroxyprogesterone (2-6 
nmol/L) 
  
TSH/FT4 (mU/L/pmol/L)   
Prolactin (50-560 mU/L)   
Testosterone (<3nmol/L)   
 hs CRP   
 Total cholesterol (mmol/L)   
 Triglycerides (<2mmol/L)   
 LDL-cholesterol (mmol/L)   
 HDL-cholesterol (mmol/L)   
 adiponectin   
 Plasminogen activator-1   
 Retinol binding protein 4   
 Brain natriuretic peptide   
 Intercellular adhesion molecule 1   
 Vascular cell adhesion molecule 
1 
  
Thiobarbituric acid reactive 
substance 
0 min         120 min  
Urine   
8-epi-prostaglandin-F2α (pg/ml)   
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Medical Physics Department, UHW 
 
CT Abdomen  Date………………….. 
 
Total Fat Subcutaneous fat Visceral fat 
   
 
 
DEXA scan  Date………………… 
 
  
Absolute total body fat (kg)  
Relative total body fat (%)  
Absolute total lean mass (kg)  
Relative total lean mass (%)  
Absolute total abdominal fat (kg)  
Relative total abdominal fat (%)  
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Welsh Heart Research Institute Date……………………………. 
 
Augmentation Index and Pulse Wave Velocity  
 
Distance      Blood Pressure 
 
SSN to carotid pulse………………..mm  A………………………..mmHg 
 
SSN to radial pulse…………………mm  B………………………..mmHg
        
 
SSN to femoral pulse………………mm  Average……………….mmHg 
 
 
Augmentation Index 
 
 
 
A B Average 
Augmentation Index 
(%) 
   
Central aortic 
pressure (mmHg) 
   
Tr (ms) 
 
   
Heart Rate (bpm) 
 
   
 
 
Pulse Wave Velocity 
 
 
 
A B Average 
Carotid-radial (m/s) 
 
   
Carotid-femoral (m/s) 
 
   
 
 
 
 
 
 
 
 
 
 
___________________________________________________ 
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Carotid Intima 
 
 mm mm 
Right Carotid   
Left Carotid   
Wave Intensity   
 
 
Echocardiogram 
 
  
Systolic fn – long axis fn  
Diastolic fn – e’  
Diastolic fn – a’  
Diastolic fn – e’:a’ ratio  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________ 
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End of Study 
 
Study completed:  Yes [   ]   date……………………..    
     No  [   ]    date…………………….. 
 
If No, reason study not completed [   ] patient withdrawal of consent 
      [   ] other……………………………… 
……………………………………………………………………………………………
……………………………………………………………………………………… 
  
 
 
 
 
Adverse Events 
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________ 
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